Document:

Exhibit 10.1

 

PLACEMENT AGENCY AGREEMENT

 

June 17, 2019

 

ThinkEquity, a division of

Fordham Financial Management, Inc.

17 State Street, 22nd Floor

New York, NY 10004

 

Ladies and Gentlemen:

 

Introductory.
This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity, a division of
Fordham Financial Management, Inc., (“ThinkEquity” or the “Placement Agent”) shall be engaged
by Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), to act as the exclusive Placement Agent
in connection with the offering (hereinafter referred to as the “Offering”) of securities of the Company, as
more fully described below. Capitalized terms used but not defined in this Agreement shall have the meaning ascribed to them in
the Securities Purchase Agreement (defined below).

 

		1.	Agreement to Act as Placement Agent; Closing; Placement
Agent Compensation.

 

1.1           On
the basis of the representations, warranties and agreements of the Company herein contained, and subject to all the terms and conditions
of this Agreement between the Company and the Placement Agent, the Placement Agent is appointed as the Company’s exclusive
placement agent during the Offering Period. On the basis of such representations and warranties and subject to such terms and conditions,
the Placement Agent hereby accepts such appointment and agrees to perform the services hereunder diligently and in good faith and
in a professional and businesslike manner and to use its commercially reasonable efforts to assist the Company in finding subscribers
of the Securities and to complete the Offering. The Placement Agent has no obligation to purchase any of the Securities. Unless
sooner terminated in accordance with this Agreement, the engagement of the Placement Agent hereunder shall continue until the later
of the Termination Date or the Closing. The Offering will be made on a “best efforts” basis. The Placement Agent may
retain other brokers or dealers to act as sub-placement agents on its behalf in connection with the Offering, with any fees they
may be entitled to being paid out of the fee paid to such Placement Agent pursuant to Section 1.6.

 

1.2           The
Common Shares are being sold to the Buyers and the Other Investors pursuant to a Securities Purchase Agreement dated the date hereof
(the “Securities Purchase Agreement”) at the following initial public offering price: $0.40 per Common Share
(the “Public Offering Price”).

 

1.3           Payment
of the purchase price equal to the Public Offering Price less the Cash Fee (the “Purchase Price”) for, and delivery
of, the Securities (the “Closing”) shall be made at the offices of Loeb & Loeb LLP (“Placement
Agent Counsel”), 345 Park Avenue, New York, NY 10154, or at such other place as shall be agreed upon by the Placement
Agent and the Company, at 10:00 a.m. (New York City time) on June 19, 2019, or such other time not later than ten Business
Days after such date as shall be agreed upon by the Placement Agent and the Company (such time and date of payment and delivery
being herein called “Closing Date”). The term “Business Day” means any day other than a Saturday,
a Sunday or a legal holiday or a day on which banking institutions are authorized or obligated by law to close in New York, New
York.

 

     

     

    

 

1.4           On
the Closing Date, (i) the Purchase Price will be released to the Company either (a) by the Placement Agent on behalf of each Buyer
or Other Investor for the Common Shares to be issued and sold to such Buyer or Other Investor at the Closing, by wire transfer
of immediately available funds in accordance with the flow of funds letter regarding the Closing, or (b) by the Buyer or Other
Investor wiring the Purchase Price to the Company by wire transfer to an account designated in writing by the Company, and (ii)
the Company shall (A) cause Corporate Stock Transfer, Inc. (together with any subsequent transfer agent, the “Transfer Agent”)
through the Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program, to credit such aggregate
number of Common Shares that each Buyer is purchasing as is set forth opposite such Buyer’s name in column (2) of the Schedule
of Buyers and as identified by each Buyer in the Purchaser Signature Page attached to the Securities Purchase Agreement or opposite
such Other Investor’s name as set forth in the flow of funds letter regarding the Closing to either (a) the Placement Agent’s
balance account with DTC through its Deposit/Withdrawal at Custodian system, or (b) directly to the account of each Buyer or Other
Investor, or its respective nominee(s), at the designated account with DTC as provided on the Purchaser Signature Page or flow
of funds letter (if applicable). All actions taken at the Closing shall be deemed to have occurred simultaneously on the Closing
Date. Any Common Shares for which payment has not been received by the Company, to the extent they have been delivered to the Placement
Agent or any such Buyer or Other Investor, shall be returned to the Company.

 

1.5           No
Shares which the Company has agreed to sell pursuant to this Agreement shall be deemed to have been purchased and paid for, or
issued and sold by the Company, until the appropriate corresponding number of Shares shall have been delivered to the Buyers, Other
Investors or the Placement Agent via DTC against payment therefor. If the Company shall default in its obligations to deliver the
Shares to the Buyers or Other Investors or the Placement Agent on behalf of such Buyers or Other Investors as per such instructions,
the Company shall indemnify and hold the Placement Agent harmless against any loss, claim, damage or liability directly or indirectly
arising from or as a result of such default by the Company.

 

1.6         
As compensation for services rendered, on the Closing Date, the Company shall (i) pay to the Placement Agent a cash fee (the “Cash
Fee”) equal to 7% of the aggregate purchase price paid by the Buyers and the Other Investors in respect of the Common
Shares purchased at the Closing, which shall be deducted from the Purchase Price payable at Closing, (ii) pay to the Placement
Agent a non-accountable expense reimbursement equal to 1% of the aggregate purchase price paid by the Buyers and the Other Investors
in respect of the Common Shares purchased at the Closing, and (iii) issue to the Placement Agent or its designees Common Stock
purchase warrants to purchase an aggregate number of shares of Common Stock (the “Placement Agent Warrant Shares”)
equal to 7% of the Common Shares sold to Buyers and the Other Investors (the “Placement Agent Warrants”) in
exchange for the payment of $100 at the closing, which may be deducted from amounts otherwise due Placement Agent. The Placement
Agent Warrants, in the form attached hereto as Exhibit A (the “Placement Agent Warrants”), shall be exercisable, in
whole or in part, commencing on a date which is one hundred eighty (180) days after the date hereof and expiring on the four and
one-half year anniversary thereof at an initial exercise price per share of Common Stock of $0.50, which is equal to 125% of the
Public Offering Price. The Placement Agent Warrants and the shares of Common Stock issuable upon exercise thereof are hereinafter
referred to together as the “Placement Agent’s Securities.” The Placement Agent understands and agrees that there
are significant restrictions pursuant to FINRA Rule 5110 against transferring the Placement Agent Warrants and the underlying shares
of Common Stock for a period of one hundred eighty (180) days following the date hereof and by its acceptance thereof shall agree
that it will not sell, transfer, assign, pledge or hypothecate the Placement Agent Warrants, or any portion thereof, or be the
subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition
of such securities for a period of one hundred eighty (180) days following the date hereof to anyone other than a bona fide officer
or partner of the Placement Agent; and only if any such transferee agrees to the foregoing lock-up restrictions.

 

    	 	- 2 -	 

     

    

 

1.7           The
Company hereby acknowledges that (i) the Offering, including the determination of the offering price of the Common Shares and
any related discounts, commissions and fees, shall be an arm’s-length commercial transaction between the Company and the
Buyers and the Other Investors, (ii) the Placement Agent will be acting as an independent contractor and will not be the agent
or fiduciary of the Company or its shareholders, creditors, employees, the Buyers, the Other Investors or any other party, (iii)
the Placement Agent shall not assume an advisory or fiduciary responsibility in favor of the Company (irrespective of whether
the Placement Agent has advised or is currently advising the Company on other matters) and the Placement Agent shall not have
any obligation to the Company with respect to the Offering, except as may be set forth expressly herein, (iv) the Placement Agent
and its Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company
and (v) the Placement Agent will not provide any legal, accounting, regulatory or tax advice with respect to the Offering, and
the Company shall consult its own legal, accounting, regulatory and tax advisors to the extent it deems appropriate.

 

1.8           The
Company is and will be solely responsible for the contents of any and all written or oral communications provided to the Buyers
and the Other Investors regarding the Offering or the Common Shares; and the Company recognizes that the Placement Agent, in acting
pursuant to this Agreement, will be using information provided by the Company and its agents and representatives and Placement
Agent assumes no responsibility for, and may rely, without independent verification, on the accuracy and completeness of any such
information.

 

1.9           The
Company agrees that any information or advice rendered by the Placement Agent or any of its representatives in connection with
this engagement is for the confidential use of the Board of Directors of the Company (the “Board”) only and
the Company will not, and will not permit any third party to, disclose or otherwise refer to such advice or information, in any
manner without the Placement Agent’s prior written consent.

 

2.          Representations
and Warranties of the Company. The Company represents and warrants to the Placement Agent and each Other Investor as of the
Applicable Time (as defined below), as of the Closing Date as follows:

 

2.1         Filing
of Registration Statement.

 

2.1.1           Pursuant
to the Securities Act. The Company has filed with the U.S. Securities and Exchange Commission (the “Commission”)
a “shelf” registration statement on Form S-3 (File No. 333-224177), including any related prospectus or prospectuses,
for the registration of the Common Shares under the Securities Act of 1933, as amended (the “Securities Act”),
which registration statement was prepared by the Company in all material respects in conformity with the requirements of the Securities
Act and the rules and regulations of the Commission under the Securities Act (the “Securities Act Regulations”)
and contains and will contain all material statements that are required to be stated therein in accordance with the Securities
Act and the Securities Act Regulations. Except as the context may otherwise require, such registration statement on file with
the Commission at any given time, including any amendments thereto to such time, exhibits and schedules thereto at such time,
documents filed as a part thereof or incorporated pursuant to Item 12 of Form S-3 under the Securities Act at such time and the
documents and information otherwise deemed to be a part thereof or included therein pursuant to Rule 430B of the Securities Act
Regulations (the “Rule 430B Information”) or otherwise pursuant to the Securities Act Regulations at such time,
is referred to herein as the “Registration Statement.” The Registration Statement at the time it originally
became effective is referred to herein as the “Initial Registration Statement.” If the Company files any registration
statement pursuant to Rule 462(b) of the Securities Act Regulations, then after such filing, the term “Registration Statement”
shall include such registration statement filed pursuant to Rule 462(b). The Registration Statement was declared effective by
the Commission on April 20, 2017 (the “Effective Date”).

 

    	 	- 3 -	 

     

    

 

The prospectus in
the form in which it was filed with the Commission in connection with the Initial Registration Statement is herein called the
“Base Prospectus.” Each preliminary prospectus supplement to the Base Prospectus (including the Base Prospectus
as so supplemented) that described the Common Shares and the Offering and omitted the Rule 430B Information and that was used
prior to the filing of the final prospectus supplement referred to in the following paragraph is herein called a “Preliminary
Prospectus.”

 

Promptly after the execution
and delivery of this Agreement, the Company will prepare and file with the Commission a final prospectus supplement to the Base
Prospectus relating to the Common Shares and the Offering in accordance with the provisions of Rule 430B and Rule 424(b) of the
Securities Act Regulations. Such final prospectus supplement (including the Base Prospectus as so supplemented), in the form filed
with the Commission pursuant to Rule 424(b) under the Securities Act is herein called the “Prospectus.” Any
reference herein to the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include
the documents incorporated by reference therein pursuant to Item 12 of Form S-3 under the Securities Act as of the date of such
prospectus.

 

“Applicable
Time” means 8:00 a.m., Eastern time, on June 17, 2019, on the date of this Agreement.

 

“Disclosure
Package” means any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time, the Preliminary
Prospectus Supplement dated June 17, 2019 and the information included on Schedule 2-A hereto, all considered together.

 

“Issuer Free
Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 of the Securities
Act Regulations (“Rule 433”), including without limitation any “free writing prospectus” (as defined
in Rule 405 of the Securities Act Regulations) relating to the Common Shares that is (i) required to be filed with the Commission
by the Company, (ii) a “road show that is a written communication” within the meaning of Rule 433(d)(8)(i), whether
or not required to be filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i)
because it contains a description of the Common Shares or of the Offering that does not reflect the final terms, in each case
in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s
records pursuant to Rule 433(g).

 

“Issuer General
Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is intended for general distribution to prospective
investors (other than a “bona fide electronic road show,” as defined in Rule 433), as evidenced by its being
specified in Schedule 2-B hereto.

 

“Issuer Limited
Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing
Prospectus.

 

2.1.2        Pursuant
to the Exchange Act. The Company has filed with the Commission a Form 8-A (Accession No. 001-35182) providing for the registration
pursuant to Section 12(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), of the
shares of Common Stock. The registration of the shares of Common Stock and related Form 8-A have become effective under the Exchange
Act on or prior to the date hereof. The Company has taken no action designed to, or likely to have the effect of, terminating
the registration of the shares of Common Stock under the Exchange Act, nor has the Company received any notification that the
Commission is contemplating terminating such registration.

 

    	 	- 4 -	 

     

    

 

2.2         Stock
Exchange Listing. The shares of Common Stock have been approved for listing on The NYSE American LLC (the “Exchange”),
and the Company has taken no action designed to, or likely to have the effect of, delisting the shares of Common Stock from the
Exchange, nor has the Company received any notification that the Exchange is contemplating terminating such listing except as
described in the Registration Statement, the Disclosure Package and the Prospectus. The Company has submitted the Listing of Additional
Shares application with the Exchange with respect to the Offering of the Common Shares.

 

2.3         No
Stop Orders, etc. Neither the Commission nor, to the Company’s knowledge, any state regulatory authority has issued
any order preventing or suspending the use of the Registration Statement, any Preliminary Prospectus or the Prospectus or has
instituted or, to the Company’s knowledge, threatened to institute, any proceedings with respect to such an order. The Company
has complied with each request (if any) from the Commission for additional information.

 

2.4         Disclosures
in Registration Statement.

 

2.4.1     Compliance
with Securities Act and 10b-5 Representation.

 

(i)          Each
of the Registration Statement and any post-effective amendment thereto, at the time it became effective (including each deemed
effective date with respect to the Placement Agent pursuant to Rule 430B or otherwise under the Securities Act) complied and will
comply in all material respects with the requirements of the Securities Act and the Securities Act Regulations. The conditions
for use of Form S-3, set forth in the General Instructions thereto, including, but not limited to, General Instruction I.B.6 and
other conditions related to the offer and sale of the Common Shares, have been satisfied. Each Preliminary Prospectus and the
Prospectus, at the time each was or will be filed with the Commission, complied and will comply in all material respects with
the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus delivered to the Placement
Agent for use in connection with this Offering and the Prospectus was or will be identical to the electronically transmitted copies
thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

 

(ii)         Neither
the Registration Statement nor any amendment thereto, at its effective time, as of the Applicable Time or at the Closing Date
contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material
fact required to be stated therein or necessary to make the statements therein not misleading.

 

(iii)        The
Disclosure Package, as of the Applicable Time, at the Closing Date, did not, does not and will not include an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; and any Issuer Limited Use Free Writing Prospectus hereto does not conflict with the
information contained in the Registration Statement, any Preliminary Prospectus or the Prospectus, and each such Issuer Limited
Use Free Writing Prospectus, as supplemented by and taken together with the Prospectus as of the Applicable Time, did not include
an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in
light of the circumstances under which they were made, not misleading.

 

(iv)        Neither
the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of
any filing with the Commission pursuant to Rule 424(b), at the Closing Date, included, includes or will include an untrue statement
of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; provided, however, that this representation
and warranty shall not apply to the Placement Agent’ Information.

 

    	 	- 5 -	 

     

    

 

(v)         The
documents incorporated by reference in the Registration Statement, the Disclosure Package and the Prospectus, when they became
effective or were filed with the Commission, as the case may be, conformed in all material respects to the requirements of the
Securities Act or the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder and none of such
documents contained any untrue statement of a material fact or omitted to state any material fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and
any further documents so filed and incorporated by reference in the Registration Statement, the Disclosure Package and the Prospectus,
when such documents become effective or are filed with the Commission, as the case may be, will conform in all material respects
to the requirements of the Securities Act or the Exchange Act, as applicable, and the rules and regulations of the Commission
thereunder, and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.

 

2.4.2           Disclosure
of Agreements. The agreements and documents described in the Registration Statement, the Disclosure Package and the Prospectus
conform in all material respects to the descriptions thereof contained or incorporated by reference therein and there are no agreements
or other documents required by the Securities Act and the Securities Act Regulations to be described in the Registration Statement,
the Disclosure Package and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement or to be
incorporated by reference in the Registration Statement, the Disclosure Package or the Prospectus, that have not been so described
or filed or incorporated by reference. Each agreement or other instrument (however characterized or described) to which the Company
is a party or by which it is or may be bound or affected and (i) that is referred to or incorporated by reference in the Registration
Statement, the Disclosure Package and the Prospectus, or (ii) is material to the Company’s business, has been duly authorized
and validly executed by the Company, is in full force and effect in all material respects and is enforceable against the Company
and, to the Company’s knowledge, the other parties thereto, in accordance with its terms, except (x) as such enforceability
may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally, (y) as enforceability
of any indemnification or contribution provision may be limited under the federal and state securities laws, and (z) that the
remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and
to the discretion of the court before which any proceeding therefor may be brought. None of such agreements or instruments has
been assigned by the Company, and neither the Company nor, to the best of the Company’s knowledge, any other party is in
default thereunder and, to the best of the Company’s knowledge, no event has occurred that, with the lapse of time or the
giving of notice, or both, would constitute a default thereunder. To the Company’s knowledge, performance by the Company
of the material provisions of such agreements or instruments will not result in a violation of any existing applicable law, rule,
regulation, judgment, order or decree of any governmental agency or court, domestic or foreign, having jurisdiction over the Company
or any of its assets or businesses (each, a “Governmental Entity”), including, without limitation, those relating
to environmental laws and regulations.

 

2.4.3        Prior
Securities Transactions. No securities of the Company have been sold by the Company or by or on behalf of, or for the benefit
of, any person or persons controlling, controlled by or under common control with the Company, except as disclosed in the Registration
Statement, the Disclosure Package and the Preliminary Prospectus.

 

    	 	- 6 -	 

     

    

 

2.4.4       Regulations.
The disclosures in the Registration Statement, the Disclosure Package and the Prospectus concerning the effects of federal, state,
local and all foreign regulation on the Offering and the Company’s business as currently contemplated are correct in all
material respects and no other such regulations are required to be disclosed in the Registration Statement, the Disclosure Package
and the Prospectus which are not so disclosed.

 

2.4.5       No
Other Distribution of Offering Materials. The Company has not, directly or indirectly, distributed and will not distribute
any offering material in connection with the Offering other than any Preliminary Prospectus, the Disclosure Package, the Prospectus
and other materials, if any, permitted under the Securities Act and consistent with Section 3.2 below.

 

2.5         Changes
After Dates in Registration Statement.

 

2.5.1       No
Material Adverse Change. Since the respective dates as of which information is given in the Registration Statement, the Disclosure
Package and the Prospectus: (i) there has been no material adverse change in the financial position or results of operations of
the Company, nor any change or development that, singularly or in the aggregate, would have or reasonably be expected to result
in a material adverse change or a prospective material adverse change, in or affecting the condition (financial or otherwise),
results of operations, business, assets or prospects of the Company (a “Material Adverse Change”); (ii) there
have been no material transactions entered into by the Company, other than as contemplated pursuant to this Agreement; and (iii)
no officer or director of the Company has resigned from any position with the Company except as disclosed therein.

 

2.5.2       Recent
Securities Transactions, etc. Subsequent to the respective dates as of which information is given in the Registration Statement,
the Disclosure Package and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed in the
Registration Statement, the Disclosure Package and the Prospectus, the Company has not: (i) issued any securities or incurred
any liability or obligation, direct or contingent, for borrowed money; or (ii) declared or paid any dividend or made any other
distribution on or in respect to its capital stock.

 

2.6         Disclosures
in Commission Filings. Since January 1, 2016, (i) none of the Company’s filings with the Commission contained any untrue
statement of a material fact or omitted to state any material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading; and (ii) the Company has made all filings with the Commission
required under the Exchange Act and the rules and regulations of the Commission promulgated thereunder (the “Exchange
Act Regulations”).

 

2.7         Independent
Accountants. To the knowledge of the Company, Plante & Moran, PLLC (the “Auditors”), whose respective
reports are filed with the Commission and included or incorporated by reference in the Registration Statement, the Disclosure
Package and the Prospectus, is each an independent registered public accounting firm as required by the Securities Act and the
Securities Act Regulations and the Public Company Accounting Oversight Board. The Auditors have not, during the periods covered
by the financial statements included or incorporated by reference in the Registration Statement, the Disclosure Package and the
Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange Act.

 

    	 	- 7 -	 

     

    

 

2.8         Financial
Statements, etc. The financial statements, including the notes thereto and supporting schedules included or incorporated by
reference in the Registration Statement, the Disclosure Package and the Prospectus, fairly present the financial position and
the results of operations of the Company at the dates and for the periods to which they apply; and such financial statements have
been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), consistently applied
throughout the periods involved (provided that unaudited interim financial statements are subject to year-end audit adjustments
that are not expected to be material in the aggregate and do not contain all footnotes required by GAAP); and the supporting schedules
included or incorporated by reference in the Registration Statement present fairly the information required to be stated therein.
No other historical or pro forma financial statements or supporting schedules are required to be included in the Registration
Statement, the Disclosure Package or the Prospectus by the Securities Act or the Securities Act Regulations. The pro forma financial
statements and the related notes, if any, included or incorporated by reference in the Registration Statement, the Disclosure
Package and the Prospectus have been properly compiled and prepared in accordance with the applicable requirements of the Securities
Act, the Securities Act Regulations, the Exchange Act or the Exchange Act Regulations and present fairly the information shown
therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate to
give effect to the transactions and circumstances referred to therein. All disclosures contained in the Registration Statement,
the Disclosure Package or the Prospectus, or incorporated or deemed incorporated by reference therein, regarding “non-GAAP
financial measures” (as such term is defined by the rules and regulations of the Commission), if any, comply with Regulation
G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable. Each of the Registration
Statement, the Disclosure Package and the Prospectus discloses all material off-balance sheet transactions, arrangements, obligations
(including contingent obligations), and other relationships of the Company with unconsolidated entities or other persons that
may have a material current or future effect on the Company’s financial condition, changes in financial condition, results
of operations, liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. Except as
disclosed in the Registration Statement, the Disclosure Package and the Prospectus, (a) neither the Company nor any of its direct
and indirect subsidiaries, including each entity disclosed or described in the Registration Statement, the Disclosure Package
and the Prospectus as being a subsidiary of the Company (each, a “Subsidiary” and, collectively, the “Subsidiaries”),
has incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions other than
in the ordinary course of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind
with respect to its capital stock, (c) there has not been any change in the capital stock of the Company or any of its Subsidiaries,
or, other than in the course of business or any grants under any stock compensation plan, and (d) there has not been any Material
Adverse Change in the Company’s long-term or short-term debt.

 

2.9         Authorized
Capital; Options, etc. The Company had, at the date or dates indicated in the Registration Statement, the Disclosure Package
and the Prospectus, the duly authorized, issued and outstanding capitalization as set forth therein. Based on the assumptions
stated in the Registration Statement, the Disclosure Package and the Prospectus, the Company will have on the Closing Date the
adjusted stock capitalization set forth therein. Except as set forth in, or contemplated by, the Registration Statement, the Disclosure
Package and the Prospectus, on the Effective Date, as of the Applicable Time and on the Closing Date, there will be no stock options,
warrants, or other rights to purchase or otherwise acquire any authorized, but unissued shares of Common Stock of the Company
or any security convertible or exercisable into shares of Common Stock of the Company, or any contracts or commitments to issue
or sell shares of Common Stock or any such options, warrants, rights or convertible securities.

 

2.10       Valid
Issuance of Securities, etc.

 

2.10.1         Outstanding
Securities. All issued and outstanding securities of the Company issued prior to the transactions contemplated by this Agreement
have been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have no rights of rescission
or similar rights with respect thereto or put rights, and are not subject to personal liability by reason of being such holders;
and none of such securities were issued in violation of the preemptive rights, rights of first refusal or rights of participation
of any holders of any security of the Company or similar contractual rights granted by the Company. The authorized shares of Common
Stock conform in all material respects to all statements relating thereto contained in the Registration Statement, the Disclosure
Package and the Prospectus. The offers and sales of the outstanding shares of Common Stock were at all relevant times either registered
under the Securities Act and the applicable state securities or “blue sky” laws or, based in part on the representations
and warranties of the purchasers of such Shares, exempt from such registration requirements.

 

    	 	- 8 -	 

     

    

 

2.10.2      Securities
Sold Pursuant to this Agreement. The Common Shares have been duly authorized for issuance and sale and, when issued and paid
for, will be validly issued, fully paid and non-assessable; the holders thereof are not and will not be subject to personal liability
by reason of being such holders; the Common Shares are not and will not be subject to the preemptive rights of any holders of
any security of the Company or similar contractual rights granted by the Company; and all corporate action required to be taken
for the authorization, issuance and sale of the Common Shares has been duly and validly taken. The Common Shares conform in all
material respects to all statements with respect thereto contained in the Registration Statement, the Disclosure Package and the
Prospectus.

 

2.11       Registration
Rights of Third Parties. As of the Applicable time and immediately prior to the Closing, no holders of any securities of the
Company or any rights exercisable for or convertible or exchangeable into securities of the Company have the right to require
the Company to register any such securities of the Company under the Securities Act or to include any such securities in a registration
statement to be filed by the Company.

 

2.12       Validity
and Binding Effect of Agreements. This Agreement has been duly and validly authorized by the Company, and, when executed and
delivered, will constitute, the valid and binding agreement of the Company, enforceable against the Company in accordance with
its terms, except: (i) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar
laws affecting creditors’ rights generally; (ii) as enforceability of any indemnification or contribution provision may
be limited under the federal and state securities laws; and (iii) that the remedy of specific performance and injunctive and other
forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding
therefor may be brought.

 

2.13       No
Conflicts, etc. The execution, delivery and performance by the Company of this Agreement and all ancillary documents, the
consummation by the Company of the transactions herein and therein contemplated and the compliance by the Company with the terms
hereof and thereof do not and will not, with or without the giving of notice or the lapse of time or both: (i) result in a material
breach of, or conflict with any of the terms and provisions of, or constitute a material default under, or result in the creation,
modification, termination or imposition of any lien, charge, mortgage, pledge, security interest, claim, equity, trust or other
encumbrance, preferential arrangement, defect or restriction of any kind whatsoever or encumbrance upon any property or assets
of the Company pursuant to the terms of any indenture, mortgage, deed of trust, note, lease, loan agreement or any other agreement
or instrument, franchise, license or permit to which the Company is a party or as to which any property of the Company is a party;
(ii) result in any violation of the provisions of the Company’s Articles of Incorporation (as the same may be amended or
restated from time to time, the “Charter”) or the by-laws of the Company (as the same may be amended or restated
from time to time, the “Bylaws”); or (iii) violate any existing applicable law, rule, regulation, judgment,
order or decree of any Governmental Entity as of the date hereof (including, without limitation, those promulgated by the Food
and Drug Administration of the U.S. Department of Health and Human Services (the “FDA”) or by any foreign,
federal, state or local regulatory authority performing functions similar to those performed by the FDA).

 

2.14       No
Defaults; Violations. No material default exists in the due performance and observance of any term, covenant or condition
of any material license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement
or instrument evidencing an obligation for borrowed money, or any other material agreement or instrument to which the Company
is a party or by which the Company may be bound or to which any of the properties or assets of the Company is subject. The Company
is not in violation of any term or provision of its Charter or by-laws, or in violation of any franchise, license, permit, applicable
law, rule, regulation, judgment or decree of any Governmental Entity.

 

    	 	- 9 -	 

     

    

 

2.15       Corporate
Power; Licenses; Consents.

 

2.15.1      Conduct
of Business. The Company has all requisite corporate power and authority, and has all necessary authorizations, approvals,
orders, licenses, certificates and permits of and from all governmental regulatory officials and bodies that it needs as of the
date hereof to conduct its business purpose as described in the Registration Statement, the Disclosure Package and the Prospectus.

 

2.15.2      Transactions
Contemplated Herein. The Company has all corporate power and authority to enter into this Agreement and to carry out the provisions
and conditions hereof, and all consents, authorizations, approvals and orders required in connection therewith have been obtained.
No consent, authorization or order of, and no filing with, any court, government agency or other body is required for the valid
issuance, sale and delivery of the Common Shares and the consummation of the transactions and agreements contemplated by this
Agreement and as contemplated by the Registration Statement, the Disclosure Package and the Prospectus, except with respect to
applicable federal and state securities laws and the rules and regulations of the Exchange and the Financial Industry Regulatory
Authority, Inc. (“FINRA”).

 

2.16      D&O
Questionnaires. To the Company’s knowledge, all information contained in the questionnaires (the “Questionnaires”)
completed by each of the Company’s directors and officers immediately prior to the Offering (the “Insiders”),
as supplemented by all information concerning the Company’s directors, officers and principal shareholders as described
in the Registration Statement, the Disclosure Package and the Prospectus, as well as in the Lock-Up Agreement (as defined in Section
2.27 below) provided to the Placement Agent, is true and correct in all material respects and the Company has not become aware
of any information which would cause the information disclosed in the Questionnaires to become materially inaccurate and incorrect.

 

2.17       Litigation;
Governmental Proceedings. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental
proceeding pending or, to the Company’s knowledge, threatened against, or involving the Company or, to the Company’s
knowledge, any executive officer or director which has not been disclosed in the Registration Statement, the Disclosure Package
and the Prospectus, or in connection with the Company’s listing application for the listing of the Common Shares on the
Exchange, and which is required to be disclosed.

 

2.18       Good
Standing. The Company has been duly incorporated and is validly existing as a corporation and is in good standing under the
laws of the State of Delaware as of the date hereof, and is duly qualified to do business and is in good standing in each other
jurisdiction in which its ownership or lease of property or the conduct of business requires such qualification, except where
the failure to be so qualified or in good standing, singularly or in the aggregate, would not have or reasonably be expected to
result in a Material Adverse Change.

 

2.19       Insurance.
The Company carries or is entitled to the benefits of insurance, with reputable insurers, in such amounts and covering such risks
which the Company believes are adequate, including, but not limited to, directors and officers insurance coverage at least equal
to $5,000,000 and the Company has included Placement Agent as an additional insured party to the directors and officers insurance
coverage, and all such insurance is in full force and effect. The Company has no reason to believe that it will not be able (i)
to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions
as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material
Adverse Change.

 

    	 	- 10 -	 

     

    

 

2.20       Transactions
Affecting Disclosure to FINRA.

 

2.20.1     Finder’s
Fees. Except as described in the Registration Statement, the Disclosure Package and the Prospectus, there are no claims, payments,
arrangements, agreements or understandings relating to the payment of a finder’s, consulting or origination fee by the Company
or any Insider with respect to the sale of the Common Shares hereunder or any other arrangements, agreements or understandings
of the Company or, to the Company’s knowledge, any of its shareholders that may affect the Placement Agent’ compensation,
as determined by FINRA.

 

2.20.2     Payments
Within Twelve Months. Except for payments made to the Placement Agent and except as described in the Registration Statement,
the Disclosure Package and the Prospectus, the Company has not made any direct or indirect payments (in cash, securities or otherwise)
to: (i) any person, as a finder’s fee, consulting fee or otherwise, in consideration of such person raising capital for
the Company or introducing to the Company persons who raised or provided capital to the Company; (ii) any FINRA member; or (iii)
any person or entity that has any direct or indirect affiliation or association with any FINRA member, within the twelve months
prior to the date of this Agreement, other than the payment to the Placement Agent as provided hereunder in connection with the
Offering.

 

2.20.3     Use
of Proceeds. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its
affiliates, except as specifically authorized herein.

 

2.20.4     FINRA
Affiliation. There is no (i) officer or director of the Company, (ii) beneficial owner of 5% or more of any class of the Company's
securities or (iii) beneficial owner of the Company’s unregistered equity securities which were acquired during the 180-day
period immediately preceding the filing of the Registration Statement that is an affiliate or associated person of a FINRA member
participating in the Offering (as determined in accordance with the rules and regulations of FINRA). Except as disclosed in the
Registration Statement, the Disclosure Package and the Prospectus, the Company (i) does not have any material lending or other
relationship with any bank or lending affiliate of the Placement Agent and (ii) does not intend to use any of the proceeds from
the sale of the Common Shares to repay any outstanding debt owed to any affiliate of the Placement Agent.

 

2.20.5     Information.
All information provided by the Company in its FINRA questionnaire to Placement Agent Counsel specifically for use by Placement
Agent Counsel in connection with its Public Offering System filings (and related disclosure) with FINRA is true, correct and complete
in all material respects.

 

2.21       Foreign
Corrupt Practices Act. None of the Company and its Subsidiaries or, to the Company’s knowledge, any director, officer,
agent, employee or affiliate of the Company and its Subsidiaries or any other person acting on behalf of the Company and its Subsidiaries,
has, directly or indirectly, given or agreed to give any money, gift or similar benefit (other than legal price concessions to
customers in the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or official
or employee of any governmental agency or instrumentality of any government (domestic or foreign) or any political party or candidate
for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company
(or assist it in connection with any actual or proposed transaction) that (i) might subject the Company to any damage or penalty
in any civil, criminal or governmental litigation or proceeding, (ii) if not given in the past, might have had a Material Adverse
Change; (iii) if not continued in the future, might adversely affect the assets, business, operations or prospects of the Company.
The Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company
to comply in all material respects with the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder
(collectively, the “FCPA”) or employee; (iv) violated or is in violation of any provision of the FCPA or any
applicable non-U.S. anti-bribery statute or regulation; (v) made any bribe, rebate, payoff, influence payment, kickback or other
unlawful payment; or (vi) received notice of any investigation, proceeding or inquiry by any Governmental Entity regarding any
of the matters in clauses (i)-(v) above; and the Company and, to the knowledge of the Company, the Company’s affiliates
have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures
designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.

 

    	 	- 11 -	 

     

    

 

2.22      Compliance
with OFAC. None of the Company and its Subsidiaries or, to the Company’s knowledge, any director, officer, agent, employee
or affiliate of the Company and its Subsidiaries or any other person acting on behalf of the Company and its Subsidiaries, is
currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury
(“OFAC”), and the Company will not, directly or indirectly, use the proceeds of the Offering hereunder, or
lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity,
for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.

 

2.23      Forward-Looking
Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act) contained in either the Registration Statement, Disclosure Package or Prospectus has been made or reaffirmed without a reasonable
basis or has been disclosed other than in good faith.

 

2.24      Money
Laundering Laws. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar
rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the “Money
Laundering Laws”); and no action, suit or proceeding by or before any Governmental Entity involving the Company with
respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.

 

2.25      Regulatory.
(a) All preclinical studies and clinical trials conducted by or on behalf of the Company that are material to the Company and
its Subsidiaries, taken as a whole, are or have been adequately described in the Registration Statement, the Disclosure Package
and the Prospectus in all material respects. The preclinical studies and clinical trials conducted by or on behalf of the Company
and its Subsidiaries that are described in the Registration Statement, the Disclosure Package and the Prospectus or the results
of which are referred to in the Registration Statement, the Disclosure Package and the Prospectus were and, if still ongoing,
are being conducted in material compliance with all laws and regulations applicable thereto in the jurisdictions in which they
are being conducted and with all laws and regulations applicable to preclinical studies and clinical trials from which data will
be submitted to support marketing approval. The descriptions in the Registration Statement, the Disclosure Package and the Prospectus
of the results of such studies are accurate and complete in all material respects and fairly present the data derived from such
studies, and the Company has no knowledge of, or reason to believe that, any large well-controlled clinical study the aggregate
results of which are inconsistent with or otherwise call into question the results of any clinical study conducted by or on behalf
of the Company that are described in the Registration Statement, the Disclosure Package and the Prospectus or the results of which
are referred to in the Registration Statement, the Disclosure Package and the Prospectus. Except as disclosed in the Registration
Statement, the Disclosure Package and the Prospectus, the Company has not received any written notices or statements from the
FDA, the European Medicines Agency (“EMA”) or any other governmental agency or authority imposing, requiring,
requesting or suggesting a clinical hold, termination, suspension or material modification for or of any preclinical studies and
clinical trials that are described in the Registration Statement, the Disclosure Package and the Prospectus or the results of
which are referred to in the Registration Statement, the Disclosure Package and the Prospectus. Except as disclosed in the Registration
Statement, the Disclosure Package and the Prospectus, the Company has not received any written notices or statements from the
FDA, the EMA or any other governmental agency, and otherwise has no knowledge of, or reason to believe that, (i) any investigational
new drug application for any potential product of the Company is or has been rejected or placed on clinical hold; and (ii) any
license, approval, permit or authorization to conduct any clinical trial of any potential product of the Company has been, will
be or may be suspended, revoked, modified or limited. Neither the Company nor any of its subsidiaries has failed to file with
the FDA or any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed
by the FDA, any filing, declaration, listing, registration, report or submission that is required to be so filed.  All such
filings were in material compliance with applicable laws when filed and no deficiencies have been asserted by any applicable regulatory
authority (including, without limitation, the FDA or any foreign, federal, state or local governmental or regulatory authority
performing functions similar to those performed by the FDA) with respect to any such filings, declarations, listings, registrations,
reports or submissions. To the knowledge of the Company, there are no facts that would be reasonably likely to result in any warning,
untitled or notice of violation letter or Form FDA-483 from the FDA. The Company is not aware of any studies, tests or trials
the results of which the Company believes reasonably call into question (i) the study, test or trial results of any of its products,
(ii) the efficacy or safety of any of its products or (iii) any of the Company’s filings with any Governmental Entity.

 

    	 	- 12 -	 

     

    

 

(b) Regulatory Filings
and Permits. The Company and its Subsidiaries have such permits, licenses, clearances, registrations, exemptions, patents,
franchises, certificates of need and other approvals, consents and other authorizations (“Permits”) issued
by the appropriate domestic or foreign regional, federal, state, or local regulatory agencies or bodies necessary to conduct the
business of the Company, including, without limitation, any Investigational New Drug Application (an “IND”),
Biologics License Application (“BLA”) and/or New Drug Application (an “NDA”), as required
by FDA, the Drug Enforcement Administration (the “DEA”), or any other Permits issued by domestic or foreign
regional, federal, state, or local agencies or bodies engaged in the regulation of pharmaceuticals such as those being developed
by the Company and its Subsidiaries (collectively, the “Regulatory Permits”), except for any of the foregoing
that would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect; the Company is in
compliance in all material respects with the requirements of the Regulatory Permits, and all of such Regulatory Permits are valid
and in full force and effect; the Company has not received any notice of proceedings relating to the revocation, termination,
modification or impairment of rights of any of the Regulatory Permits that, individually or in the aggregate, if the subject of
an unfavorable decision, ruling or finding, would reasonably be expected to result in a Material Adverse Effect; the Company has
not failed to submit to the FDA any IND, BLA or NDA necessary to conduct the business of the Company, any such filings that were
required to be made were in material compliance with applicable laws when filed, and no material deficiencies have been asserted
by the FDA with respect to any such filings or submissions that were made.

 

    	 	- 13 -	 

     

    

 

(c) Compliance with
Health Care Laws. Each of the Company and its Subsidiaries is, and at all times has been, in compliance in all material respects
with all applicable Health Care Laws, and has not engaged in activities which are, as applicable, cause for false claims liability,
civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state or federal health care program.
For purposes of this Agreement, “Health Care Laws” means: (i) the Federal Food, Drug, and Cosmetic Act (21
U.S.C. §§ 301 et seq.), the Public Health Service Act (42 U.S.C. §§ 201 et seq.), and the regulations promulgated
thereunder; (ii) all applicable federal, state, local and all applicable foreign health care related fraud and abuse laws, including,
without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the U.S. Physician Payment Sunshine Act (42
U.S.C. § 1320a-7h), the U.S. Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal False Claims Law (42 U.S.C.
§ 1320a-7b(a)), all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections
286 and 287, and the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act
of 1996 (“HIPAA”) (42 U.S.C. Section 1320d et seq.), the exclusion laws (42 U.S.C. § 1320a-7), the civil monetary
penalties law (42 U.S.C. § 1320a-7a), HIPAA, as amended by the Health Information Technology for Economic and Clinical Health
Act (42 U.S.C. Section 17921 et seq.), and the regulations promulgated pursuant to such statutes; (iii) Medicare (Title XVIII
of the Social Security Act); (iv) Medicaid (Title XIX of the Social Security Act); (v) the Controlled Substances Act (21 U.S.C.
§§ 801 et seq.) and the regulations promulgated thereunder; and (vi) any and all other applicable health care laws and
regulations. Neither the Company nor, to the knowledge of the Company, any subsidiary has received notice of any claim, action,
suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental
or regulatory authority or third party alleging that any product operation or activity is in material violation of any Health
Care Laws, and, to the Company’s knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action is threatened. Neither the Company nor, to the knowledge of the Company, any subsidiary is a party
to or has any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring
agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any governmental
or regulatory authority. Additionally, neither the Company, its Subsidiaries nor any of its respective employees, officers or
directors has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical
research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar
action that could reasonably be expected to result in debarment, suspension, or exclusion.

 

2.26       Officers’
Certificate. Any certificate signed by any duly authorized officer of the Company and delivered to you or to Placement Agent
Counsel shall be deemed a representation and warranty by the Company to the Placement Agent as to the matters covered thereby.

 

2.27       Lock-Up
Agreements. Schedule 3 hereto contains a complete and accurate list of the Company’s officers and directors (collectively,
the “Lock-Up Parties”). The Company has caused each of the Lock-Up Parties to deliver to the Placement Agent
an executed Lock-Up Agreement, in the form attached hereto as Exhibit B (the “Lock-Up Agreement”),
prior to the execution of this Agreement.

 

2.28       Subsidiaries.
All direct and indirect Subsidiaries of the Company are duly organized and in good standing under the laws of the place of organization
or incorporation, and each Subsidiary is in good standing in each jurisdiction in which its ownership or lease of property or
the conduct of business requires such qualification, except where the failure to qualify would not have a Material Adverse Change.
The Company’s ownership and control of each Subsidiary is as described in the Registration Statement, the Disclosure Package
and the Prospectus.

 

2.29       Related
Party Transactions.

 

2.29.1     Business
Relationships. There are no business relationships or related party transactions involving the Company or any other person
required to be described in the Registration Statement, the Disclosure Package and the Prospectus that have not been described
as required.

 

2.29.2     No
Relationships with Customers and Suppliers. No relationship, direct or indirect, exists between or among the Company on the
one hand, and the directors, officers, 5% or greater stockholders, customers or suppliers of the Company or any of the Company’s
affiliates on the other hand, which is required to be described in the Disclosure Package and the Prospectus or a document incorporated
by reference therein and which is not so described.

 

    	 	- 14 -	 

     

    

 

2.29.3     No
Unconsolidated Entities. There are no transactions, arrangements or other relationships between and/or among the Company,
any of its affiliates (as such term is defined in Rule 405 of the Securities Act) and any unconsolidated entity, including, but
not limited to, any structure finance, special purpose or limited purpose entity that could reasonably be expected to materially
affect the Company’s liquidity or the availability of or requirements for its capital resources required to be described
in the Disclosure Package and the Prospectus or a document incorporated by reference therein which have not been described as
required.

 

2.29.4     No
Loans or Advances to Affiliates. There are no outstanding loans, advances (except normal advances for business expenses in
the ordinary course of business) or guarantees or indebtedness by the Company to or for the benefit of any of the officers or
directors of the Company, any other affiliates of the Company or any of their respective family members, except as disclosed in
the Registration Statement, the Disclosure Package and the Prospectus.

 

2.30      Board
of Directors. The Board is comprised of the persons disclosed in the Registration Statement, the Disclosure Package and the
Prospectus. The qualifications of the persons serving as Board members and the overall composition of the Board comply with the
Exchange Act, the Exchange Act Regulations, the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder (the “Sarbanes-Oxley
Act”) applicable to the Company and the listing rules of the Exchange. At least one member of the Audit Committee of
the Board qualifies as an “audit committee financial expert,” as such term is defined under Regulation S-K and the
listing rules of the Exchange. In addition, at least a majority of the persons serving on the Board qualify as “independent,”
as defined under the listing rules of the Exchange.

 

2.31       Sarbanes-Oxley
Compliance.

 

2.31.1     Disclosure
Controls. Except as disclosed in the Registration Statement, the Disclosure Package and the Prospectus, the Company has developed
and currently maintains disclosure controls and procedures that will comply with Rule 13a-15 or 15d-15 under the Exchange Act
Regulations, and such controls and procedures are effective to ensure that all material information concerning the Company will
be made known on a timely basis to the individuals responsible for the preparation of the Company’s Exchange Act filings
and other public disclosure documents.

 

2.31.2     Compliance.
The Company is, or at the Applicable Time and on the Closing Date will be, in material compliance with the provisions of the Sarbanes-Oxley
Act applicable to it, and has implemented or will implement such programs and taken reasonable steps to ensure the Company’s
future compliance (not later than the relevant statutory and regulatory deadlines therefor) with all of the material provisions
of the Sarbanes-Oxley Act.

 

2.32       Accounting
Controls. The Company and its Subsidiaries maintain systems of “internal control over financial reporting” (as
defined under Rules 13a-15 and 15d-15 under the Exchange Act Regulations) that comply with the requirements of the Exchange Act
and have been designed by, or under the supervision of, their respective principal executive and principal financial officers,
or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with GAAP, including, but not limited to, internal
accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s
general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements
in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s
general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. Except as disclosed in the Registration Statement,
the Disclosure Package and the Prospectus, the Company is not aware of any material weaknesses in its internal controls. The Company’s
auditors and the Audit Committee of the Board of the Company have been advised of: (i) all significant deficiencies and material
weaknesses in the design or operation of internal controls over financial reporting which are known to the Company’s management
and that have adversely affected or are reasonably likely to adversely affect the Company’ ability to record, process, summarize
and report financial information; and (ii) any fraud known to the Company’s management, whether or not material, that involves
management or other employees who have a significant role in the Company’s internal controls over financial reporting. Since
the date of the latest audited financial statements included in the Disclosure Package, there has been no change in the Company’s
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s
internal control over financial reporting.

 

    	 	- 15 -	 

     

    

 

2.33      No
Investment Company Status. The Company is not and, after giving effect to the Offering and the application of the proceeds
thereof as described in the Registration Statement, the Disclosure Package and the Prospectus, will not be, required to register
as an “investment company,” as defined in the Investment Company Act of 1940, as amended.

 

2.34      No
Labor Disputes. No labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the knowledge
of the Company, is imminent.

 

2.35      Intellectual
Property Rights. The Company and each of its Subsidiaries owns or possesses or has valid rights to use all patents, patent
applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses,
inventions, trade secrets and similar rights (“Intellectual Property Rights”) necessary for the conduct of
the business of the Company and its Subsidiaries as currently carried on and as described in the Registration Statement, the Disclosure
Package and the Prospectus. To the knowledge of the Company, no action or use by the Company or any of its Subsidiaries necessary
for the conduct of its business as currently carried on and as described in the Registration Statement and the Prospectus will
involve or give rise to any infringement of, or license or similar fees (other than license or similar fees described or contemplated
in the Registration Statement, the Disclosure Package and the Prospectus) for, any Intellectual Property Rights of others. Neither
the Company nor any of its Subsidiaries has received any notice alleging any such infringement of, license or similar fees for,
or conflict with, any asserted Intellectual Property Rights of others. Except as would not reasonably be expected to result, individually
or in the aggregate, in a Material Adverse Change, (i) to the knowledge of the Company, there is no infringement, misappropriation
or violation by third parties of any of the Intellectual Property Rights owned by the Company; (ii) there is no pending or, to
the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the rights of the Company in
or to any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any
such claim, that would, individually or in the aggregate, together with any other claims in this Section 2.35, reasonably be expected
to result in a Material Adverse Change; (iii) the Intellectual Property Rights owned by the Company and, to the knowledge of the
Company, the Intellectual Property Rights licensed to the Company have not been adjudged by a court of competent jurisdiction
invalid or unenforceable, in whole or in part, and there is no pending or, to the Company’s knowledge, threatened action,
suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property Rights, and the Company
is unaware of any facts which would form a reasonable basis for any such claim that would, individually or in the aggregate, together
with any other claims in this Section 2.35, reasonably be expected to result in a Material Adverse Change; (iv) there is no pending
or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others that the Company infringes, misappropriates
or otherwise violates any Intellectual Property Rights or other proprietary rights of others, the Company has not received any
written notice of such claim and the Company is unaware of any other facts which would form a reasonable basis for any such claim
that would, individually or in the aggregate, together with any other claims in this Section 2.35, reasonably be expected to result
in a Material Adverse Change; and (v) to the Company’s knowledge, no employee of the Company is in or has ever been in violation
in any material respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition
agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where
the basis of such violation relates to such employee’s employment with the Company, or actions undertaken by the employee
while employed with the Company and could reasonably be expected to result, individually or in the aggregate, in a Material Adverse
Change. To the Company’s knowledge, all material technical information developed by and belonging to the Company which has
not been disclosed in a filed patent application has been kept confidential. The Company is not a party to or bound by any options,
licenses or agreements with respect to the Intellectual Property Rights of any other person or entity that are required to be
set forth in the Registration Statement, the Disclosure Package and the Prospectus and are not described therein. The Registration
Statement, the Disclosure Package and the Prospectus contain in all material respects the same description of the matters set
forth in the preceding sentence. None of the technology employed by the Company has been obtained or is being used by the Company
in violation of any contractual obligation binding on the Company or, to the Company’s knowledge, any of its officers, directors
or employees, or otherwise in violation of the rights of any persons.

 

    	 	- 16 -	 

     

    

 

All licenses for the
use of the Intellectual Property described in the Registration Statement, the Disclosure Package and the Prospectus are in full
force and effect in all material respects and are enforceable by the Company and, to the Company’s knowledge, the other
parties thereto, in accordance with their terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization
or similar laws affecting creditors’ rights generally, (y) as enforceability of any indemnification or contribution provision
may be limited under the federal and state securities laws, and (z) that the remedy of specific performance and injunctive and
other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding
therefor may be brought. None of such agreements or instruments has been assigned by the Company, and the Company has not, and
to the Company’s knowledge, no other party is in default thereunder and no event has occurred that, with the lapse of time
or the giving of notice, or both, would constitute a default thereunder.

 

2.36       Clinical
Studies. All preclinical and clinical studies conducted by or on behalf of the Company Parties that are material to an understanding
of the Company’s business and an investment in the Company Parties, are or have been adequately described in the Registration
Statement, the Disclosure Package and the Prospectus in all material respects. To the Company’s knowledge, after reasonable
inquiry, the clinical and preclinical studies conducted by or on behalf of the Company Parties that are described in the Registration
Statement, the Pricing Package and Prospectus or the results of which are referred to in the Registration Statement, the Disclosure
Package and the Prospectus were and, if still ongoing, are being conducted in material compliance with all laws and regulations
applicable thereto in the jurisdictions in which they are being conducted and with all laws and regulations applicable to preclinical
and clinical studies from which data will be submitted to support marketing approval. The descriptions in the Registration Statement,
the Disclosure Package and the Prospectus of the results of such studies are accurate and complete in all material respects and
fairly present the data derived from such studies, and Company has no knowledge of any large well-controlled clinical study the
aggregate results of which are inconsistent with or otherwise call into question the results of any clinical study conducted by
or on behalf of the Company that are described in the Registration Statement, the Disclosure Package and the Prospectus. Except
as disclosed in the Registration Statement, the Disclosure Package and the Prospectus, the Company has not received any written
notices or statements from the FDA, the European Medicines Agency (“EMA”) or any other Governmental Entity
imposing, requiring, requesting or suggesting a clinical hold, termination, suspension or material modification for or of any
clinical or preclinical studies that are described in the Registration Statement, the Disclosure Package and the Prospectus or
the results of which are referred to in the Registration Statement, the Disclosure Package and the Prospectus, the Company Parties
have not received any written notices or statements from the FDA, the EMA or any other Governmental Entity, and otherwise has
no knowledge or reason to believe, that (i) any investigational new drug application for potential product of the Company is or
has been rejected or determined to be non-approvable or conditionally approvable; and (ii) any license, approval, permit or authorization
to conduct any clinical trial of any potential product of the Company has been, will be or may be suspended, revoked, modified
or limited.

 

    	 	- 17 -	 

     

    

 

2.37       Taxes.
Each of the Company and its Subsidiaries has filed all returns (as hereinafter defined) required to be filed with taxing authorities
prior to the date hereof or has duly obtained extensions of time for the filing thereof. Each of the Company and its Subsidiaries
has paid all taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed on or
assessed against the Company or such respective Subsidiary. The provisions for taxes payable, if any, shown on the financial statements
filed with or as part of the Registration Statement are sufficient for all accrued and unpaid taxes, whether or not disputed,
and for all periods to and including the dates of such consolidated financial statements. Except as disclosed in writing to the
Placement Agent, (i) no issues have been raised (and are currently pending) by any taxing authority in connection with any of
the returns or taxes asserted as due from the Company or its Subsidiaries, and (ii) no waivers of statutes of limitation with
respect to the returns or collection of taxes have been given by or requested from the Company or its Subsidiaries. The term “taxes”
means all federal, state, local, foreign and other net income, gross income, gross receipts, sales, use, ad valorem, transfer,
franchise, profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation,
premium, property, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatever, together
with any interest and any penalties, additions to tax or additional amounts with respect thereto. The term “returns”
means all returns, declarations, reports, statements and other documents required to be filed in respect to taxes.

 

2.38      ERISA
Compliance. The Company and any “employee benefit plan” (as defined under the Employee Retirement Income Security
Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, “ERISA”))
established or maintained by the Company or its “ERISA Affiliates” (as defined below) are in compliance in all material
respects with ERISA. “ERISA Affiliate” means, with respect to the Company, any member of any group of organizations
described in Sections 414(b),(c),(m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published
interpretations thereunder (the “Code”) of which the Company is a member. No “reportable event”
(as defined under ERISA) has occurred or is reasonably expected to occur with respect to any “employee benefit plan”
established or maintained by the Company or any of its ERISA Affiliates. No “employee benefit plan” established or
maintained by the Company or any of its ERISA Affiliates, if such “employee benefit plan” were terminated, would have
any “amount of unfunded benefit liabilities” (as defined under ERISA). Neither the Company nor any of its ERISA Affiliates
has incurred or reasonably expects to incur any material liability under (i) Title IV of ERISA with respect to termination of,
or withdrawal from, any “employee benefit plan” or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each “employee
benefit plan” established or maintained by the Company or any of its ERISA Affiliates that is intended to be qualified under
Section 401(a) of the Code is so qualified and, to the knowledge of the Company, nothing has occurred, whether by action or failure
to act, which would cause the loss of such qualification.

 

    	 	- 18 -	 

     

    

 

2.39       Compliance
with Laws. The Company: (i) is and at all times has been in compliance with all statutes, rules, or regulations applicable
to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion,
sale, offer for sale, storage, import, export storage or disposal of any product manufactured or distributed by the Company (“Applicable
Laws”), except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change;
(ii) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or
written notice from the FDA or any other governmental authority alleging or asserting noncompliance with any Applicable Laws or
any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any
such Applicable Laws (“Authorizations”); (iii) possesses all material Authorizations and such Authorizations
are valid and in full force and effect and are not in material violation of any term of any such Authorizations; (iv) has not
received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action
from any governmental authority or third party alleging that any product operation or activity is in violation of any Applicable
Laws or Authorizations and has no knowledge that any such governmental authority or third party is considering any such claim,
litigation, arbitration, action, suit, investigation or proceeding; (v) has not received written notice that any governmental
authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge
that any such governmental authority is considering such action; (vi) has filed, obtained, maintained or submitted all material
reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any
Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments were complete and correct in all material respects on the date filed (or were corrected or supplemented
by a subsequent submission); and (vii) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused
to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post-sale warning, “dear
doctor” letter, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged
product defect or violation and, to the Company’s knowledge, no third party has initiated, conducted or intends to initiate
any such notice or action.

 

2.40       Environmental
Laws. The Company and its Subsidiaries are in compliance with all foreign, federal, state and local rules, laws and regulations
relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of health and safety
or the environment which are applicable to their businesses (“Environmental Laws”), except where the failure
to comply would not, singularly or in the aggregate, result in a Material Adverse Change. There has been no storage, generation,
transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic or other wastes or other
hazardous substances by, due to, or caused by the Company or any of its Subsidiaries (or, to the Company’s knowledge, any
other entity for whose acts or omissions the Company or any of its Subsidiaries is or may otherwise be liable) upon any of the
property now or previously owned or leased by the Company or any of its Subsidiaries, or upon any other property, in violation
of any law, statute, ordinance, rule, regulation, order, judgment, decree or permit or which would, under any law, statute, ordinance,
rule (including rule of common law), regulation, order, judgment, decree or permit, give rise to any liability; and there has
been no disposal, discharge, emission or other release of any kind onto such property or into the environment surrounding such
property of any toxic or other wastes or other hazardous substances with respect to which the Company has knowledge. In the ordinary
course of business, the Company and its Subsidiaries conduct periodic reviews of the effect of Environmental Laws on their business
and assets, in the course of which they identify and evaluate associated costs and liabilities (including, without limitation,
any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or governmental
permits issued thereunder, any related constraints on operating activities and any potential liabilities to third parties). On
the basis of such reviews, the Company and its Subsidiaries have reasonably concluded that such associated costs and liabilities
would not have, singularly or in the aggregate, a Material Adverse Change.

 

2.41         Real
Property. Except as set forth in the Registration Statement, the Disclosure Package and the Prospectus, the Company and each
of its Subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items
of real or personal property which are material to the business of the Company and its Subsidiaries taken as a whole, in each
case free and clear of all liens, encumbrances, security interests, claims and defects that do not, singly or in the aggregate,
materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by
the Company or any of its Subsidiaries; and all of the leases and subleases material to the business of the Company and its subsidiaries,
considered as one enterprise, and under which the Company or any of its subsidiaries holds properties described in the Registration
Statement, the Disclosure Package and the Prospectus, are in full force and effect, and neither the Company nor any Subsidiary
has received any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company
or any Subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company
or such Subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease.

 

    	 	- 19 -	 

     

    

 

2.42      Contracts
Affecting Capital. There are no transactions, arrangements or other relationships between and/or among the Company, any of
its affiliates (as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated entity, including,
but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably be expected to materially
affect the Company’s or any of its Subsidiaries’ liquidity or the availability of or requirements for their capital
resources required to be described or incorporated by reference in the Registration Statement, the Disclosure Package and the
Prospectus which have not been described or incorporated by reference as required.

 

2.43      Ineligible
Issuer. At the time of filing the Registration Statement and any post-effective amendment thereto, at the time of effectiveness
of the Registration Statement and any amendment thereto, at the earliest time thereafter that the Company or another offering
participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the Securities Act Regulations) of the Common Shares
and at the date hereof, the Company was not and is not an “ineligible issuer,” as defined in Rule 405, without taking
account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an
ineligible issuer.

 

2.44       Industry
Data. The statistical and market-related data included in each of the Registration Statement, the Disclosure Package and the
Prospectus are based on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate
or represent the Company’s good faith estimates that are made on the basis of data derived from such sources.

 

2.45       Margin
Securities. The Company owns no “margin securities” as that term is defined in Regulation U of the Board of Governors
of the Federal Reserve System (the “Federal Reserve Board”), and none of the proceeds of Offering will be used,
directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring
any indebtedness which was originally incurred to purchase or carry any margin security or for any other purpose which might cause
any of the shares of Common Stock to be considered a “purpose credit” within the meanings of Regulation T, U or X
of the Federal Reserve Board.

 

2.46      Exchange
Act Reports. The Company has filed in a timely manner all reports required to be filed pursuant to Sections 13(a), 13(e),
14 and 15(d) of the Exchange Act during the preceding 12 months (except to the extent that Section 15(d) requires reports to be
filed pursuant to Sections 13(d) and 13(g) of the Exchange Act, which shall be governed by the next clause of this sentence);
and the Company has filed in a timely manner all reports required to be filed pursuant to Sections 13(d) and 13(g) of the Exchange
Act since January 1, 2016, except where the failure to timely file could not reasonably be expected, individually or in the aggregate,
to have a Material Adverse Change.

 

2.47      Minute
Books. The minute books of the Company have been made available to the Placement Agent and counsel for the Placement Agent,
and such books (i) contain a complete summary of all meetings and actions of the Board (including each Board committee) and stockholders
of the Company (or analogous governing bodies and interest holders, as applicable), and each of its Subsidiaries since the time
of its respective incorporation or organization through the date of the latest meeting and action, except those meetings protected
by attorney client privilege, and (ii) accurately in all material respects reflect all transactions referred to in such minutes.
There are no material transactions, agreements, dispositions or other actions of the Company that are not properly approved and/or
accurately and fairly recorded in the minute books of the Company, as applicable, except as would not be expected to have a Material
Adverse Change.

 

    	 	- 20 -	 

     

    

 

2.48      Integration.
Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause the Offering
to be integrated with prior offerings by the Company for purposes of the Securities Act that would require the registration of
any such securities under the Securities Act.

 

2.49      No
Stabilization. Neither the Company nor, to its knowledge, any of its employees, directors or stockholders (without the consent
of the Placement Agent) has taken or shall take, directly or indirectly, any action designed to or that has constituted or that
might reasonably be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation
of the price of any security of the Company to facilitate the sale or resale of the Common Shares.

 

2.50      Confidentiality
and Non-Competition. To the Company’s knowledge, no director, officer, key employee or consultant of the Company is
subject to any confidentiality, non-disclosure, non-competition agreement or non-solicitation agreement with any employer or prior
employer that could reasonably be expected to materially affect his ability to be and act in his respective capacity of the Company
or be expected to result in a Material Adverse Change.

 

		3.	Covenants of the Company. The Company covenants
and agrees as follows:

 

3.1        Amendments
to Registration Statement. The Company shall deliver to the Placement Agent, prior to filing, any amendment or supplement
to the Registration Statement, Preliminary Prospectus, Disclosure Package or Prospectus proposed to be filed after the Effective
Date and not file any such amendment or supplement to which the Placement Agent shall reasonably object in writing.

 

3.2        Federal
Securities Laws.

 

3.2.1           Compliance.
The Company, subject to Section 3.2.2, shall comply with the requirements of Rule 424(b) and Rule 430B of the Securities Act Regulations,
and will notify the Placement Agent promptly, and confirm the notice in writing, (i) when any post-effective amendment to the
Registration Statement or any amendment or supplement to any Preliminary Prospectus, the Disclosure Package or the Prospectus
shall have been filed and when any post-effective amendment to the Registration Statement shall become effective; (ii) of the
receipt of any comments from the Commission; (iii) of any request by the Commission for any amendment to the Registration Statement
or any amendment or supplement to any Preliminary Prospectus, the Disclosure Package or the Prospectus or for additional information;
(iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective
amendment or of any order preventing or suspending the use of any Preliminary Prospectus, the Disclosure Package or the Prospectus,
or of the suspension of the qualification of the Common Shares for offering or sale in any jurisdiction, or of the initiation
or threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the Securities
Act concerning the Registration Statement; and (v) if the Company becomes the subject of a proceeding under Section 8A of the
Securities Act in connection with the Offering of the Common Shares. The Company shall effect all filings required under Rule
424(b) of the Securities Act Regulations, in the manner and within the time period required by Rule 424(b) (without reliance on
Rule 424(b)(8)), and shall take such steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted
for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file
such prospectus. The Company shall use its best efforts to prevent the issuance of any stop order, prevention or suspension and,
if any such order is issued, to obtain the lifting thereof at the earliest possible moment.

 

    	 	- 21 -	 

     

    

 

3.2.2        Continued
Compliance. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the Exchange
Act Regulations so as to permit the completion of the distribution of the Common Shares as contemplated in this Agreement and
in the Registration Statement, the Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Common
Shares is (or, but for the exception afforded by Rule 172 of the Securities Act Regulations (“Rule 172”), would
be) required by the Securities Act to be delivered in connection with sales of the Common Shares, any event shall occur or condition
shall exist as a result of which it is necessary, in the opinion of counsel for the Placement Agent or for the Company, to (i)
amend the Registration Statement in order that the Registration Statement will not include an untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii)
amend or supplement the Disclosure Package or the Prospectus in order that the Disclosure Package or the Prospectus, as the case
may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein not misleading in the light of the circumstances existing at the time it is delivered to a purchaser or (iii)
amend the Registration Statement or amend or supplement the Disclosure Package or the Prospectus, as the case may be, in order
to comply with the requirements of the Securities Act or the Securities Act Regulations, the Company will promptly (A) give the
Placement Agent notice of such event; (B) prepare any amendment or supplement as may be necessary to correct such statement or
omission or to make the Registration Statement, the Disclosure Package or the Prospectus comply with such requirements and, a
reasonable amount of time prior to any proposed filing or use, furnish the Placement Agent with copies of any such amendment or
supplement and (C) file with the Commission any such amendment or supplement; provided, however, that the Company
shall not file or use any such amendment or supplement to which the Placement Agent or counsel for the Placement Agent shall reasonably
object. The Company will furnish to the Placement Agent such number of copies of such amendment or supplement as the Placement
Agent may reasonably request. The Company has given the Placement Agent notice of any filings made pursuant to the Exchange Act
or the Exchange Act Regulations within 48 hours prior to the Applicable Time. The Company shall give the Placement Agent notice
of its intention to make any such filing from the Applicable Time until the Closing Date and will furnish the Placement Agent
with copies of the related document(s) a reasonable amount of time prior to such proposed filing, as the case may be, and will
not file or use any such document to which the Placement Agent or counsel for the Placement Agent shall reasonably object.

 

3.2.3       Exchange
Act Registration. For a period of three (3) years after the date of this Agreement, the Company shall use its best efforts
to maintain the registration of the shares of Common Stock under the Exchange Act. The Company shall not deregister the shares
of Common Stock under the Exchange Act without the prior written consent of the Placement Agent.

 

3.2.4       Free
Writing Prospectuses. The Company agrees that, unless it obtains the prior written consent of the Placement Agent, it shall
not make any offer relating to the Common Shares that would constitute an Issuer Free Writing Prospectus or that would otherwise
constitute a “free writing prospectus,” or a portion thereof, required to be filed by the Company with the Commission
or retained by the Company under Rule 433; provided, however, that the Placement Agent shall be deemed to have consented
to each Issuer General Use Free Writing Prospectus hereto and any “road show that is a written communication” within
the meaning of Rule 433(d)(8)(i) that has been reviewed by the Placement Agent. The Company represents that it has treated or
agrees that it will treat each such free writing prospectus consented to, or deemed consented to, by the Placement Agent as an
“issuer free writing prospectus,” as defined in Rule 433, and that it has complied and will comply with the applicable
requirements of Rule 433 with respect thereto, including timely filing with the Commission where required, legending and record
keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development
as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration
Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading,
the Company will promptly notify the Placement Agent and will promptly amend or supplement, at its own expense, such Issuer Free
Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.

 

    	 	- 22 -	 

     

    

 

3.3        Delivery
to the Placement Agent of Registration Statements. The Company has delivered or made available or shall deliver or make available
to the Placement Agent and counsel for the Placement Agent, without charge, signed copies of the Registration Statement as originally
filed and each amendment thereto (including exhibits filed therewith or incorporated by reference therein and documents incorporated
or deemed to be incorporated by reference therein) and signed copies of all consents and certificates of experts, and will also
deliver to the Placement Agent, without charge, a conformed copy of the Registration Statement as originally filed and each amendment
thereto (without exhibits) for each of the Placement Agent. The copies of the Registration Statement and each amendment thereto
furnished to the Placement Agent will be identical to the electronically transmitted copies thereof filed with the Commission
pursuant to EDGAR, except to the extent permitted by Regulation S-T.

 

3.4        Delivery
to the Placement Agent of Prospectuses. The Company has delivered or made available or will deliver or make available to the
Placement Agent, without charge, as many copies of each Preliminary Prospectus as Placement Agent reasonably requested, and the
Company hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to Placement
Agent, without charge, during the period when a prospectus relating to the Common Shares is (or, but for the exception afforded
by Rule 172, would be) required to be delivered under the Securities Act, such number of copies of the Prospectus (as amended
or supplemented) as Placement Agent may reasonably request. The Prospectus and any amendments or supplements thereto furnished
to Placement Agent will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR,
except to the extent permitted by Regulation S-T.

 

3.5        Events
Requiring Notice to the Placement Agent. The Company shall use its best efforts to cause the Registration Statement to remain
effective with a current prospectus for at least nine (9) months after the Applicable Time, and shall notify the Placement Agent
immediately and confirm the notice in writing: (i) of the issuance by the Commission of any stop order or of the initiation, or
the threatening, of any proceeding for that purpose; (ii) of the issuance by any state securities commission of any proceedings
for the suspension of the qualification of the Common Shares for offering or sale in any jurisdiction or of the initiation, or
the threatening, of any proceeding for that purpose; (iii) of the mailing and delivery to the Commission for filing of any amendment
or supplement to the Registration Statement or Prospectus; (iv) of the receipt of any comments or request for any additional information
from the Commission; and (v) of the happening of any event during the period described in this Section 3.5 that, in the judgment
of the Company, makes any statement of a material fact made in the Registration Statement, the Disclosure Package or the Prospectus
untrue or that requires the making of any changes in (a) the Registration Statement in order to make the statements therein not
misleading, or (b) in the Disclosure Package or the Prospectus in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. If the Commission or any state securities commission shall enter a stop order or suspend
such qualification at any time, the Company shall make every reasonable effort to obtain promptly the lifting of such order.

 

    	 	- 23 -	 

     

    

  

3.6        Review
of Financial Statements. For a period of five (5) years after the date of this Agreement, the Company, at its expense, shall
cause its regularly engaged independent registered public accounting firm to review (but not audit) the Company’s financial
statements for each of the three fiscal quarters immediately preceding the announcement of any quarterly financial information.

 

3.7        Listing.
The Company shall use its best efforts to maintain the listing of the shares of Common Stock (including the Common Shares) on
the Exchange for at least three years from the date of this Agreement.

 

3.8        Financial
Public Relations Firm. The Company has retained a financial public relations firm reasonably acceptable to the Placement Agent
and the Company, which shall be mutually agreed to by the Placement Agent and Company and shall be experienced in assisting issuers
in public offerings of securities and in their relations with their security holders, and shall retain such firm or another firm
reasonably acceptable to the Placement Agent for a period of not less than two (2) years after the Effective Date.

 

3.9        Reports
to the Placement Agent.

 

3.9.1       Periodic
Reports, etc. For a period of three (3) years after the date of this Agreement, the Company shall furnish or make available
to the Placement Agent copies of such financial statements and other periodic and special reports as the Company from time to
time furnishes generally to holders of any class of its securities and also promptly furnish to the Placement Agent: (i) a copy
of each periodic report the Company shall be required to file with the Commission under the Exchange Act and the Exchange Act
Regulations; (ii) a copy of every material press release and every material news item and article with respect to the Company
or its affairs which was released by the Company; (iii) a copy of each Form 8-K prepared and filed by the Company; (iv) five copies
of each registration statement filed by the Company under the Securities Act; (v) a copy of each report or other communication
furnished to stockholders and (vi) such additional documents and information with respect to the Company and the affairs of any
future subsidiaries of the Company as the Placement Agent may from time to time reasonably request; provided, however,
the Placement Agent shall sign, if requested by the Company, a Regulation FD compliant confidentiality agreement which is reasonably
acceptable to the Placement Agent and Placement Agent Counsel in connection with the Placement Agent’s receipt of such information.
Documents filed with the Commission pursuant to its EDGAR system shall be deemed to have been delivered to the Placement Agent
pursuant to this Section 3.9.1.

 

3.9.2       Transfer
Agent; Transfer Sheets. For a period of three (3) years after the date of this Agreement, the Company shall retain a transfer
agent and registrar acceptable to the Placement Agent (the “Transfer Agent”) and shall furnish to the Placement
Agent at the Company’s sole cost and expense such transfer sheets of the Company’s securities as the Placement Agent
may reasonably request, including the daily and monthly consolidated transfer sheets of the Transfer Agent. Corporate Stock Transfer,
Inc. is acceptable to the Placement Agent to act as Transfer Agent for the shares of Common Stock.

 

3.9.3       Trading
Reports. During such time as the Common Shares are listed on the Exchange, the Company shall provide
to the Placement Agent, at the Company’s expense, such reports published by Exchange relating to price trading of the Common
Shares, as the Placement Agent shall reasonably request.

 

    	 	- 24 -	 

     

    

 

3.10         Payment
of Expenses. The Company hereby agrees to pay on the Closing Date all expenses incident to the performance of the obligations
of the Company under this Agreement, including, but not limited to: (i) all filing fees and communication expenses relating to
the registration of Common Shares to be issued and sold in the Offering with the Commission; (ii) all filing fees associated with
the review of the Offering by FINRA; (iii) all fees and expenses relating to the listing of such Common Shares on the Exchange,
including any fees charged by The Depository Trust Company (DTC) for new securities; (iv) all fees, expenses and disbursements
relating to background checks of the Company’s officers and directors in an amount not to exceed $10,000 in the aggregate;
(v) all fees, expenses and disbursements relating to the registration, qualification or exemption of the Common Shares under the
securities laws of such foreign jurisdictions as the Placement Agent may reasonably designate; (vi) the costs of all mailing and
printing of the offering documents (including, without limitation, this Agreement, any blue sky surveys and, if appropriate, any
agreement among placement agents, sub-placement agreement, sub-placement questionnaire and power of attorney), Registration Statements,
Prospectuses and all amendments, supplements and exhibits thereto and as many preliminary and final Prospectuses as the Placement
Agent may reasonably deem necessary; (vii) the costs and expenses of the public relations firm referred to in Section 3.8 hereof;
(viii) the costs of preparing, printing and delivering certificates representing the Common Shares; (ix) fees and expenses of
the Transfer Agent for the shares of Common Stock; (x) stock transfer and/or stamp taxes, if any, payable upon the transfer of
securities from the Company to the Placement Agent; (xi) to the extent approved by the Company in writing, the costs associated
with post-Closing advertising of the Offering in the national editions of The Wall Street Journal and The New York Times; (xii)
up to $3,000 of the costs associated with bound volumes of the public offering materials as well as commemorative mementos and
lucite tombstones, each of which the Company or its designee will provide within a reasonable time after the Closing in such quantities
as the Placement Agent may reasonably request; (xiii) the fees and expenses of the Company’s accountants; (xiv) the fees
and expenses of the Company’s legal counsel and other agents and Placement Agents; (xv) the reasonable and documented fees
and expenses of Placement Agent’s legal counsel not to exceed $75,000; (xvi) the $29,500 cost associated with the Placement
Agent’ use of Ipreo’s book building, prospectus tracking and compliance software for the Offering; and (xvii) up to
$20,000 of the Placement Agent’ actual accountable “road show” expenses for the offering. The Placement Agent
may deduct from the net proceeds of the Offering payable to the Company on the Closing Date, the expenses set forth herein to
be paid by the Company to the Placement Agent less the $25,000 advance paid by the Company to the Placement Agent upon execution
of the engagement agreement with the Placement Agent (“Advance”), provided, however, that in the event that
the Offering is terminated, the Company agrees to reimburse the Placement Agent for each of the foregoing amounts up to $200,000
(inclusive of the Advance). Notwithstanding the foregoing, any advance received by Placement Agent will be reimbursed to the Company
to the extent not actually incurred in complaince with FINRA Rule 5110(f)(2)(C).

 

3.11      Non-accountable
Expenses. The Company further agrees that, in addition to the expenses payable pursuant to Section 3.10.1, on the Closing
Date it shall pay to the Placement Agent, by deduction from the net proceeds of the Offering contemplated herein, a non-accountable
expense allowance equal to one percent (1.0%) of the gross proceeds received by the Company from the sale of the Common Shares),
less the Advance (as such term is defined in Section 8.3 hereof), provided, however, that in the event that the Offering is terminated,
the Company agrees to reimburse the Placement Agent pursuant to Section 8.3 hereof.

 

3.12      Application
of Net Proceeds. The Company shall apply the net proceeds from the Offering received by it in a manner consistent with the
application thereof described under the caption “Use of Proceeds” in the Registration Statement, the Disclosure Package
and the Prospectus.

 

3.13      Delivery
of Earnings Statements to Security Holders. The Company shall make generally available to its security holders as soon as
practicable, but not later than the first day of the fifteenth (15th) full calendar month following the date of this
Agreement, an earnings statement (which need not be certified by independent registered public accounting firm unless required
by the Securities Act or the Securities Act Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a)
of the Securities Act) covering a period of at least twelve (12) consecutive months beginning after the date of this Agreement.

 

    	 	- 25 -	 

     

    

 

3.14      Stabilization.
Neither the Company nor, to its knowledge, any of its employees, directors or shareholders (without the consent of the Placement
Agent) has taken or shall take, directly or indirectly, any action designed to or that has constituted or that might reasonably
be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the
price of any security of the Company to facilitate the sale or resale of the Common Shares.

 

3.15      Internal
Controls. The Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances
that: (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions
are recorded as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability
for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization;
and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action
is taken with respect to any differences.

 

3.16      Accountants.
As of the date of this Agreement, the Company shall continue to retain a nationally recognized independent registered public accounting
firm for a period of at least three (3) years after the date of this Agreement. The Placement Agent acknowledges that Plante &
Moran, PLLC is acceptable to the Placement Agent.

 

3.17      FINRA.
The Company shall advise the Placement Agent (who shall make an appropriate filing with FINRA) if it is or becomes aware that
(i) any officer or director of the Company, (ii) any beneficial owner of 5% or more of any class of the Company's securities or
(iii) any beneficial owner of the Company's unregistered equity securities which were acquired during the 180 days immediately
preceding the filing of the Registration Statement is or becomes an affiliate or associated person of a FINRA member participating
in the Offering (as determined in accordance with the rules and regulations of FINRA).

 

3.18      No
Fiduciary Duties. The Company acknowledges and agrees that the Placement Agent’ responsibility to the Company is solely
contractual in nature and that none of the Placement Agent or their affiliates or any selling agent shall be deemed to be acting
in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering
and the other transactions contemplated by this Agreement.

 

3.19      Restriction
on Continuous Offerings. Notwithstanding the restrictions contained in Section 3.18, the Company, on behalf of itself and
any successor entity, agrees that, without the prior written consent of the Placement Agent, it will not, for a period of 12 months
after the date of this Agreement, directly or indirectly in any “at-the-market” or continuous equity transaction,
offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of shares of capital stock of the Company
or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company.

 

3.20      Company
Lock-Up Agreements. The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent
of the Placement Agent, it will not for a period of ninety (90) days after the date of this Agreement (the “Lock-Up Period”),
(i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant
any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital
stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company;
(ii) file or cause to be filed any registration statement with the Commission relating to the offering of any shares of capital
stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company;
or (iii) complete any offering of debt securities of the Company, other than entering into a line of credit with a traditional
bank or (iv) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences
of ownership of capital stock of the Company, whether any such transaction described in clause (i), (ii), (iii) or (iv) above
is to be settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise.

 

    	 	- 26 -	 

     

    

 

The restrictions contained
in this Section 3.20 shall not apply to (i) the shares of Common Stock and the Placement Agent’s Warrant to be sold hereunder,
(ii) the issuance by the Company of shares of Common Stock upon the exercise of the Placement Agent’s Warrant or a stock
option or warrant or the conversion of a security outstanding on the date hereof, which is disclosed in the Registration Statement,
Disclosure Package and Prospectus, (iii) the issuance by the Company of stock options, shares of capital stock of the Company
or other awards under any equity compensation plan of the Company and (iv) securities issued pursuant to acquisitions or strategic
transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only
be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an
owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits
in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily
for the purpose of raising capital or to an entity whose primary business is investing in securities, provided that in each of
(ii), (iii) and (iv) above, the underlying shares shall be restricted from sale during the entire Lock-Up Period.

 

3.21         Release
of D&O Lock-up Period. If the Placement Agent, in its sole discretion, agrees to release or waive the restrictions set
forth in the Lock-Up Agreements described in Section 2.27 hereof for an officer or director of the Company and provide the Company
with notice of the impending release or waiver at least three (3) Business Days before the effective date of the release or waiver,
the Company agrees to announce the impending release or waiver by a press release substantially in the form of Exhibit B
hereto through a major news service at least two (2) Business Days before the effective date of the release or waiver.

 

3.22         Blue
Sky Qualifications. The Company shall use its best efforts, in cooperation with the Placement Agent, if necessary, to qualify
the Common Shares for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic
or foreign) as the Placement Agent may designate and to maintain such qualifications in effect so long as required to complete
the distribution of the Common Shares; provided, however, that the Company shall not be obligated to file any general
consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which
it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise
so subject.

 

3.23         Reporting
Requirements. The Company, during the period when a prospectus relating to the Common Shares is (or, but for the exception
afforded by Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be filed
with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations.
Additionally, the Company shall report the use of proceeds from the issuance of the Common Shares as may be required under Rule
463 under the Securities Act Regulations.

 

3.24         Press
Releases. Prior to the Closing Date, the Company shall not issue any press release or other communication directly or indirectly
or hold any press conference with respect to the Company, its condition, financial or otherwise, or earnings, business affairs
or business prospects (except for routine oral marketing communications in the ordinary course of business and consistent with
the past practices of the Company and of which the Placement Agent is notified), without the prior written consent of the Placement
Agent, which consent shall not be unreasonably withheld, unless in the judgment of the Company and its counsel, and after notification
to the Placement Agent, such press release or communication is required by law.

 

    	 	- 27 -	 

     

    

 

3.25       Sarbanes-Oxley.
Except as disclosed in the Registration Statement, the Disclosure Package and the Prospectus, the Company shall at all times comply
with all applicable provisions of the Sarbanes-Oxley Act in effect from time to time.

 

4.          Conditions
of Placement Agent’s Obligations. The obligations of the Buyers to purchase and pay for the Common Shares, as provided
in the Securities Purchase Agreement, and the obligations of the Placement Agent to arrange for the aggregate purchase amount
to be paid to the Company, shall be subject to (i) the continuing accuracy of the representations and warranties of the Company
as of the date hereof and as of each of the Closing Date; (ii) the accuracy of the statements of officers of the Company made
pursuant to the provisions hereof; (iii) the performance by the Company of its obligations hereunder; and (iv) the following conditions:

 

4.1         Regulatory
Matters.

 

4.1.1       Commission
Actions; Required Filings. At the Closing Date, no stop order suspending the effectiveness of the Registration Statement or
any post-effective amendment thereto shall have been issued under the Securities Act, no order preventing or suspending the use
of any Preliminary Prospectus or the Prospectus shall have been issued and no proceedings for any of those purposes shall have
been instituted or are pending or, to the Company’s knowledge, contemplated by the Commission. The Company has complied
with each request (if any) from the Commission for additional information. A prospectus containing the Rule 430B Information shall
have been filed with the Commission in the manner and within the time frame required by Rule 424(b) under the Securities Act Regulations
(without reliance on Rule 424(b)(8)) or a post-effective amendment providing such information shall have been filed with, and
declared effective by, the Commission in accordance with the requirements of Rule 430B under the Securities Act Regulations.

 

4.1.2       FINRA
Clearance. On or before the date of this Agreement, the Placement Agent shall have received clearance from FINRA as to the
amount of compensation allowable or payable to the Placement Agent as described in the Registration Statement.

 

4.1.3       Exchange Stock
Market Clearance. On the Closing Date, the Company’s shares of Common Stock, including the Common Shares, shall have
been approved for listing on the Exchange, subject only to official notice of issuance.

 

4.2        Company
Counsel Matters.

 

4.2.1        Closing
Date Opinion of Counsel. On the Closing Date, the Placement Agent shall have received the favorable opinion of Squire Patton
Boggs (US) LLP, counsel to the Company, and a written statement providing certain “10b-5” negative assurances, dated
the Closing Date and addressed to the Placement Agent and each Other Investor not party to the Securities Purchase Agreement,
substantially in the form of Exhibit C attached hereto.

 

4.2.2        Opinion
of Special Intellectual Property Counsel for the Company. On the Closing Date, the Placement Agent shall have received the
opinion of Sheridan Ross P.C., as special intellectual property counsel for the Company, and a written statement providing certain
“10b-5” negative assurances, dated the Closing Date and addressed to the Placement Agent, in a form reasonably acceptable
to the Placement Agent.

 

4.2.3        Opinion
of Special Regulatory Counsel for the Company. On the Closing Date, the Placement Agent shall have received the opinion of
Hogan Lovells US LLP, as special regulatory counsel for the Company, in a form reasonably acceptable to the Placement Agent.

 

    	 	- 28 -	 

     

    

 

4.2.4       Reliance.
In rendering such opinions, such counsel may rely: (i) as to matters involving the application of laws other than the laws of
the United States and jurisdictions in which they are admitted, to the extent such counsel deems proper and to the extent specified
in such opinion, if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to the Placement Agent)
of other counsel reasonably acceptable to the Placement Agent, familiar with the applicable laws; and (ii) as to matters of fact,
to the extent they deem proper, on certificates or other written statements of officers of the Company and officers of departments
of various jurisdictions having custody of documents respecting the corporate existence or good standing of the Company; provided
that copies of any such statements or certificates shall be delivered to Placement Agent Counsel if requested. The opinions
of Squire Patton Boggs (US) LLP, and any opinion relied upon by Squire Patton Boggs (US) LLP, shall include a statement to the
effect that it may be relied upon by Placement Agent Counsel in its opinion delivered to the Placement Agent.

 

4.3         Comfort
Letters.

 

4.3.1       Cold
Comfort Letter. At the time this Agreement is executed you shall have received cold comfort letters from the Auditors containing
statements and information of the type customarily included in accountants’ comfort letters with respect to the financial
statements and certain financial information contained or incorporated or deemed incorporated by reference in the Registration
Statement, the Disclosure Package and the Prospectus, addressed to the Placement Agent and in form and substance satisfactory
in all respects to you and to the Auditors, dated as of the date of this Agreement.

 

4.3.2       Bring-down
Comfort Letter. At the Closing Date the Placement Agent shall have received from the Auditors a letter, dated as of the Closing
Date to the effect that the Auditors reaffirm the statements made in their letters furnished pursuant to Section 4.3.1, except
that the specified date referred to shall be a date not more than three (3) business days prior to the Closing Date, as applicable.

 

4.4         Officers’
Certificates.

 

4.4.1        Officer’s
Certificate. The Company shall have furnished to the Placement Agent and each Other Investor not party to the Securities Purchase
Agreement a certificate, dated the Closing Date, of its Chief Executive Officer stating that (i) such officer has carefully examined
the Registration Statement, the Disclosure Package, any Issuer Free Writing Prospectus and the Prospectus and, in his opinion,
the Registration Statement and each amendment thereto, as of the Applicable Time and as of the Closing Date did not include any
untrue statement of a material fact and did not omit to state a material fact required to be stated therein or necessary to make
the statements therein not misleading, and the Disclosure Package, as of the Applicable Time and as of the Closing Date, any Issuer
Free Writing Prospectus as of its date and as of the Closing Date, and the Prospectus and each amendment or supplement thereto,
as of the respective date thereof and as of the Closing Date, did not include any untrue statement of a material fact and did
not omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances in which
they were made, not misleading, (ii) since the effective date of the Registration Statement, no event has occurred which should
have been, and was not, set forth in a supplement or amendment to the Registration Statement, the Disclosure Package or the Prospectus,
(iii) to the best of his knowledge after reasonable investigation, as of the Closing Date, the representations and warranties
of the Company in this Agreement are true and correct and the Company has complied with all agreements and satisfied all conditions
on its part to be performed or satisfied hereunder at or prior to the Closing Date, and (iv) there has not been, subsequent to
the date of the most recent audited financial statements included or incorporated by reference in the Disclosure Package, any
material adverse change in the financial position or results of operations of the Company, or any change or development that,
singularly or in the aggregate, would involve a material adverse change or a prospective material adverse change, in or affecting
the condition (financial or otherwise), results of operations, business, assets or prospects of the Company, except as set forth
in the Prospectus.

 

    	 	- 29 -	 

     

    

 

4.4.2       Secretary’s
Certificate. At the Closing Date, the Placement Agent shall have received a certificate of the Company signed by the Secretary
of the Company, dated the Closing Date certifying: (i) that each of the Charter and Bylaws is true and
complete, has not been modified and is in full force and effect; (ii) that the resolutions of the Board relating to the Offering
are in full force and effect and have not been modified; (iii) as to the accuracy and completeness of all correspondence between
the Company or its counsel and the Commission; and (iv) as to the incumbency of the officers of the Company. The documents referred
to in such certificate shall be attached to such certificate.

 

4.5         No
Material Changes. Prior to and on the Closing Date: (i) there shall have been no material adverse change or development involving
a prospective material adverse change in the condition or prospects or the business activities, financial or otherwise, of the
Company from the latest dates as of which such condition is set forth in the Registration Statement and no change in the capital
stock or debt of the Company, the Disclosure Package and the Prospectus; (ii) no action, suit or proceeding, at law or in equity,
shall have been pending or threatened against the Company or any Insider before or by any court or federal or state commission,
board or other administrative agency wherein an unfavorable decision, ruling or finding may materially adversely affect the business,
operations, prospects or financial condition or income of the Company, except as set forth in the Registration Statement, the
Disclosure Package and the Prospectus; (iii) no stop order shall have been issued under the Securities Act and no proceedings
therefor shall have been initiated or threatened by the Commission; (iv) no action shall have been taken and no law, statute,
rule, regulation or order shall have been enacted, adopted or issued by any Governmental Entity which would prevent the issuance
or sale of the Common Shares or materially and adversely affect or potentially materially and adversely affect the business or
operations of the Company; (v) no injunction, restraining order or order of any other nature by any federal or state court of
competent jurisdiction shall have been issued which would prevent the issuance or sale of the Common Shares or materially and
adversely affect or potentially materially and adversely affect the business or operations of the Company and (vi) the Registration
Statement, the Disclosure Package and the Prospectus and any amendments or supplements thereto shall contain all material statements
which are required to be stated therein in accordance with the Securities Act and the Securities Act Regulations and shall conform
in all material respects to the requirements of the Securities Act and the Securities Act Regulations, and neither the Registration
Statement, the Disclosure Package, the Prospectus nor any amendment or supplement thereto shall contain any untrue statement of
a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading.

 

4.6         Corporate
Proceedings. All corporate proceedings and other legal matters incident to the authorization, form and validity of each of
this Agreement, the Common Shares, the Registration Statement, the Disclosure Package and the Prospectus and all other legal matters
relating to this Agreement and the transactions contemplated hereby and thereby shall be reasonably satisfactory in all material
respects to counsel for the Placement Agent, and the Company shall have furnished to such counsel all documents and information
that they may reasonably request to enable them to pass upon such matters.

 

4.7         Delivery
of Agreements.

 

4.7.1       Lock-Up
Agreements. On or before the date of this Agreement, the Company shall have delivered to the Placement Agent executed copies
of the Lock-Up Agreements from each of the persons listed in Schedule 3 hereto.

 

    	 	- 30 -	 

     

    

 

4.8         Additional
Documents. At the Closing Date, Placement Agent Counsel shall have been furnished with such documents and opinions as they
may require for the purpose of enabling Placement Agent Counsel to deliver an opinion to the Placement Agent, or in order to evidence
the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions, herein contained; and all
proceedings taken by the Company in connection with the issuance and sale of the Common Shares as herein contemplated shall be
satisfactory in form and substance to the Placement Agent and Placement Agent Counsel.

 

5.          Indemnification.

 

5.1         Indemnification
of the Placement Agent. In consideration of the Placement Agent’s execution and delivery of, and the performance of
its obligations under, this Agreement, and in addition to all of the Company’s other obligations under the Offering Documents,
the Company shall defend, indemnify and hold harmless Placement Agent, each of its Affiliates, each Person, if any, who controls
Placement Agent or any of its Affiliates within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, and each
of its and its directors, officers, partners, members, shareholders, direct or indirect investors, employees, representatives
and agents (including, without limitation, those attorneys, sub-placement agents and other agents retained by Placement Agent
or any such other Person in connection with the transactions contemplated by this Agreement and the other Offering Documents)
(collectively, the “Placement Agent Indemnified Parties,” and each a “Placement Agent Indemnified
Party”), from and against any and all claims, actions, causes of action, suits, proceedings (including, without limitation,
as a party in interest or otherwise in any action or proceeding for injunctive or other equitable relief), including, without
limitation, any and all derivative actions brought on behalf of the Company or any Subsidiary, and any and all civil, criminal
or regulatory investigations, whether formal or informal, to which any Placement Agent Indemnified Party may become subject (irrespective
of whether any such Placement Agent Indemnified Party is a party, threatened to be made a party, or a witness to the claim, action,
cause of action, suit, proceeding or investigation for which indemnification hereunder is sought), and all damages, losses, liabilities
and expenses (including the reasonable fees and expenses of counsel) incurred by any Placement Agent Indemnified Party (including,
without limitation, in settlement of any claim, action, cause of action, suit, proceeding or investigation), in each case as incurred
(collectively, a “Claim”), as a result of, or arising out of, or relating to (i) any misrepresentation, inaccuracy
or breach of any representation or warranty made by the Company or any Subsidiary in this Agreement or in the Registration Statement,
the Disclosure Package, any Issuer Free Writing Prospectus and the Prospectus, (ii) any breach of any covenant, agreement or obligation
of the Company or any Subsidiary contained in this Agreement or in the Registration Statement, the Disclosure Package, any Issuer
Free Writing Prospectus and the Prospectus, (iii) the execution, delivery, performance or enforcement of this Agreement or the
Registration Statement, the Disclosure Package, any Issuer Free Writing Prospectus and the Prospectus, (iv) any transaction financed
or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the Securities, (v) any untrue
statement or alleged untrue statement of a material fact contained in any the Registration Statement, the Disclosure Package,
any Issuer Free Writing Prospectus and the Prospectus, or any amendment thereto, or the omission or alleged omission therefrom
of a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading, (vi) the status of such Placement Agent Indemnified Party as a holder of any equity
or debt securities of the Company or any of its subsidiaries, including, without limitation, any of the Securities or the Placement
Agent Securities, or as a party (or agent or attorney of such party) to this Agreement, (vii) any act or failure to act or any
alleged act or failure to act by any Placement Agent Indemnified Party in connection with, or relating in any manner to, the Securities,
the Offering or any of the transactions contemplated by this Agreement, provided that the Company shall not be liable under this
clause (vii) to the extent that a court of competent jurisdiction shall have determined by a final, non-appealable judgment that
such claim, action, cause of action, suit, proceeding, investigation, damage,
loss, liability or expense resulted exclusively from the bad faith or willful misconduct of such Placement Agent Indemnified
Party; and to reimburse such Placement Agent Indemnified Party for any and all expenses (including the reasonable fees and disbursements
of counsel chosen by such Placement Agent Indemnified Party) as such expenses are incurred by such Placement Agent Indemnified
Party in connection with investigating, defending, settling, compromising or paying any such claim,
action, cause of action, suit, proceeding, investigation, damage, loss, liability or expense.
To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make
the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable
law.

 

    	 	- 31 -	 

     

    

 

5.2         Notifications
and Other Indemnification Procedures. Promptly after receipt by a Placement Agent Indemnified Party under this Section 5 of
notice of the commencement of any action, such Placement Agent Indemnified Party will, if a claim in respect thereof is to be
made against the Company under this Section 5, notify the Company in writing of the commencement thereof, but the omission so
to notify the Company will not relieve it from any liability, which it may have to any Placement Agent Indemnified Party for contribution
to the extent it is not prejudiced as a proximate result of such failure. In case any such action is brought against any Placement
Agent Indemnified Party and the such Placement Agent Indemnified Party seeks or intends to seek indemnity from the Company, the
Company will be entitled to participate in, and, by written notice delivered to such Placement Agent Indemnified Party promptly
after receiving the aforesaid notice from such Placement Agent Indemnified Party, to assume the defense thereof with counsel reasonably
satisfactory to such Placement Agent Indemnified Party; provided, however, if the defendants in any such action
include both the Placement Agent Indemnified Party and the Company, and the Placement Agent Indemnified Party shall have reasonably
concluded that a conflict may arise between the positions of the Company and the Placement Agent Indemnified Party in conducting
the defense of any such action or that there may be legal defenses available to it and/or other Placement Agent Indemnified Parties
which are different from or additional to those available to the Company, such Placement Agent Indemnified Party or Placement
Agent Indemnified Parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate
in the defense of such action on behalf of such Placement Agent Indemnified Party or Placement Agent Indemnified Parties. Upon
receipt of notice from the Company to the Placement Agent Indemnified Party of the Company’s election so to assume the defense
of such action and approval by such Placement Agent Indemnified Party of counsel, the Company will not be liable to such Placement
Agent Indemnified Party under this Section 8 for any legal or other expenses subsequently incurred by such Placement Agent Indemnified
Party in connection with the defense thereof unless: (i) the Placement Agent Indemnified Party shall have employed separate counsel
in accordance with the proviso to the next preceding sentence (it being understood, however, that the Company shall not be liable
for the expenses of more than one separate counsel (together with local counsel), approved by the Company), representing the Placement
Agent Indemnified Parties who are parties to such action); (ii) the Company shall not have employed counsel satisfactory to the
Placement Agent Indemnified Party to represent the Placement Agent Indemnified Party within a reasonable time after notice of
commencement of the action; or (iii) the Company has authorized the employment of counsel for the Placement Agent Indemnified
Party at the expense of the Company, in each of which cases the fees and expenses of counsel shall be at the expense of the Company.

 

5.3        Settlements.
The Company shall not be liable under this Section 5 for any settlement of any proceeding effected without its written consent,
which consent shall not be unreasonably conditioned, withheld or delayed, but if settled with such consent or if there be a final
judgment for the plaintiff, the Company agrees to indemnify the applicable Placement Agent Indemnified Party or Placement Agent
Indemnified Parties against any claim, action, cause of action, suit, proceeding, investigation,
damage, loss, liability or expense by reason of such settlement or judgment. The Company
shall not, without the prior written consent of the Placement Agent Indemnified Party, effect any settlement, compromise or consent
to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any Placement Agent Indemnified
Party is or could have been a party and indemnity was or could have been sought hereunder by such Placement Agent Indemnified
Party, unless such settlement, compromise or consent includes: (i) an unconditional release of such Placement Agent Indemnified
Party from all liability on claims that are the subject matter of such action, suit or proceeding; and (ii) does not include a
statement as to or an admission of fault, culpability or a failure to act by or on behalf of any Placement Agent Indemnified Party.

 

    	 	- 32 -	 

     

    

 

5.4         Contribution.
If the indemnification provided for in this Section 5 is unavailable to or insufficient to hold harmless a Placement Agent Indemnified
Party under Section 5(a) above in respect of any claim, action, cause of action, suit, proceeding,
investigation, damage, loss, liability or expense, then the Company shall contribute
to the aggregate amount paid or payable by such Placement Agent Indemnified Party in such proportion as is appropriate to reflect
the relative benefits received by the Company, on the one hand, and such Placement Agent Indemnified Party, on the other, from
the Offering. If, however, the allocation provided by the immediately preceding sentence is not permitted by applicable law then
the Company shall contribute to such amount paid or payable by such Placement Agent Indemnified Party in such proportion as is
appropriate to reflect not only such relative benefits but also the relative fault of the Company, on the one hand, and such Placement
Agent Indemnified Party, on the other, in connection with the actions or omissions which resulted in such losses, claims, damages
or liabilities (or actions or proceedings in respect thereof), as well as any other relevant equitable considerations. The relative
fault shall be determined by reference to, among other things, the parties’ relative intent, knowledge, access to information
and opportunity to correct or prevent such action or omission.

 

The Company and Placement
Agent agree that it would not be just and equitable if contributions pursuant to this Section 5(d) were determined by pro rata
allocation or by any other method of allocation which does not take account of the equitable considerations referred to above
in this Section 5(d). The amount paid or payable by a Placement Agent Indemnified Party as a result of the losses, claims, damages
or liabilities (or actions or proceedings in respect thereof) referred to above in this Section 5(d) shall be deemed to include
any legal or other expenses reasonably incurred by such Placement Agent Indemnified Party in connection with investigating or
defending any such claim, action, cause of action, suit, proceeding or investigation. Notwithstanding the provisions of this subsection
(d): (i) Placement Agent shall not be required to contribute any amount in excess of the amount of the Cash Fee actually received
by Placement Agent pursuant to this Agreement; and (ii) no person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

 

5.5         Timing
of Any Payments of Indemnification. Any losses, claims, damages, liabilities or expenses for which a Placement Agent Indemnified
Party is entitled to indemnification or contribution under this Section 5 shall be paid by the Company to the Placement Agent
Indemnified Party as such losses, claims, damages, liabilities or expenses are incurred, but in all cases, no later than fifteen
(15) days of invoice to the Company.

 

5.6         Acknowledgements
of Parties. The parties to this Agreement hereby acknowledge that they are sophisticated business persons who were represented
by counsel during the negotiations regarding the provisions hereof including, without limitation, the provisions of this Section
5, and are fully informed regarding said provisions. They further acknowledge that the provisions of this Section 5 fairly allocate
the risks in light of the ability of the parties to investigate the Company and its business in order to assure that adequate
disclosure is made in the Disclosure Package.

 

    	 	- 33 -	 

     

    

 

6.           Right
of First Refusal. Provided that the Common Shares are sold in accordance with the terms of this Agreement resulting in gross
proceeds of not less than $9.0 million, the Placement Agent shall have an irrevocable right of first refusal (the “Right
of First Refusal”), for a period of twenty four (24) months after the date the Offering is completed, to act as sole
and exclusive investment banker, sole and exclusive book-runner, sole and exclusive financial advisor, sole and exclusive underwriter
and/or sole and exclusive placement agent, at the Placement Agent’s sole and exclusive discretion, for each and every future
public and private equity and debt offering, including all equity linked financings (each, a “Subject Transaction”),
during such twelve (12) month period, of the Company, or any successor to or subsidiary of the Company, on terms and conditions
customary to the Placement Agent for such Subject Transactions. For the avoidance of any doubt, the Company shall not retain,
engage or solicit any additional investment banker, book-runner, financial advisor, underwriter and/or placement agent in a Subject
Transaction without the express written consent of the Placement Agent.

 

The Company shall notify
the Placement Agent of its intention to pursue a Subject Transaction, including the material terms thereof, by providing written
notice thereof by registered mail or overnight courier service addressed to the Placement Agent.  If the Placement Agent
fails to exercise its Right of First Refusal with respect to any Subject Transaction within ten (10) Business Days after the mailing
of such written notice, then the Placement Agent shall have no further claim or right with respect to the Subject Transaction.
The Placement Agent may elect, in its sole and absolute discretion, not to exercise its Right of First Refusal with respect to
any Subject Transaction; provided that any such election by the Placement Agent shall not adversely affect the Placement Agent’s
Right of First Refusal with respect to any other Subject Transaction during the twenty four (24) month period agreed to above.  

 

7.           Miscellaneous.

 

7.1         Notices.
All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed (registered
or certified mail, return receipt requested), personally delivered or sent by e-mail or facsimile transmission and confirmed and
shall be deemed given when so delivered, e-mailed or faxed and confirmed or if mailed, two (2) days after such mailing.

 

If to the Placement Agent:

 

ThinkEquity, a division of Fordham Financial Management,
Inc.

17 State Street, 22nd Floor

New York, New York 10004

Attention: Mr. Eric Lord, Head of Investment Banking

Fax No.: [•]

E-mail: el@think-equity.com

 

with a copy (which shall not constitute notice) to:

 

Loeb & Loeb LLP

345 Park Avenue

New York, NY 10154

Attn: Mitchell S. Nussbaum, Esq.

Fax No.:  (212) 504-3013

 

If to the Company:

 

Ampio Pharmaceuticals, Inc.

373 Inverness Parkway, Suite 200

Englewood, Colorado 80112

Attention: Chairman and Chief Executive Officer

Fax No:

 

    	 	- 34 -	 

     

    

 

with a copy (which shall not constitute notice) to:

 

Squire Patton Boggs (US) LLP

900 Key Tower 127 Public Square

Cleveland, OH 44114

Attention: Leah Brownlee, Esq.

Fax No: (216) 479-8780

 

7.2         Headings.
The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the
meaning or interpretation of any of the terms or provisions of this Agreement.

 

7.3         Amendment.
This Agreement may only be amended by a written instrument executed by each of the parties hereto.

 

7.4         Entire
Agreement. This Agreement (together with the other agreements and documents being delivered pursuant to or in connection with
this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof,
and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.
Notwithstanding anything to the contrary set forth herein, it is understood and agreed by the parties hereto that all other terms
and conditions of that certain engagement letter between the Company and ThinkEquity, a division of Fordham Financial Management,
Inc., dated June 10, 2019, shall remain in full force and effect.

 

7.5         Binding
Effect. This Agreement shall inure solely to the benefit of and shall be binding upon the Placement Agent, the Company and
the controlling persons, directors and officers referred to in Section 5 hereof, and their respective successors, legal representatives,
heirs and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under
or in respect of or by virtue of this Agreement or any provisions herein contained.

 

7.6         Governing
Law; Consent to Jurisdiction; Trial by Jury. This Agreement shall be governed by and construed and enforced in accordance
with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees
that any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and
enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of
New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection
to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any such process or summons to be served
upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage
prepaid, addressed to it at the address set forth in Section 9.1 hereof. Such mailing shall be deemed personal service and shall
be legal and binding upon the Company in any action, proceeding or claim. The Company agrees that the prevailing party(ies) in
any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys’ fees and expenses
relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf
and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and each of the Placement Agent
hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal
proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

 

    	 	- 35 -	 

     

    

 

7.7         Execution
in Counterparts. This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate
counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same
agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered
to each of the other parties hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission
shall constitute valid and sufficient delivery thereof.

 

7.8         Waiver,
etc. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be
deemed or construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision
hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of
any breach, non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in
a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver
of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach,
non-compliance or non-fulfillment.

 

[Signature Page Follows]

 

    	 	- 36 -	 

     

    

 

If the foregoing correctly
sets forth the understanding between the Placement Agent and the Company, please so indicate in the space provided below for that
purpose, whereupon this letter shall constitute a binding agreement between us.

 

	 	Very truly yours,
	 	 
	 	AMPIO PHARMACEUTICALS, INC.
	 	 	 
	 	By:	/s/ Michael Macaluso
	 	 	Name: Michael Macaluso
	 	 	Title: Chief Executive Officer

 

	Confirmed as of the date first written above mentioned	 
	 	 
	THINKEQUITY	 
	 	 
	A Division of Fordham Financial Management, Inc.	 
	 	 	 
	By:	/s/ Eric Lord	 
	 	Name: Eric Lord	 
	 	Title: Head of Investment Banking	 

 

     

     

    

 

SCHEDULE 1

 

List of Lock-Up Parties

 

Michael Macaluso

 

David Bar-Or, MD

 

Philip H. Coelho

 

Richard B. Giles

 

David R. Stevens, Ph.D.

 

Holli Cherevka

 

    Sch. 1-1

     

    

 

EXHIBIT A

 

Form of Placement Agent Warrants

 

THE REGISTERED HOLDER
OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT
AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR
HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE DATE OF THE PLACEMENT AGENCY AGREEMENT
(DEFINED BELOW) TO ANYONE OTHER THAN (I) THINKEQUITY, A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC., OR A SUB-PLACEMENT AGENT
IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF THINKEQUITY, A DIVISION OF FORDHAM FINANCIAL MANAGEMENT,
INC., OR OF ANY SUCH SUB-PLACEMENT AGENT.

 

THIS PURCHASE WARRANT
IS NOT EXERCISABLE PRIOR TO [________________] [DATE THAT IS 180 DAYS FROM THE DATE OF THE PLACEMENT AGENCY AGREEMENT].
VOID AFTER 5:00 P.M., EASTERN TIME, [___________________] [DATE THAT IS FIVE YEARS FROM THE DATE OF THE PLACEMENT AGENCY AGREEMENT].

 

WARRANT TO PURCHASE COMMON STOCK 

 

AMPIO PHARMACEUTICALS, INC.

 

Warrant Shares: _______

 

Initial Exercise Date: ______, 2019

 

THIS WARRANT TO PURCHASE
COMMON STOCK (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after ____, 2019 (the “Initial Exercise Date”) and, in accordance with FINRA Rule 5110(f)(2)(G)(i), prior
to at 5:00 p.m. (New York time) on the date that is five (5) years following the date of the Placement Agency Agreement (as defined
herein)(the “Termination Date”) but not thereafter, to subscribe for and purchase from Ampio Pharmaceuticals,
Inc., a Delaware corporation (the “Company”), up to ______ shares of Common Stock, par value $0.0001 per share,
of the Company (the “Warrant Shares”), as subject to adjustment hereunder. The purchase price of one share
of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

 

Section 1.
Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings indicated
in this Section 1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

    	 	Ex. A-1	 

     

    

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Trading
Day” means a day on which the New York Stock Exchange is open for trading.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the
New York Stock Exchange (or any successors to any of the foregoing).

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)  if OTCQB or OTCQX is not a Trading Market,
the volume weighted average price of a share of Common Stock for such date (or the nearest preceding date) on the OTCQB or OTCQX
as applicable, (c) if Common Stock is not then listed or quoted for trading on the OTCQB or OTCQX and if prices for Common Stock
are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in all other
cases, the fair market value of the Common Stock as determined by an independent appraiser selected in good faith by the Holder
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

    	 	Ex. A-2	 

     

    

 

Section 2.
Exercise.

 

a)                 
Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after
the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of
the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books
of the Company) of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise Form annexed hereto. Within
two (2) Trading Days following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice
of Exercise form be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant
has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within five
(5) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder
and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company
shall deliver any objection to any Notice of Exercise Form within two (2) Business Days of receipt of such notice. The Holder
and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any
given time may be less than the amount stated on the face hereof.

 

b)                 
Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be $0.50, subject to adjustment
hereunder (the “Exercise Price”).

 

c)                 
Cashless Exercise. If at any time on or after the Initial Exercise Date, there is no effective registration statement registering,
or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may
also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be
entitled to receive the number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

(A) = the
VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless
exercise,” as set forth in the applicable Notice of Exercise;

 

(B) = the
Exercise Price of this Warrant, as adjusted hereunder; and

 

(X)
= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
if such exercise were by means of a cash exercise rather than a cashless exercise.

 

If
Warrant Shares are issued in such a “cashless exercise,” the parties acknowledge and agree that in accordance with
Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised,
and the holding period of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares.  The
Company agrees not to take any position contrary to this Section 2(c). 

 

 Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise
pursuant to this Section 2(c).

 

    	 	Ex. A-3	 

     

    

 

d)                
Mechanics of Exercise.

 

i.           
Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by its transfer agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with
The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company
is then a participant in such system and either (A) there is an effective registration statement permitting the issuance
of the Warrant Shares to or resale of the Warrant Shares by Holder, or (B) the Warrant Shares are eligible for resale by the Holder
without volume or manner-of-sale limitations pursuant to Rule 144 and, in either case, the Warrant Shares have been sold by the
Holder prior to the Warrant Share Delivery Date (as defined below), and otherwise by physical delivery of a certificate, registered
in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the
Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that
is two (2) Trading Days after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share
Delivery Date”). If the Warrant Shares can be delivered via DWAC, the transfer agent shall have received from the Company,
at the expense of the Company, any legal opinions or other documentation required by it to deliver such Warrant Shares without
legend (subject to receipt by the Company of reasonable back up documentation from the Holder, including with respect to affiliate
status) and, if applicable and requested by the Company prior to the Warrant Share Delivery Date, the transfer agent shall have
received from the Holder a confirmation of sale of the Warrant Shares (provided the requirement of the Holder to provide a confirmation
as to the sale of Warrant Shares shall not be applicable to the issuance of unlegended Warrant Shares upon a cashless exercise
of this Warrant if the Warrant Shares are then eligible for resale pursuant to Rule 144(b)(1)). The Warrant Shares shall be deemed
to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder
of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise
Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi)
prior to the issuance of such shares, having been paid. If the Company fails for any reason to deliver to the Holder the Warrant
Shares subject to a Notice of Exercise by the second Trading Day following the Warrant Share Delivery Date, the Company shall
pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20
per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after the second
Trading Day following such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.

    

ii.           
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder
a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which
new Warrant shall in all other respects be identical with this Warrant.

 

    	 	Ex. A-4	 

     

    

 

iii.           
Rescission Rights. If the Company fails to cause its transfer agent to deliver to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise; provided,
however, that the Holder shall be required to return any Warrant Shares or Common Stock subject to any such rescinded exercise
notice concurrently with the return to Holder of the aggregate Exercise Price paid to the Company for such Warrant Shares and
the restoration of Holder’s right to acquire such Warrant Shares pursuant to this Warrant (including, issuance of a replacement
warrant certificate evidencing such restored right).

 

iv.           
Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available
to the Holder, if the Company fails to cause its transfer agent to transmit to the Holder the Warrant Shares pursuant to an exercise
on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open
market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in
satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue
times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored
(in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would
have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder
purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice
indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law
or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s
failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

  

v.           
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.

    	 	Ex. A-5	 

     

    

 

vi.           
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid
by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other than the
name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly
executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for
any transfer tax incidental thereto. The Company shall pay all transfer agent fees required for same-day processing of any Notice
of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions)
required for same-day electronic delivery of the Warrant Shares.

 

vii.           
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

viii.           
Signature. This Section 2 and the exercise form attached hereto set forth the totality of the procedures required of the
Holder in order to exercise this Purchase Warrant.  Without limiting the preceding sentences, no ink-original exercise form
shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any exercise form be required
in order to exercise this Purchase Warrant.  No additional legal opinion, other information or instructions shall be required
of the Holder to exercise this Purchase Warrant.  The Company shall honor exercises of this Purchase Warrant and shall deliver
Shares underlying this Purchase Warrant in accordance with the terms, conditions and time periods set forth herein.

    

    	 	Ex. A-6	 

     

    

 

e)                 
Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect
to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially
own in excess of the Beneficial Ownership Limitation (as defined below).  For purposes of the foregoing sentence, the number
of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock
issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of
shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially
owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any
other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on
conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. 
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged
by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of
the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall
be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and
of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a
Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic
or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a
more recent written notice by the Company or the Company’s transfer agent setting forth the number of shares of Common Stock
outstanding.  Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and
in writing to the Holder the number of shares of Common Stock then outstanding.  In any case, the number of outstanding shares
of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including
this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was
reported. The “Beneficial Ownership Limitation” shall be 9.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant.
The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section
2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the
Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will
not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph
shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation
herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations
contained in this paragraph shall apply to a successor holder of this Warrant. 

  

Section 3.
Certain Adjustments.

 

a)                 
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a)
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.
For the purposes of clarification, the Exercise Price of this Warrant will not be adjusted in the event that the Company or any
Subsidiary thereof, as applicable, sells or grants any option to purchase, or sell or grant any right to reprice, or otherwise
dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or Common
Stock Equivalents, at an effective price per share less than the Exercise Price then in effect.

    	 	Ex. A-7	 

     

    

 

b)                 
[RESERVED]

  

c)                 
Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company
grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata
to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will
be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could
have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result
in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

d)                
Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend
(other than cash dividends) or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common
Stock, by way of return of capital or otherwise (including, without limitation, any distribution of shares or other securities,
property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other
similar transaction) (a "Distribution"), at any time after the issuance of this Warrant, then, in each such case,
the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, to
the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial
ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the
Holder exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised
at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until
the Holder has exercised this Warrant.

 

    	 	Ex. A-8	 

     

    

  

e)                 
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common
Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making
or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would
have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the
Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(the “Alternate Consideration”) receivable by holders of Common Stock as a result of such Fundamental Transaction
for each share of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without
regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion
the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the
obligations of the Company under this Warrant in accordance with the provisions of this Section 3(e) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such
Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is
exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to
the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise
of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder
to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being
for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction),
and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction,
the provisions of this Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise
every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect
as if such Successor Entity had been named as the Company herein.

    	 	Ex. A-9	 

     

    

  

f)                  
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as
of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

g)                 
Notice to Holder.

 

i.           
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the
Company shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii.           
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a
party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed
a notice to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days
prior to the applicable record or effective date hereinafter specified, stating (x) the date on which a record is to be taken
for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is
expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall
be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to provide such notice or any defect therein
shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided
hereunder constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled
to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice except as may otherwise be expressly set forth herein.

 

    	 	Ex. A-10	 

     

    

 

Section 4.
Transfer of Warrant.

 

a)                 
Transferability. Pursuant to FINRA Rule 5110(g)(1), neither this Warrant nor any Warrant Shares issued upon exercise of
this Warrant shall be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative,
put, or call transaction that would result in the effective economic disposition of the securities by any person for a period
of 180 days immediately following the date of effectiveness or commencement of sales of the offering pursuant to which this Warrant
is being issued, except the transfer of any security:

 

i.                         by operation of law or by reason of reorganization of the Company;

 

ii.                       
to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred
remain subject to the lock-up restriction in this Section 4(a) for the remainder of the time period;

 

iii.                      
if the aggregate amount of securities of the Company held by the Holder or related person do not exceed 1% of the securities being
offered;

 

iv.                       that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member
manages or otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the
equity in the fund; or

 

v.                        the exercise or conversion of any security, if all securities received remain subject to the lock-up restriction in this Section
4(a) for the remainder of the time period.

  

Subject to
the foregoing restriction, any applicable securities laws and the conditions set forth in Section 4(d), this Warrant and all rights
hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this
Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially
in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes
payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver
a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified
in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not
be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which
case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date the Holder delivers an
assignment form to the Company assigning this Warrant full. The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

    	 	Ex. A-11	 

     

    

 

b)                 
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable
pursuant thereto.

 

c)                 
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.

 

d)                
Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a
view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable
state securities law, except pursuant to sales registered or exempted under the Securities Act.

 

Section 5. Registration
Rights.

 

5.1         Demand
Registration.

 

5.1.1          Grant
of Right. The Company, upon written demand (a “Demand Notice”) of the Holder(s) of at least 51% of the Warrants
(“Majority Holders”), agrees to register, on one occasion, all or any portion of the shares of Common Stock
underlying the Warrants (collectively, the “Registrable Securities”). On such occasion, the Company will file
a registration statement with the Commission covering the Registrable Securities within sixty (60) days after receipt of a Demand
Notice and use its reasonable best efforts to have the registration statement declared effective promptly thereafter, subject
to compliance with review by the Commission; provided, however, that the Company shall not be required to comply with a Demand
Notice if the Company has filed a registration statement with respect to which the Holder is entitled to piggyback registration
rights pursuant to Section 5.2 hereof and either: (i) the Holder has elected to participate in the offering covered by such registration
statement or (ii) if such registration statement relates to an underwritten primary offering of securities of the Company, until
the offering covered by such registration statement has been withdrawn or until thirty (30) days after such offering is consummated.
The demand for registration may be made at any time during a period of four (4) years beginning on the Initial Exercise Date.
The Company covenants and agrees to give written notice of its receipt of any Demand Notice by any Holder(s) to all other registered
Holders of the Warrants and/or the Registrable Securities within ten (10) days after the date of the receipt of any such Demand
Notice.

 

    	 	Ex. A-12	 

     

    

 

5.1.2           Terms.
The Company shall bear all fees and expenses attendant to the registration of the Registrable Securities pursuant to Section 5.1.1,
but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to
represent them in connection with the sale of the Registrable Securities. The Company agrees to use its reasonable best efforts
to cause the filing required herein to become effective promptly and to qualify or register the Registrable Securities in such
States as are reasonably requested by the Holder(s); provided, however, that in no event shall the Company be required to register
the Registrable Securities in a State in which such registration would cause: (i) the Company to be obligated to register or license
to do business in such State or submit to general service of process in such State, or (ii) the principal shareholders of the
Company to be obligated to escrow their shares of capital stock of the Company. The Company shall cause any registration statement
filed pursuant to the demand right granted under Section 5.1.1 to remain effective for a period of at least twelve (12) consecutive
months after the date that the Holders of the Registrable Securities covered by such registration statement are first given the
opportunity to sell all of such securities. The Holders shall only use the prospectuses provided by the Company to sell the shares
of Common Stock covered by such registration statement, and will immediately cease to use any prospectus furnished by the Company
if the Company advises the Holder that such prospectus may no longer be used due to a material misstatement or omission. Notwithstanding
the provisions of this Section 5.1.2, the Holder shall be entitled to a demand registration under this Section 5.1.2 on only one
(1) occasion and such demand registration right shall terminate on the fifth anniversary of the date of the Placement Agency Agreement
(as defined below) in accordance with FINRA Rule 5110(f)(2)(G)(iv).

 

5.2          “Piggy-Back”
Registration.

 

5.2.1          Grant
of Right. In addition to the demand right of registration described in Section 5.1 hereof, the Holder shall have the right, for
a period of no more than two (2) years from the Initial Exercise Date in accordance with FINRA Rule 5110(f)(2)(G)(v), to include
the Registrable Securities as part of any other registration of securities filed by the Company (other than in connection with
a transaction contemplated by Rule 145(a) promulgated under the Securities Act or pursuant to Form S-8 or any equivalent form);
provided, however, that if, solely in connection with any primary underwritten public offering for the account of the Company,
the managing underwriter(s) thereof shall, in its reasonable discretion, impose a limitation on the number of shares of Common
Stock which may be included in the Registration Statement because, in such underwriter(s)’ judgment, marketing or other
factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include
in such Registration Statement only such limited portion of the Registrable Securities with respect to which the Holder requested
inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of Registrable Securities shall be made pro rata
among the Holders seeking to include Registrable Securities in proportion to the number of Registrable Securities sought to be
included by such Holders; provided, however, that the Company shall not exclude any Registrable Securities unless the Company
has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities in such Registration
Statement or are not entitled to pro rata inclusion with the Registrable Securities.

 

    	 	Ex. A-13	 

     

    

 

5.2.2           Terms.
The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 5.2.1 hereof,
but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to
represent them in connection with the sale of the Registrable Securities. In the event of such a proposed registration, the Company
shall furnish the then Holders of outstanding Registrable Securities with not less than thirty (30) days written notice prior
to the proposed date of filing of such registration statement. Such notice to the Holders shall continue to be given for each
registration statement filed by the Company during the two (2) year period following the Initial Exercise Date until such time
as all of the Registrable Securities have been sold by the Holder. The holders of the Registrable Securities shall exercise the
“piggy-back” rights provided for herein by giving written notice within ten (10) days of the receipt of the Company’s
notice of its intention to file a registration statement. Except as otherwise provided in this Warrant, there shall be no limit
on the number of times the Holder may request registration under this Section 5.2.2; provided, however, that such registration
rights shall terminate on the second anniversary of the Initial Exercise Date.

 

5.3         General
Terms

 

5.3.1          Indemnification.
The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder
and each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20 (a) of
the Exchange Act against all loss, claim, damage, expense or liability (including all reasonable attorneys’ fees and other
expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become
subject under the Securities Act, the Exchange Act or otherwise, arising from such registration statement but only to the same
extent and with the same effect as the provisions pursuant to which the Company has agreed to indemnify the Placement Agent contained
in Section 5.1 of the Placement Agency Agreement (as defined below). The Holder(s) of the Registrable Securities to be sold pursuant
to such registration statement, and their successors and assigns, shall severally, and not jointly, indemnify the Company, against
all loss, claim, damage, expense or liability (including all reasonable attorneys’ fees and other expenses reasonably incurred
in investigating, preparing or defending against any claim whatsoever) to which they may become subject under the Securities Act,
the Exchange Act or otherwise, arising from information furnished by or on behalf of such Holders, or their successors or assigns,
in writing, for specific inclusion in such registration statement to the same extent and with the same effect as the foregoing
provisions.

 

5.3.2           Exercise
of Warrants. Nothing contained in this Warrant shall be construed as requiring the Holder(s) to exercise their Warrants prior
to or after the initial filing of any registration statement or the effectiveness thereof.

 

5.3.3           Documents
Delivered to Holders. The Company shall furnish to each Holder participating in any of the foregoing offerings and to each underwriter
of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an opinion of counsel to
the Company, dated the effective date of such registration statement (and, if such registration includes an underwritten public
offering, an opinion dated the date of the closing under any underwriting agreement related thereto), and (ii) a “cold comfort”
letter dated the effective date of such registration statement (and, if such registration includes an underwritten public offering,
a letter dated the date of the closing under the underwriting agreement) signed by the independent registered public accounting
firm which has issued a report on the Company’s financial statements included in such registration statement, in each case
covering substantially the same matters with respect to such registration statement (and the prospectus included therein) and,
in the case of such accountants’ letter, with respect to events subsequent to the date of such financial statements, as
are customarily covered in opinions of issuer’s counsel and in accountants’ letters delivered to underwriters in underwritten
public offerings of securities. The Company shall also deliver promptly to each Holder participating in the offering requesting
the correspondence and memoranda described below and to the managing underwriter, if any, copies of all correspondence between
the Commission and the Company, its counsel or auditors and all memoranda relating to discussions with the Commission or its staff
with respect to the registration statement and permit each Holder and underwriter to do such investigation, upon reasonable advance
notice, with respect to information contained in or omitted from the registration statement as it deems reasonably necessary to
comply with applicable securities laws or rules of FINRA. Such investigation shall include access to books, records and properties
and opportunities to discuss the business of the Company with its officers and independent auditors, all to such reasonable extent
and at such reasonable times as any such Holder shall reasonably request.

 

    	 	Ex. A-14	 

     

    

 

5.3.4           Underwriting
Agreement. The Company shall enter into an underwriting agreement with the managing underwriter(s), if any, selected by any Holders
whose Registrable Securities are being registered pursuant to this Section 5, which managing underwriter shall be reasonably satisfactory
to the Company. Such agreement shall be reasonably satisfactory in form and substance to the Company, each Holder and such managing
underwriters, and shall contain such representations, warranties and covenants by the Company and such other terms as are customarily
contained in agreements of that type used by the managing underwriter. The Holders shall be parties to any underwriting agreement
relating to an underwritten sale of their Registrable Securities and may, at their option, require that any or all the representations,
warranties and covenants of the Company to or for the benefit of such underwriters shall also be made to and for the benefit of
such Holders. Such Holders shall not be required to make any representations or warranties to or agreements with the Company or
the underwriters except as they may relate to such Holders, their Warrant ADSs and their intended methods of distribution.

 

5.3.5           Documents
to be Delivered by Holder(s). Each of the Holder(s) participating in any of the foregoing offerings shall furnish to the Company
a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security holders.

 

5.3.6           Damages.
Should the registration or the effectiveness thereof required by Sections 5.1 and 5.2 hereof be delayed by the Company or the
Company otherwise fails to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available
to the Holder(s), be entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened
breach of such provisions or the continuation of any such breach, without the necessity of proving actual damages and without
the necessity of posting bond or other security.

  

Section 6.
Miscellaneous.

 

a)                 
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other
rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).

 

b)                 
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated,
the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu
of such Warrant or stock certificate.

 

    	 	Ex. A-15	 

     

    

 

c)                 
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next
succeeding Trading Day.

 

d)                 
Authorized Shares.

 

The Company
covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this
Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are
charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The
Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided
herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common
Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights
represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant
Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens
and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).

  

Except and
to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue
or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without
limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount
payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary
or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise
of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any
public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under
this Warrant.

 

Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.

 

e)                 
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be determined in accordance with the provisions of the placement agency agreement, dated June 17, 2019, by and between the Company
and ThinkEquity, a division of Fordham Financial Management, Inc., as Placement Agent (the “Placement Agency Agreement”).

 

    	 	Ex. A-16	 

     

    

 

f)                   Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities
laws.

 

g)                  Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting
any other provision of this Warrant or the Placement Agency Agreement, if the Company willfully and knowingly fails to comply
with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such
amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees,
including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise
enforcing any of its rights, powers or remedies hereunder.

 

h)                  Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company
shall be delivered in accordance with the notice provisions of the Placement Agency Agreement.

  

i)                    Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability
of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted
by the Company or by creditors of the Company.

 

j)                    Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not
be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)                   Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
and shall be enforceable by the Holder or holder of Warrant Shares.

 

l)                    Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and the Holder.

 

m)                  Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)                   Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.

 

********************

 

(Signature Page Follows)

 

    	 	Ex. A-17	 

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

	 	AMPIO PHARMACEUTICALS, INC.
	 	 
	 	By	 
	 	 	Name:
	 	 	Title:

 

    	 	Ex. A-18	 

     

    

 

NOTICE OF EXERCISE

 

		TO:	AMPIO PHARMACEUTICALS,
INC.

 

_________________________

 

(1)   The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.

 

(2)   Payment
shall take the form of (check applicable box):

 

 ̈ in lawful money of
the United States; or

 

 ̈ if permitted the cancellation
of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this
Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth
in subsection 2(c).

 

(3)   Please
register and issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

  

The Warrant Shares shall be delivered
to the following DWAC Account Number or by physical delivery of a certificate to:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4)   Accredited
Investor. If the Warrant is being exercised via cash exercise, the undersigned is an “accredited investor” as
defined in Regulation D promulgated under the Securities Act of 1933, as amended

 

[SIGNATURE
OF HOLDER]

 

	Name of Investing Entity: 	 

 

	Signature of Authorized Signatory of Investing Entity: 	 

 

	Name of Authorized Signatory: 	 

 

	Title of Authorized Signatory: 	 

 

	Date:	 

 

    	 	Ex. A-19	 

     

    

 

ASSIGNMENT FORM

 

(To assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)

 

FOR VALUE RECEIVED,
[____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

  

_______________________________________________
whose address is

 

_______________________________________________________________.

  

_______________________________________________________________

 

Dated: ______________,
_______

 

Holder’s Signature: _____________________________

 

Holder’s Address: _____________________________

 

_____________________________

  

NOTE: The signature to this Assignment
Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever.
Officers of corporations and those acting in a fiduciary or other Placement Agent capacity should file proper evidence of authority
to assign the foregoing Warrant.

 

    	 	Ex. A-20	 

     

    

 

EXHIBIT B

 

Form of Lock-Up Agreement

June 17, 2019

 

ThinkEquity

A Division of Fordham Financial Management, Inc.

17 State Street, 22nd Fl

New York, NY 10004

 

Ladies and Gentlemen:

 

The undersigned understands
that ThinkEquity, a division of Fordham Financial Management, Inc., (the “Placement Agent”) proposes to enter
into an Placement Agency Agreement (the “Placement Agency Agreement”) with Ampio Pharmaceuticals, Inc., a Delaware
corporation (the “Company”), providing for the public offering (the “Public Offering”) of
shares of common stock, par value $0.001 per share, of the Company (the “Shares”).

 

To induce the Placement
Agent to continue its efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written
consent of the Placement Agent, the undersigned will not, during the period commencing on the date hereof and ending 180 days
after the date of the final prospectus (the “Prospectus”) relating to the Public Offering (the “Lock-Up
Period”), (1) offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly,
any Shares or any securities convertible into or exercisable or exchangeable for Shares, whether now owned or hereafter acquired
by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (collectively,
the “Lock-Up Securities”); (2) enter into any swap or other arrangement that transfers to another, in whole
or in part, any of the economic consequences of ownership of the Lock-Up Securities, whether any such transaction described in
clause (1) or (2) above is to be settled by delivery of Lock-Up Securities, in cash or otherwise; (3) make any demand for or exercise
any right with respect to the registration of any Lock-Up Securities; or (4) publicly disclose the intention to make any offer,
sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement relating to any Lock-Up Securities.
Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer Lock-Up Securities without the
prior written consent of the Placement Agent in connection with (a) transactions relating to Lock-Up Securities acquired in open
market transactions after the completion of the Public Offering; provided that no filing under Section 16(a) of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), shall be required or shall be voluntarily
made in connection with subsequent sales of Lock-Up Securities acquired in such open market transactions; (b) transfers of Lock-Up
Securities as a bona fide gift, by will or intestacy or to a family member or trust for the benefit of a family member
(for purposes of this lock-up agreement, “family member” means any relationship by blood, marriage or adoption, not
more remote than first cousin); (c) transfers of Lock-Up Securities to a charity or educational institution; or (d) if the undersigned,
directly or indirectly, controls a corporation, partnership, limited liability company or other business entity, any transfers
of Lock-Up Securities to any shareholder, partner or member of, or owner of similar equity interests in, the undersigned, as the
case may be; provided that in the case of any transfer pursuant to the foregoing clauses (b), (c) or (d), (i) any
such transfer shall not involve a disposition for value, (ii) each transferee shall sign and deliver to the Placement Agent a
lock-up agreement substantially in the form of this lock-up agreement and (iii) no filing under Section 16(a) of the Exchange
Act shall be required or shall be voluntarily made. The undersigned also agrees and consents to the entry of stop transfer instructions
with the Company’s transfer agent and registrar against the transfer of the undersigned’s Lock-Up Securities except
in compliance with this lock-up agreement.

 

    	 	Ex. B-1	 

     

    

 

The undersigned agrees
that, prior to engaging in any transaction or taking any other action that is subject to the terms of this lock-up agreement during
the period from the date hereof to and including the 34th day following the expiration of the initial Lock-Up Period,
the undersigned will give notice thereof to the Company and will not consummate any such transaction or take any such action unless
it has received written confirmation from the Company that the Lock-Up Period (as may have been extended pursuant to the previous
paragraph) has expired.

 

If the undersigned
is an officer or director of the Company, (i) the undersigned agrees that the foregoing restrictions shall be equally applicable
to any issuer-directed or “friends and family” Shares that the undersigned may purchase in the Public Offering; (ii)
the Placement Agent agrees that, at least three (3) business days before the effective date of any release or waiver of the foregoing
restrictions in connection with a transfer of Lock-Up Securities, the Placement Agent will notify the Company of the impending
release or waiver; and (iii) the Company has agreed in the Placement Agency Agreement to announce the impending release or waiver
by press release through a major news service at least two (2) business days before the effective date of the release or waiver.
Any release or waiver granted by the Placement Agent hereunder to any such officer or director shall only be effective two (2)
business days after the publication date of such press release. The provisions of this paragraph will not apply if (a) the release
or waiver is effected solely to permit a transfer of Lock-Up Securities not for consideration and (b) the transferee has agreed
in writing to be bound by the same terms described in this lock-up agreement to the extent and for the duration that such terms
remain in effect at the time of such transfer.

 

No provision in this
agreement shall be deemed to restrict or prohibit the exercise, exchange or conversion by the undersigned of any securities exercisable
or exchangeable for or convertible into Shares, as applicable; provided that the undersigned does not transfer the Shares
acquired on such exercise, exchange or conversion during the Lock-Up Period, unless otherwise permitted pursuant to the terms
of this lock-up agreement. In addition, no provision herein shall be deemed to restrict or prohibit the entry into or modification
of a so-called “10b5-1” plan at any time (other than the entry into or modification of such a plan in such a manner
as to cause the sale of any Lock-Up Securities within the Lock-Up Period).

 

The undersigned understands
that the Company and the Placement Agent are relying upon this lock-up agreement in proceeding toward consummation of the Public
Offering. The undersigned further understands that this lock-up agreement is irrevocable and shall be binding upon the undersigned’s
heirs, legal Placement Agents, successors and assigns.

 

The undersigned understands
that, if the Placement Agency Agreement is not executed by July 31, 2019, or if the Placement Agency Agreement (other than the
provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Shares
to be sold thereunder, then this lock-up agreement shall be void and of no further force or effect.

 

Whether or not the
Public Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only be
made pursuant to a Placement Agency Agreement, the terms of which are subject to negotiation between the Company and the Placement
Agent.

 

	 	Very truly yours,	 
	 	 	 
	 	 	 
	 	(Name - Please Print)	 

 

    	 	Ex. B-2	 

     

    

 

	 	 	 (Signature)
	 	 	 
	 	 	 
	 	(Name of Signatory, in the case of entities - Please Print)
	 	 
	 	 	 
	 	(Title of Signatory, in the case of entities - Please Print)

 

	 	Address:	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

    	 	Ex. B-3	 

     

    

 

EXHIBIT C

 

Form of Press Release

 

AMPIO PHARMACEUTICALS, INC.

 

[Date]

 

[COMPANY] (the “Company”)
announced today that ThinkEquity, a division of Fordham Financial Management, Inc., acting as Placement Agent in the Company’s
recent public offering of  _______ shares of the Company’s common stock, is [waiving] [releasing] a lock-up restriction
with respect to _________  shares of the Company’s common stock held by [certain officers or directors] [an officer
or director] of the Company.  The [waiver] [release] will take effect on  _________, 20___, and the shares may be sold
on or after such date.  

 

This press release is not an offer
or sale of the securities in the United States or in any other jurisdiction where such offer or sale is prohibited, and such securities
may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act
of 1933, as amended.

 

    	 	Ex. C-1Exhibit 10.2

 

SECURITIES PURCHASE AGREEMENT 

 

This SECURITIES PURCHASE AGREEMENT (this
“Agreement”), dated as of June 17, 2019, is by and among Ampio Pharmaceuticals, Inc., a Delaware corporation
with headquarters located at 373 Inverness Parkway, Suite 200, Englewood, Colorado 80112 (the “Company”),
and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively,
the “Buyers”).

 

RECITALS 

 

A. The Company and each Buyer desire to
enter into this transaction to purchase the Common Shares (as defined below) pursuant to a currently effective shelf registration
statement on Form S-3, which originally registered $100,000,000 of unallocated securities, including Common Stock (as defined below)
registered thereunder (Registration Number 333-217094) (the “Registration Statement”), which Registration Statement
has been declared effective in accordance with the Securities Act of 1933, as amended (the “1933 Act”), by the
United States Securities and Exchange Commission (the “SEC”). The Company has announced a public offering (the
“Offering” pursuant to the Registration Statement, which will include the securities offered and sold to the
Buyers and such other investors (the “Other Investors”) identified by the Placement Agent (as defined below)
or such selected dealers engaged by the Placement Agent in connection with the Offering.

 

B. Each Buyer wishes to purchase, and the
Company wishes to sell, upon the terms and conditions stated in this Agreement, such aggregate number of shares of Common Stock
as set forth opposite such Buyer’s name in column (2) on the Schedule of Buyers (which aggregate amount for all Buyers
and the Other Investors shall be 30,000,000 shares of Common Stock and shall collectively be referred to herein as the “Common
Shares”).

 

AGREEMENT 

 

NOW, THEREFORE, in consideration of the
premises and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Company and each Buyer hereby agree as follows:

 

1. PURCHASE AND SALE OF COMMON SHARES. 

 

(a) Purchase of Common Shares. Subject
to the satisfaction (or waiver) of the conditions set forth in Sections 6 and 7 below, the Company shall issue and sell to each
Buyer, and each Buyer severally, but not jointly, agrees to purchase from the Company on the Closing Date (as defined below) such
aggregate number of Common Shares as is set forth opposite such Buyer’s name in column (2) on the Schedule of Buyers
or as identified by each Buyer in the Purchaser Signature Page attached to this Agreement.

 

(b) Closing. The closing (the
“Closing”) of the purchase of the Common Shares by the Buyers shall occur at the offices of Loeb & Loeb
LLP, 345 Park Avenue, New York, NY 10154. The date and time of the Closing (the “Closing Date”) shall be 10:00
a.m., New York time, on the first (1st) Business Day (as defined below) on which the conditions to the Closing set forth in
Sections 6 and 7 below are satisfied or waived (or such other date as is mutually agreed to by the Company and each Buyer). As
used herein “Business Day” means any day other than a Saturday, Sunday or other day on which commercial banks
in New York, New York are authorized or required by law to remain closed.

 

(c) Purchase Price. The aggregate
purchase price for the Common Shares to be purchased by each Buyer (the “Purchase Price”) shall be the amount
set forth opposite such Buyer’s name in column (3) on the Schedule of Buyers or as identified by each Buyer in the Purchaser
Signature Page attached to this Agreement.

 

     

     

    

 

(d) Form of Payment; Deliveries.
On the Closing Date, (i) the Purchase Price will be released to the Company either (a) by ThinkEquity, a Division of Fordham
Financial Management, Inc. (the “Placement Agent”) on behalf of each Buyer for the Common Shares to be issued
and sold to such Buyer at the Closing, by wire transfer of immediately available funds in accordance with the flow of funds letter
regarding the Closing, or (b) by the Buyer wiring the Purchase Price to the Company by wire transfer to an account designated in
writing by the Company, and (ii) the Company shall (A) cause Corporate Stock Transfer, Inc. (together with
any subsequent transfer agent, the “Transfer Agent”) through the Depository Trust Company (“DTC”)
Fast Automated Securities Transfer Program, to credit such aggregate number of Common Shares that each Buyer is purchasing as is
set forth opposite such Buyer’s name in column (2) of the Schedule of Buyers and as identified by each Buyer in the
Purchaser Signature Page attached to this Agreement to either(a) the Placement Agent’s balance account with DTC through its
Deposit/Withdrawal at Custodian system, or (b) directly to the account of each Buyer, or its respective nominee(s), at the designated
account with DTC as provided on the Purchaser Signature Page (if applicable).

 

2. BUYER’S REPRESENTATIONS AND WARRANTIES. 

 

Each Buyer, severally and not jointly,
represents and warrants to the Company with respect to only itself that, as of the date hereof and as of the Closing Date:

 

(a) Organization; Authority.
If such Buyer is an entity, it is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction
of its organization with the requisite power and authority to enter into and to consummate the transactions contemplated by the
Transaction Documents (as defined below) to which it is a party and otherwise to carry out its obligations hereunder and thereunder.

 

(b) Validity; Enforcement. This
Agreement has been duly and validly authorized, executed and delivered on behalf of such Buyer and shall constitute the legal,
valid and binding obligations of such Buyer enforceable against such Buyer in accordance with its terms, except as such enforceability
may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation
and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

(c) No Conflicts. The execution,
delivery and performance by such Buyer of this Agreement and the consummation by such Buyer of the transactions contemplated hereby
will not (i) result in a violation of the organizational documents of such Buyer, (ii) conflict with, or constitute a
default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such Buyer is a party
or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities
laws) applicable to such Buyer, except, in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights
or violations which could not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the
ability of such Buyer to perform its obligations hereunder.

 

(d) Certain Transactions and Confidentiality.
Other than consummating the transactions contemplated hereunder, such Buyer has not, nor has any Person acting on behalf of or
pursuant to any understanding with such Buyer, directly or indirectly executed any purchases or sales, including “short sales”
(as defined in Rule 200 of Regulation SHO under the 1934 Act) of the securities of the Company during the period commencing
as of the time that such Buyer first sent to, or received from, the Company or any other Person representing the Company (including
the Placement Agent) a term sheet (written or oral) setting forth the material terms of the transactions contemplated hereunder
and ending immediately prior to the execution hereof. Other than to other Persons party to this Agreement or to such Buyer’s
representatives and financing partners, including, without limitation, their respective officers, directors, partners, legal and
other advisors, employees, agents and affiliates, such Buyer has maintained the confidentiality of all disclosures made to it in
connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance
of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the
identification of the availability of, or securing of, available shares to borrow in order to effect short sales or similar transactions
in the future.

 

    2

     

    

 

3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. 

 

The Company represents and warrants to
each of the Buyers that, as of the date hereof and as of the Closing Date:

 

(a) Organization and Qualification.
Each of the Company and each of its Subsidiaries are entities duly organized and validly existing and in good standing under the
laws of the jurisdiction in which they are formed, and have the requisite power and authority to own their properties and to carry
on their business as now being conducted and as presently proposed to be conducted. Each of the Company and each of its Subsidiaries
is duly qualified as a foreign entity to do business and is in good standing in every jurisdiction in which its ownership of property
or the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so
qualified or be in good standing would not reasonably be expected to have a Material Adverse Effect (as defined below). As used
in this Agreement, “Material Adverse Effect” means any material adverse effect on (i) the business, properties,
assets, liabilities, operations (including results thereof), condition (financial or otherwise) or prospects of the Company, taken
as a whole, (ii) the transactions contemplated hereby or in any of the other Transaction Documents or any other agreements
or instruments to be entered into in connection herewith or therewith or (iii) the authority or ability of the Company or
any of its Subsidiaries to perform any of their respective obligations under any of the Transaction Documents (as defined below).
Other than the persons set forth on Schedule 3.(a) attached hereto, the Company has no Subsidiaries. “Subsidiaries”
means any Person in which the Company, directly or indirectly, (A) owns any of the outstanding capital stock or holds any
equity or similar interest of such Person or (B) controls or operates all or any part of the business, operations or administration
of such Person, and each of the foregoing, is individually referred to herein as a “Subsidiary”.

 

(b) Authorization; Enforcement;
Validity. The Company has the requisite power and authority to enter into and perform its obligations under this Agreement
and the other Transaction Documents and to issue the Common Shares in accordance with the terms hereof and thereof. The execution
and delivery of this Agreement and the other Transaction Documents by the Company and the consummation by the Company of the transactions
contemplated hereby and thereby (including, without limitation, the issuance of the Common Shares) have been duly authorized by
the Company’s board of directors and (other than the filing with the SEC of the prospectus supplement required by the Registration
Statement pursuant to Rule 424(b) under the 1933 Act (the “Prospectus Supplement”) supplementing the base prospectus
forming part of the Registration Statement (the “Prospectus”) and any other filings as may be required by any
state securities agencies) no further filing, consent or authorization is required by the Company, its board of directors or its
stockholders or other governing body. This Agreement has been, and the other Transaction Documents will be prior to the Closing,
duly executed and delivered by the Company, and each constitutes the legal, valid and binding obligations of the Company, enforceable
against the Company in accordance with its respective terms, except as such enforceability may be limited by general principles
of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting
generally, the enforcement of applicable creditors’ rights and remedies and except as rights to indemnification and to contribution
may be limited by federal or state securities law. “Transaction Documents” means, collectively, this Agreement,
the Common Shares, the Irrevocable Transfer Agent Instructions (as defined below), and each of the other agreements and instruments
entered into or delivered by any of the parties hereto in connection with the transactions contemplated hereby and thereby, as
may be amended from time to time.

 

(c) Issuance of Common Shares;
Registration Statement. The issuance of the Common Shares is duly authorized and, upon issuance and payment in accordance with
the terms of the Transaction Documents such Common Shares shall be validly issued, fully paid and non-assessable and free from
all preemptive or similar rights, mortgages, defects, claims, liens, pledges, charges, taxes, rights of first refusal, encumbrances,
security interests and other encumbrances (collectively “Liens”) with respect to the issuance thereof. The issuance
by the Company of the Common Shares has been registered under the 1933 Act, the Common Shares are being issued pursuant to the
Registration Statement and all of the Common Shares are freely transferable and freely tradable by each of the Buyers without restriction,
whether by way of registration or some exemption therefrom. The Registration Statement is effective and available for the issuance
of the Common Shares thereunder and the Company has not received any notice that the SEC has issued or intends to issue a stop-order
with respect to the Registration Statement or that the SEC otherwise has suspended or withdrawn the effectiveness of the Registration
Statement, either temporarily or permanently, or intends or has threatened in writing to do so. The “Plan of Distribution”
section under the Registration Statement permits the issuance and sale of the Common Shares hereunder and as contemplated by the
other Transaction Documents. Upon receipt of the Common Shares, each of the Buyers will have good and marketable title to the Common
Shares. The Registration Statement and any prospectus included therein, including the Prospectus and the Prospectus Supplement,
complied in all material respects with the requirements of the 1933 Act and the Securities Exchange Act of 1934, as amended (the
“1934 Act”) and the rules and regulations of the SEC promulgated thereunder and all other applicable laws and
regulations. At the time the Registration Statement and any amendments thereto became effective, at the date of this Agreement
and at each deemed effective date thereof pursuant to Rule 430B(f)(2) of the 1933 Act, the Registration Statement and any amendments
thereto complied and will comply in all material respects with the requirements of the 1933 Act and did not and will not contain
any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the
statements therein not misleading. The Prospectus and any amendments or supplements thereto (including, without limitation the
Prospectus Supplement), at the time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, complied,
and will comply, in all material respects with the requirements of the 1933 Act and did not, and will not, contain any untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. The Company meets all of the requirements for the use of Form S-3 under the 1933 Act
for the offering and sale of the Common Shares contemplated by this Agreement and the other Transaction Documents, and the SEC
has not notified the Company of any objection to the use of the form of the Registration Statement pursuant to Rule 401(g)(1) under
the 1933 Act. The Registration Statement meets the requirements set forth in Rule 415(a)(1)(x) under the 1933 Act. At the earliest
time after the filing of the Registration Statement that the Company or another offering participant made a bona fide offer (within
the meaning of Rule 164(h)(2) under the 1933 Act) relating to any of the Common Shares, the Company was not and is not an “Ineligible
Issuer” (as defined in Rule 405 under the 1933 Act). The Company (i) has not distributed any offering material in connection
with the offer or sale of any of the Common Shares and (ii)  shall not distribute any offering material in connection with
the offer or sale of any of the Common Shares, in each case, other than the Registration Statement, the Prospectus, any Permitted
Free Writing Prospectus or the Prospectus Supplement.

 

    3

     

    

 

(d) No Conflicts. The execution,
delivery and performance of the Transaction Documents by the Company and the consummation by the Company of the transactions contemplated
hereby and thereby (including, without limitation, the issuance of the Common Shares) will not (i) result in a violation of
the Certificate of Incorporation (as defined below) (including, without limitation, any certificate of designation contained therein),
Bylaws (as defined below), certificate of formation, memorandum of association, articles of association, bylaws or other organizational
documents of the Company or any of its Subsidiaries, or any capital stock or other securities of the Company or any of its Subsidiaries,
(ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default)
in any respect under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture
or instrument to which the Company or any of its Subsidiaries is a party, or (iii) result in a violation of any law, rule,
regulation, order, judgment or decree (including, without limitation, foreign, federal and state securities laws and regulations
and the rules and regulations of NYSE American (the “Principal Market”) and including all applicable foreign,
federal and state laws, rules and regulations) applicable to the Company or any of its Subsidiaries or by which any property or
asset of the Company or any of its Subsidiaries is bound or affected; except in the case of each of clauses (ii) and
(iii), such as would not reasonably be expected to result in a Material Adverse Effect.

 

(e) Consents. Neither the Company
nor any Subsidiary is required to obtain any consent from, authorization or order of, or make any filing or registration with (other
than the filing with the SEC of the Prospectus Supplement and any other filings as may be required by any state securities agencies),
any Governmental Entity (as defined below) or any regulatory or self-regulatory agency (other than filings required to be made
with the Principal Market relating to the listing of additional shares) any other Person in order for it to execute, deliver or
perform any of its respective obligations under or contemplated by the Transaction Documents, in each case, in accordance with
the terms hereof or thereof. All consents, authorizations, orders, filings and registrations which the Company or any Subsidiary
is required to obtain pursuant to the preceding sentence have been or will be obtained or effected on or prior to the Closing Date,
and neither the Company nor any of its Subsidiaries are aware of any facts or circumstances which might prevent the Company or
any of its Subsidiaries from obtaining or effecting any of the registration, application or filings contemplated by the Transaction
Documents except as would not reasonably be expected to result in a Material Adverse Effect. “Governmental Entity”
means any nation, state, county, city, town, village, district, or other political jurisdiction of any nature, federal, state,
local, municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including any governmental
agency, branch, department, official, or entity and any court or other tribunal), multi-national organization or body; or body
exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority
or power of any nature or instrumentality of any of the foregoing, including any entity or enterprise owned or controlled by a
government or a public international organization or any of the foregoing.

 

    4

     

    

 

(f) Acknowledgment Regarding Buyer’s
Purchase of Common Shares. The Company acknowledges and agrees that each Buyer is acting solely in the capacity of an arm’s
length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby and that no Buyer
is (i) an officer or director of the Company or any of its Subsidiaries, (ii) an “affiliate” (as defined
in Rule 144 promulgated under the 1933 Act (or a successor rule thereto) (collectively, “Rule 144”)) of the
Company or any of its Subsidiaries or (iii) to its knowledge, a “beneficial owner” of more than 10% of the shares
of Common Stock (as defined for purposes of Rule 13d-3 of the 1934 Act). The Company further acknowledges that no Buyer is acting
as a financial advisor or fiduciary of the Company or any of its Subsidiaries (or in any similar capacity) with respect to the
Transaction Documents and the transactions contemplated hereby and thereby, and any advice given by a Buyer or any of its representatives
or agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental
to such Buyer’s purchase of the Common Shares. The Company further represents to each Buyer that the Company’s decision
to enter into the Transaction Documents is based solely on the independent evaluation by the Company and its representatives.

 

(g) Placement Agent’s Fees.
The Company shall be responsible for the payment of any placement agent’s fees, financial advisory fees, or brokers’
commissions (other than for Persons engaged by any Buyer or its investment advisor) relating to or arising out of the transactions
contemplated hereby, including, without limitation, placement agent fees payable to the Placement Agent in connection with the
sale of the Common Shares. The fees and expenses of the Placement Agent to be paid by the Company or any of its Subsidiaries are
as set forth on Schedule 3.(g) attached hereto. The Company shall pay, and hold each Buyer harmless against, any liability,
loss or expense (including, without limitation, attorney’s fees and out-of-pocket expenses) arising in connection with any
such claim. The Company acknowledges that it has engaged the Placement Agent in connection with the sale of the Common Shares.
Other than the Placement Agent and such agent’s advisors, neither the Company nor any of its Subsidiaries has engaged any
placement agent or other agent in connection with the offer or sale of the Common Shares.

 

(h) No Integrated Offering.
Assuming the accuracy of the Buyers’ representations and warranties set forth in Section 2, neither the Company, nor
any of its affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any
security or solicited any offers to buy any security, under circumstances that would cause this offering of the Common Shares to
be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Principal
Market on which any of the securities of the Company are listed or designated.

 

(i) Application of Takeover Protections;
Rights Agreement. The Company and its board of directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, interested stockholder, business combination, poison pill (including, without limitation, any distribution
under a rights agreement), stockholder rights plan or other similar anti-takeover provision under the Certificate of Incorporation,
Bylaws or other organizational documents or the laws of the jurisdiction of its incorporation or otherwise which is or could become
applicable to any Buyer as a result of the transactions contemplated by this Agreement, including, without limitation, the Company’s
issuance of the Common Shares and any Buyer’s ownership of the Common Shares. The Company and its board of directors have
taken all necessary action, if any, in order to render inapplicable any stockholder rights plan or similar arrangement relating
to accumulations of beneficial ownership of shares of Common Stock or a change in control of the Company or any of its Subsidiaries.

 

(j) SEC Documents; Financial Statements.
During the two (2) years prior to the date hereof, the Company has timely filed all reports, schedules, forms, proxy statements,
statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the 1934 Act (all
of the foregoing filed prior to the date hereof and all exhibits and appendices included therein and financial statements, notes
and schedules thereto and documents incorporated by reference therein being hereinafter referred to as the “SEC Documents”).
As of their respective dates, the SEC Documents complied in all material respects with the requirements of the 1934 Act and the
rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents, at the
time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required
to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading. As of their respective dates, the financial statements of the Company included in the SEC Documents complied
in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect
thereto as in effect as of the time of filing. Such financial statements have been prepared in accordance with generally accepted
accounting principles (“GAAP”), consistently applied, during the periods involved (except (i) as may be
otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited interim statements,
to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects
the financial position of the Company as of the dates thereof and the results of its operations and cash flows for the periods
then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments which will not be material, either
individually or in the aggregate). The reserves, if any, established by the Company or the lack of reserves, if applicable, are
reasonable based upon facts and circumstances known by the Company on the date hereof and there are no loss contingencies that
are required to be accrued by the Statement of Financial Accounting Standard No. 5 of the Financial Accounting Standards Board
which are not provided for by the Company in its financial statements or otherwise. The Company is not currently contemplating
to amend or restate any of the financial statements (including, without limitation, any notes or any letter of the independent
accountants of the Company with respect thereto) included in the SEC Documents (the “Financial Statements”),
nor is the Company currently aware of facts or circumstances which would require the Company to amend or restate any of the Financial
Statements, in each case, in order for any of the Financials Statements to be in compliance with GAAP and the rules and regulations
of the SEC. The Company has not been informed by its independent accountants that they recommend that the Company amend or restate
any of the Financial Statements or that there is any need for the Company to amend or restate any of the Financial Statements.

 

    5

     

    

 

(k) Absence of Certain Changes.
Since the date of the Company’s most recent audited financial statements contained in a Form 10-K, there has been no event,
occurrence or development that has had or that would reasonably be expected to result in a Material Adverse Effect. Since the date
of the Company’s most recent audited financial statements contained in a Form 10-K, neither the Company nor any of its Subsidiaries
has (i) declared or paid any dividends, (ii) sold any assets, individually or in the aggregate, outside of the ordinary
course of business or (iii) made any capital expenditures, individually or in the aggregate, outside of the ordinary course
of business. Neither the Company nor any of its Subsidiaries has taken any steps to seek protection pursuant to any law or statute
relating to bankruptcy, insolvency, reorganization, receivership, liquidation or winding up, nor does the Company or any Subsidiary
have any knowledge or reason to believe that any of their respective creditors intend to initiate involuntary bankruptcy proceedings
or any actual knowledge of any fact which would reasonably lead a creditor to do so. The Company and its Subsidiaries, on a consolidated
basis, after giving effect to the transactions contemplated hereby to occur at the Closing, will not be Insolvent (as defined below).
For purposes of this Section 3.(k), “Insolvent” means, (i) with respect to the Company and its Subsidiaries,
on a consolidated basis, (A) the present fair saleable value of the Company’s and its Subsidiaries’ assets is
less than the amount required to pay the Company’s and its Subsidiaries’ total Indebtedness (as defined below), (B) the
Company and its Subsidiaries are unable to pay their debts and liabilities, subordinated, contingent or otherwise, as such debts
and liabilities become absolute and matured or (C) the Company and its Subsidiaries intend to incur or believe that they will
incur debts that would be beyond their ability to pay as such debts mature; and (ii) with respect to the Company and each
Subsidiary, individually, (A) the present fair saleable value of the Company’s or such Subsidiary’s (as the case
may be) assets is less than the amount required to pay its respective total Indebtedness, (B) the Company or such Subsidiary
(as the case may be) is unable to pay its respective debts and liabilities, subordinated, contingent or otherwise, as such debts
and liabilities become absolute and matured or (C) the Company or such Subsidiary (as the case may be) intends to incur or
believes that it will incur debts that would be beyond its respective ability to pay as such debts mature. Neither the Company
nor any of its Subsidiaries has engaged in any business or in any transaction, and is not about to engage in any business or in
any transaction, for which the Company’s or such Subsidiary’s remaining assets constitute unreasonably small capital
with which to conduct the business in which it is engaged as such business is now conducted and is proposed to be conducted.

 

(l) No Undisclosed Events, Liabilities,
Developments or Circumstances. No event, liability, development or circumstance has occurred or exists, or is reasonably expected
to exist or occur with respect to the Company, any of its Subsidiaries or any of their respective businesses, properties, liabilities,
prospects, operations (including results thereof) or condition (financial or otherwise), that (i) would be required to be
disclosed by the Company under applicable securities laws and (ii) would reasonably be expected to result in a Material Adverse
Effect.

 

    6

     

    

 

(m) Conduct of Business; Regulatory
Permits. Neither the Company nor any of its Subsidiaries is in violation of any term of or in default under its Certificate
of Incorporation, any certificate of designation, preferences or rights of any other outstanding series of preferred stock of the
Company or any of its Subsidiaries or Bylaws or their organizational charter, certificate of formation, memorandum of association,
articles of association, Certificate of Incorporation or certificate of incorporation or bylaws, respectively. Neither the Company
nor any of its Subsidiaries is in violation of any judgment, decree or order or any statute, ordinance, rule or regulation applicable
to the Company or any of its Subsidiaries, and neither the Company nor any of its Subsidiaries will conduct its business in violation
of any of the foregoing, except in all cases for possible violations which would not, individually or in the aggregate, reasonably
be expected to result in a Material Adverse Effect. During the two years prior to the date hereof, (i) the Common Stock has
been listed or designated for quotation on the Principal Market, (ii) trading in the Common Stock has not been suspended by
the SEC or the Principal Market and (iii) except as disclosed in the SEC Documents, the Company has received no communication,
written or oral, from the SEC or the Principal Market regarding the suspension or delisting of the Common Stock from the Principal
Market. The Company and each of its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
regulatory authorities necessary to conduct their respective businesses, except where the failure to possess such certificates,
authorizations or permits would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect,
and neither the Company nor any such Subsidiary has received any notice of proceedings relating to the revocation or modification
of any such certificate, authorization or permit. There is no agreement, commitment, judgment, injunction, order or decree binding
upon the Company or any of its Subsidiaries or to which the Company or any of its Subsidiaries is a party which has or would reasonably
be expected to have the effect of prohibiting or materially impairing any business practice of the Company or any of its Subsidiaries,
any acquisition of property by the Company or any of its Subsidiaries or the conduct of business by the Company or any of its Subsidiaries
as currently conducted other than such effects, individually or in the aggregate, which would not, individually or in the aggregate,
reasonably be expected to result in a Material Adverse Effect on the Company or any of its Subsidiaries.

 

(n) Foreign Corrupt Practices. None
of the Company, its Subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, nor any other person
acting for or on behalf of the foregoing (individually and collectively, a “Company Affiliate”) have violated
the U.S. Foreign Corrupt Practices Act (the “FCPA”) or any other applicable anti-bribery or anti-corruption
laws, nor has any Company Affiliate offered, paid, promised to pay, or authorized the payment of any money, or offered, given,
promised to give, or authorized the giving of anything of value, to any officer, employee or any other person acting in an official
capacity for any Governmental Entity to any political party or official thereof or to any candidate for political office (individually
and collectively, a “Government Official”) or to any person under circumstances where such Company Affiliate
knew or was aware of a high probability that all or a portion of such money or thing of value would be offered, given or promised,
directly or indirectly, to any Government Official, for the purpose of:

 

(i) (A) influencing any
act or decision of such Government Official in his/her official capacity, (B) inducing such Government Official to do or omit
to do any act in violation of his/her lawful duty, (C) securing any improper advantage, or (D) inducing such Government
Official to influence or affect any act or decision of any Governmental Entity, or

 

(ii) assisting the Company
or its Subsidiaries in obtaining or retaining business for or with, or directing business to, the Company or its Subsidiaries.

 

(o) Sarbanes-Oxley Act. The
Company is in material compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, and any
and all applicable rules and regulations promulgated by the SEC thereunder.

 

(p) Transactions With Affiliates.
Except as disclosed in the SEC Documents or set forth on Schedule 3(p), there are no transactions between the Company or
any Subsidiaries, on the one hand, and Affiliates of the Company or any Subsidiaries, on the other hand.

 

(q) Equity Capitalization.

 

(i) Definitions:

 

(A) “Common Stock”
means (x) the Company’s shares of common stock, $0.0001 par value per share, and (y) any capital stock into which
such common stock shall have been changed or any share capital resulting from a reclassification of such common stock.

 

(B) “Preferred Stock”
means (x) the Company’s blank check preferred stock, $0.0001 par value per share, the terms of which may be designated
by the board of directors of the Company in a certificate of designations and (y) any capital stock into which such preferred
stock shall have been changed or any share capital resulting from a reclassification of such preferred stock (other than a conversion
of such preferred stock into Common Stock in accordance with the terms of such certificate of designations).

 

(ii) Authorized and
Outstanding Capital Stock. Immediately prior to the consummation of the transactions contemplated hereby, the authorized capital
stock of the Company consists of (A) 200,000,000 shares of Common Stock, of which, 111,382,862 are issued and outstanding
and 27,729,856 shares are reserved for issuance pursuant to Convertible Securities (as defined below exercisable or exchangeable
for, or convertible into, shares of Common Stock and (B) 10,000,000 shares of Preferred Stock, none of which are issued and
outstanding. No shares of Common Stock are held in the treasury of the Company.

 

    7

     

    

 

(iii) Valid Issuance; Available
Shares; Affiliates. All of such outstanding shares are duly authorized and have been, or upon issuance will be, validly issued
and are fully paid and nonassessable. Schedule 3.(q)(iii) sets forth the number of shares of Common Stock that are
reserved for issuance pursuant to Convertible Securities (as defined below). To the Company’s knowledge, except as set forth
on Schedule 3.(q)(iii) no Person owns 10% or more of the Company’s issued and outstanding shares of Common Stock (calculated
based on the assumption that all Convertible Securities (as defined below), whether or not presently exercisable or convertible,
have been fully exercised or converted (as the case may be) taking account of any limitations on exercise or conversion
(including “blockers”) contained therein without conceding that such identified Person is a 10% stockholder for purposes
of federal securities laws).

 

(iv) Existing Securities;
Obligations. Except as set forth on Schedule 3(q)(iv): (A) none of the Company’s or any Subsidiary’s
shares, interests or capital stock is subject to preemptive rights or any other similar rights or Liens suffered or permitted by
the Company or any Subsidiary; (B) there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments
of any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any shares,
interests or capital stock of the Company or any of its Subsidiaries (“Convertible Securities”), or contracts, commitments,
understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional shares,
interests or capital stock of the Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls
or commitments of any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable
for, any shares, interests or capital stock of the Company or any of its Subsidiaries; (C) there are no agreements or arrangements
under which the Company or any of its Subsidiaries is obligated to register the sale of any of their securities under the 1933
Act (except pursuant to this Agreement); (D) there are no outstanding securities or instruments of the Company or any of its
Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements
by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries;
(E) there are no securities or instruments containing anti-dilution or similar provisions; and (F) neither the Company
nor any Subsidiary has any stock appreciation rights or “phantom stock” plans or agreements or any similar plan or
agreement.

 

(v) Organizational
Documents. The Company has filed on EDGAR true, correct and complete copies of the Company’s Certificate of Incorporation,
as amended and as in effect on the date hereof (the “Certificate of Incorporation”), and the Company’s
bylaws, as amended and as in effect on the date hereof (the “Bylaws”), and the terms of all Convertible Securities
and the material rights of the holders thereof in respect thereto.

 

(r) Indebtedness and Other Contracts.
Neither the Company nor any of its Subsidiaries, (i) except as set forth in the SEC Documents or on Schedule 3(r),
has any outstanding debt securities, notes, credit agreements, credit facilities or other agreements, documents or instruments
evidencing Indebtedness of the Company or any of its Subsidiaries or by which the Company or any of its Subsidiaries is or may
become bound other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent
with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to
GAAP or disclosed in filings made with the SEC, (ii) is a party to any contract, agreement or instrument, the violation of
which, or default under which, by the other party(ies) to such contract, agreement or instrument would reasonably be expected to
result in a Material Adverse Effect, (iii) has any financing statements securing obligations in any amounts filed in connection
with the Company or any of its Subsidiaries; (iv) is in violation of any term of, or in default under, any contract, agreement
or instrument relating to any Indebtedness, except where such violations and defaults would not, individually or in the aggregate,
reasonably be expected to result in a Material Adverse Effect, or (v) is a party to any contract, agreement or instrument
relating to any Indebtedness, the performance of which, in the judgment of the Company’s officers, has or would reasonably
be expected to result in a Material Adverse Effect. For purposes of this Agreement: (x) “Indebtedness”
of any Person means, without duplication (A) all indebtedness for borrowed money, (B) all obligations issued, undertaken
or assumed as the deferred purchase price of property or services (including, without limitation, “capital leases”
in accordance with GAAP) (other than trade payables entered into in the ordinary course of business consistent with past practice),
(C) all reimbursement or payment obligations with respect to letters of credit, surety bonds and other similar instruments,
(D) all obligations evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred
in connection with the acquisition of property, assets or businesses, (E) all indebtedness created or arising under any conditional
sale or other title retention agreement, or incurred as financing, in either case with respect to any property or assets acquired
with the proceeds of such indebtedness (even though the rights and remedies of the seller or bank under such agreement in the event
of default are limited to repossession or sale of such property), (F) all monetary obligations under any leasing or similar
arrangement which, in connection with GAAP, consistently applied for the periods covered thereby, is classified as a capital lease,
(G) all indebtedness referred to in clauses (A) through (F) above secured by (or for which the holder of such Indebtedness
has an existing right, contingent or otherwise, to be secured by) any Lien upon or in any property or assets (including accounts
and contract rights) owned by any Person, even though the Person which owns such assets or property has not assumed or become liable
for the payment of such indebtedness, and (H) all Contingent Obligations in respect of indebtedness or obligations of others
of the kinds referred to in clauses (A) through (G) above; (y) “Contingent Obligation” means,
as to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to any Indebtedness, lease,
dividend or other obligation of another Person if the primary purpose or intent of the Person incurring such liability, or the
primary effect thereof, is to provide assurance to the obligee of such liability that such liability will be paid or discharged,
or that any agreements relating thereto will be complied with, or that the holders of such liability will be protected (in whole
or in part) against loss with respect thereto; and (z) “Person” means an individual, a limited liability
company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and any Governmental
Entity or any department or agency thereof.

 

    8

     

    

 

(s) Litigation. Except as disclosed
in the SEC Documents or the Prospectus Supplement, there is no action, suit, arbitration, proceeding, inquiry or investigation
before or by the Principal Market, any court, public board, other Governmental Entity, self-regulatory organization or body pending
or, to the knowledge of the Company, threatened in writing against or affecting the Company or any of its Subsidiaries, the Common
Stock or any of the Company’s or its Subsidiaries’ officers or directors, whether of a civil or criminal nature or
otherwise, in their capacities as such, which (i) adversely affects or challenges the legality, validity or enforceability
of any of the Transaction Documents or the Common Shares or (ii) would, if there were an unfavorable decision, have or reasonably
be expected to result in a Material Adverse Effect. To the Company’s knowledge, no director, officer or employee of the Company
or any of its Subsidiaries has willfully violated 18 U.S.C. §1519 or engaged in spoliation in reasonable anticipation of litigation.
Without limitation of the foregoing, there has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation by the SEC involving the Company, any of its Subsidiaries or any current or former director or officer of the
Company or any of its Subsidiaries other than as disclosed in the SEC Documents or the Prospectus Supplement. The SEC has not issued
any stop order or other order suspending the effectiveness of any registration statement filed by the Company under the 1933 Act
or the 1934 Act, including, without limitation, the Registration Statement. Neither the Company nor any of its Subsidiaries is
subject to any order, writ, judgment, injunction, decree, determination or award of any Governmental Entity that would be required
to be disclosed in the SEC Documents.

 

(t) Insurance. The Company
and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and its Subsidiaries
are engaged. Neither the Company nor any such Subsidiary has been refused any insurance coverage sought or applied for, and neither
the Company nor any such Subsidiary has any reason to believe that it will be unable to renew its existing insurance coverage as
and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business
at a cost that would not reasonably be expected to have a Material Adverse Effect.

 

(u) Employee Relations. Neither
the Company nor any of its Subsidiaries is a party to any collective bargaining agreement or employs any member of a union. The
Company and its Subsidiaries believe that their relations with their employees are good. No executive officer (as defined in Rule
501(f) promulgated under the 1933 Act) or other key employee of the Company or any of its Subsidiaries has notified the Company
or any such Subsidiary that such officer intends to leave the Company or any such Subsidiary or otherwise terminate such officer’s
employment with the Company or any such Subsidiary. The Company and its Subsidiaries are in compliance with all federal, state,
local and foreign laws and regulations respecting labor, employment and employment practices and benefits, terms and conditions
of employment and wages and hours, except where failure to be in compliance would not, individually or in the aggregate, reasonably
be expected to result in a Material Adverse Effect.

 

    9

     

    

 

(v) Real Property. Each of
the Company and its Subsidiaries holds good title to or has valid rights to lease or use, as the case may be, all real property,
facilities or other interests in real property owned or held by the Company or any of its Subsidiaries (the “Real Property”).
The Real Property is free and clear of all Liens and is not subject to any rights of way, building use restrictions, exceptions,
variances, reservations, or limitations of any nature except for (a) Liens for current taxes not yet due and (b) Liens
that do not impair the present or anticipated use of the property subject thereto. Any Real Property held under lease by the Company
or any of its Subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not material
and do not interfere with the use made and proposed to be made of such property and buildings by the Company or any of its Subsidiaries.

 

(w) Potential Products; FDA; EMEA

 

(i) Except as described in the SEC Documents,
the Company possesses all certificates, authorizations and permits issued by the appropriate federal, state or foreign regulatory
authorities necessary to conduct its business as currently conducted, including without limitation all such certificates, authorizations
and permits required by the United States Food and Drug Administration (the “FDA”) or any other federal, state
or foreign agencies or bodies engaged in the regulation of pharmaceuticals or biohazardous materials, except where the failure
to so possess such certificates, authorizations and permits, individually or in the aggregate, would not reasonably be expected
to result in a Material Adverse Effect. Except as described in the SEC Documents, the Company has not received any written notice
of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, individually
or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to have a Material
Adverse Effect.

 

(ii) Except to the extent disclosed in
the SEC Documents, the Company has not received any written notices or statements from the FDA, the European Medicines Agency (the
“EMEA”) or any other governmental agency that (i) any drug candidate of the Company described in the SEC
Documents (each a “Potential Product”) may or will be rejected or determined to be non-approvable; (ii) a
delay in time for review and/or approval of a marketing authorization application or marketing approval application in any jurisdiction
for any Potential Product is or may be required, requested or being implemented; (iii) one or more clinical studies for any
Potential Product shall or may be requested or required in addition to the clinical studies submitted to the FDA prior to the date
hereof as a precondition to or condition of issuance or maintenance of a marketing approval for any Potential Product; (iv) any
license, approval, permit or authorization to conduct any clinical trial of or market any product or Potential Product of the Company
has been, will be or may be suspended, revoked, modified or limited, except in the cases of clauses (i), (ii), (iii) and (iv) where
such rejections, determinations, delays, requests, suspensions, revocations, modifications or limitations would not reasonably
be expected to have, individually or in the aggregate, a Material Adverse Effect.

 

(iii) Except to the extent disclosed in
the SEC Documents, to the Company’s knowledge, the preclinical and clinical testing, application for marketing approval of,
manufacture, distribution, promotion and sale of the products and Potential Products of the Company is in compliance, in all material
respects, with all laws, rules and regulations applicable to such activities, including without limitation applicable good laboratory
practices, good clinical practices and good manufacturing practices, except for such non-compliance as would not reasonably be
expected to have, individually or in the aggregate, have a Material Adverse Effect. The descriptions of the results of such tests
and trials contained in the SEC Documents are complete and accurate in all material respects such that there would be no untrue
statement of a material fact or omission of a material fact necessary to make the statements in the SEC Documents, in light of
the circumstances under which they are made, not misleading. The Company is not aware of any studies, tests or trial the results
of which reasonably call into question the results of the tests and trials conducted by or on behalf of the Company that are described
or referred to in the SEC Documents. Except to the extent disclosed in the SEC Documents, the Company has not received written
notice of adverse finding, warning letter or clinical hold notice from the FDA or any non-U.S. counterpart of any of the foregoing,
or any untitled letter or other correspondence or notice from the FDA or any other governmental authority or agency or any institutional
or ethical review board alleging or asserting noncompliance with any law, rule or regulation applicable in any jurisdiction, except
notices, letters, and correspondences and non-U.S. counterparts thereof alleging or asserting such noncompliance as would not reasonably
be expected to have, individually or in the aggregate, have a Material Adverse Effect. Except to the extent disclosed in the SEC
Documents, the Company has not, either voluntarily or involuntarily, initiated, conducted or issued, or caused to be initiated,
conducted or issued, any recall, field correction, market withdrawal or replacement, safety alert, warning, “dear doctor”
letter, investigator notice, or other notice or action relating to an alleged or potential lack of safety or efficacy of any product
or Potential Product of the Company, any alleged product defect of any product or Potential Product of the Company, or any violation
of any material applicable law, rule, regulation or any clinical trial or marketing license, approval, permit or authorization
for any product or potential product of the Company, and the Company is not aware of any facts or information that would cause
it to initiate any such notice or action and has no knowledge or reason to believe that the FDA, the EMEA or any other governmental
agency or authority or any institutional or ethical review board or other non-governmental authority intends to impose, require,
request or suggest such notice or action.

 

    10

     

    

 

(x) Intellectual Property Rights.
The Company and its Subsidiaries own or possess, or can acquire on reasonable terms, adequate rights or licenses to use all trademarks,
trade names, service marks, service mark registrations, service names, original works of authorship, patents, patent rights, copyrights,
inventions, licenses, approvals, governmental authorizations, trade secrets and other intellectual property rights and all applications
and registrations therefor (“Intellectual Property Rights”) necessary to conduct their respective businesses
as now conducted. The Company does not have any knowledge of any infringement by the Company or its Subsidiaries of Intellectual
Property Rights of others. Except as disclosed in the SEC Documents, there is no claim, action or proceeding being made or brought,
or to the knowledge of the Company or any of its Subsidiaries, being threatened in writing, against the Company or any of its Subsidiaries
regarding its Intellectual Property Rights. Neither the Company nor any of its Subsidiaries is aware of any facts or circumstances
which might give rise to any of the foregoing infringements or claims, actions or proceedings. The Company and its Subsidiaries
have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their Intellectual Property
Rights.

 

(y) Environmental Laws. (i) The
Company and its Subsidiaries (A) are in compliance with any and all Environmental Laws (as defined below) applicable to their
business and operations, (B) have received all permits, licenses or other approvals required of them under applicable Environmental
Laws to conduct their respective businesses and (C) are in compliance with all terms and conditions of any such permit, license
or approval where, in each of the foregoing clauses (A), (B) and (C), the failure to so comply would be reasonably expected
to have, individually or in the aggregate, a Material Adverse Effect. The term “Environmental Laws” means all
federal, state, local or foreign laws relating to pollution or protection of human health or the environment (including, without
limitation, ambient air, surface water, groundwater, land surface or subsurface strata), including, without limitation, laws relating
to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances
or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating to the manufacture,
processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations,
codes, decrees, demands or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans
or regulations issued, entered, promulgated or approved thereunder.

 

(ii) No Hazardous Materials:

 

(A) have been disposed of or
otherwise released into any Real Property (as defined below) in violation of any Environmental Laws; or

 

(B) are present on, over, beneath,
in or upon any Real Property or any portion thereof in quantities that would constitute a violation of any Environmental Laws.
No prior use by the Company or any of its Subsidiaries of any Real Property has occurred that violates any Environmental Laws,
which violation would have a Material Adverse Effect.

 

(iii) Neither the Company nor
any of its Subsidiaries knows of any other person who or entity which has stored, treated, recycled, disposed of or otherwise located
any Hazardous Materials on any Real Property, including, without limitation, such substances as asbestos and polychlorinated biphenyls.

 

(iv) None of the Real Properties
are on any federal or state “Superfund” list or Liability Information System (“CERCLIS”) list or
any state environmental agency list of sites under consideration for CERCLIS, nor subject to any environmental related Liens.

 

(z) Subsidiary Rights. The
Company or one of its Subsidiaries has the unrestricted right to vote, and (subject to limitations imposed by applicable law) to
receive dividends and distributions on, all capital securities of its Subsidiaries as owned by the Company or such Subsidiary.

 

    11

     

    

 

(aa) Tax Status. The Company and
each of its Subsidiaries (i) has timely made or filed all foreign, federal and state income and all other tax returns, reports
and declarations required by any jurisdiction to which it is subject or has requested extensions thereof (except in any case
in which the failure so to file would not have a Material Adverse Effect), (ii) has timely paid all taxes and other governmental
assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except
those being contested in good faith and (iii) has set aside on its books provision reasonably adequate for the payment of
all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. The Company is not operated
in such a manner as to qualify as a passive foreign investment company, as defined in Section 1297 of the U.S. Internal Revenue
Code of 1986, as amended (the “Code”).

 

(bb) Internal Accounting and Disclosure
Controls. The Company and each of its Subsidiaries maintains “internal control over financial reporting” (as such
term is defined in Rule 13a-15(f) under the 1934 Act) that are designed to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including that
(i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
(iii) access to assets or incurrence of liabilities is permitted only in accordance with management’s general or specific
authorization and (iv) the recorded accountability for assets is compared with the existing assets and liabilities at reasonable
intervals and appropriate action is taken with respect to any difference. The Company has developed and maintains disclosure controls
and procedures (as such term is defined in Rule 13a-15(e) under the 1934 Act) and, except as disclosed in the SEC Documents, such
controls and procedures are effective to ensure that information required to be disclosed by the Company in the reports that it
files or submits under the 1934 Act is recorded, processed, summarized and reported within the time periods specified in the rules
and forms of the SEC, including, without limitation, controls and procedures designed to ensure that information required to be
disclosed by the Company in the reports that it files or submits under the 1934 Act is accumulated and communicated to the Company’s
management, including its principal executive officer or officers and its principal financial officer or officers, and legal counsel,
as appropriate, to allow timely decisions regarding required disclosure. Except as disclosed in the SEC Documents, neither the
Company nor any of its Subsidiaries has received any written notice or correspondence from any accountant or Governmental Entity
relating to any potential material weakness or significant deficiency in any part of the internal controls over financial reporting
of the Company or any of its Subsidiaries.

 

(cc) Off Balance Sheet Arrangements.
There is no transaction, arrangement, or other relationship between the Company or any of its Subsidiaries and an unconsolidated
or other off balance sheet entity that is required to be disclosed by the Company in its SEC Documents and is not so disclosed
or that otherwise could be reasonably likely to have a Material Adverse Effect.

 

(dd) Investment Company Status.
The Company is not, and upon consummation of the sale of the Common Shares will not be, an “investment company,” as
such term is defined in the Investment Company Act of 1940, as amended.

 

(ee) Acknowledgement Regarding
Buyers’ Trading Activity. It is understood and acknowledged by the Company that (i) following the public disclosure
of the transactions contemplated by the Transaction Documents, in accordance with the terms thereof, none of the Buyers have been
asked by the Company or any of its Subsidiaries to agree, nor has any Buyer agreed with the Company or any of its Subsidiaries,
to desist from effecting any transactions in or with respect to (including, without limitation, purchasing or selling, long and/or
short) any securities of the Company, or “derivative” securities based on securities issued by the Company or to hold
any of the Common Shares for any specified term; (ii) any Buyer, and counterparties in “derivative” transactions
to which any such Buyer is a party, directly or indirectly, presently may have a “short” position in the Common Stock
which was established prior to such Buyer’s knowledge of the transactions contemplated by the Transaction Documents; and
(iii) each Buyer shall not be deemed to have any affiliation with or control over any arm’s length counterparty in any
“derivative” transaction. The Company further understands and acknowledges that following the public disclosure of
the transactions contemplated by the Transaction Documents pursuant to the Press Release (as defined below), one or more Buyers
may engage in hedging and/or trading activities at various times during the period that the Common Shares are outstanding and such
hedging and/or trading activities, if any, can reduce the value of the existing stockholders’ equity interest in the Company
both at and after the time the hedging and/or trading activities are being conducted. The Company acknowledges that such aforementioned
hedging and/or trading activities do not constitute a breach of this Agreement or any other Transaction Document or any of the
documents executed in connection herewith or therewith.

 

    12

     

    

 

(ff) Manipulation of Price.
Neither the Company nor any of its Subsidiaries has, and, to the knowledge of the Company, no Person acting on their behalf has,
directly or indirectly, (i) taken any action designed to cause or to result in the stabilization or manipulation of the price
of any security of the Company or any of its Subsidiaries to facilitate the sale or resale of any of the Common Shares, (ii) sold,
bid for, purchased, or paid any compensation for soliciting purchases of, any of the Common Shares (other than the Placement Agent),
(iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the
Company or any of its Subsidiaries or (iv) paid or agreed to pay any Person for research services with respect to any securities
of the Company or any of its Subsidiaries.

 

(gg) U.S. Real Property Holding
Corporation. Neither the Company nor any of its Subsidiaries is, or has ever been, and so long as any of the Common Shares
are held by any of the Buyers, shall become, a U.S. real property holding corporation within the meaning of Section 897 of
the Code, and the Company and each Subsidiary shall so certify upon any Buyer’s request.

 

(hh) Registration Eligibility.
The Company is eligible to register the issuance of the Common Shares by the Company using Form S-3 promulgated under the 1933
Act.

 

(ii) Transfer Taxes. On the
Closing Date, all stock transfer or other taxes (other than income or similar taxes) which are required to be paid in connection
with the issuance, sale and transfer of the Common Shares to be sold to each Buyer hereunder will be, or will have been, fully
paid or provided for by the Company, and all laws imposing such taxes will be or will have been complied with.

 

(jj) Bank Holding Company Act.
Neither the Company nor any of its Subsidiaries is subject to the Bank Holding Company Act of 1956, as amended (the “BHCA”)
and to regulation by the Board of Governors of the Federal Reserve System (the “Federal Reserve”). Neither the
Company nor any of its Subsidiaries or affiliates owns or controls, directly or indirectly, five percent (5%) or more of the
outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of a bank or
any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries
or affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the
BHCA and to regulation by the Federal Reserve.

 

(kk) Shell Company Status. The Company
is not, and has never been, an issuer identified in, or subject to, Rule 144(i) of the 1933 Act.

 

(ll) Illegal or Unauthorized Payments;
Political Contributions. Neither the Company nor any of its Subsidiaries nor, to the Company’s knowledge, any of the
officers, directors, employees, agents or other representatives of the Company or any of its Subsidiaries, has, directly or indirectly,
made or authorized any payment, contribution or gift of money, property, or services, whether or not in contravention of applicable
law, (i) as a kickback or bribe to any Person or (ii) to any political organization, or the holder of or any aspirant
to any elective or appointive public office except for personal political contributions not involving the direct or indirect use
of funds of the Company or any of its Subsidiaries.

 

(mm) Money Laundering. The
Company and its Subsidiaries are in compliance with, and have not previously violated, the USA Patriot Act of 2001 and all other
applicable U.S. and non-U.S. anti-money laundering laws and regulations, including, but not limited to, the laws, regulations and
Executive Orders and sanctions programs administered by the U.S. Office of Foreign Assets Control, including, without limitation,
(i) Executive Order 13224 of September 23, 2001 entitled, “Blocking Property and Prohibiting Transactions With
Persons Who Commit, Threaten to Commit, or Support Terrorism” (66 Fed. Reg. 49079 (2001)); and (ii) any regulations
contained in 31 CFR, Subtitle B, Chapter V.

 

(nn) Management. Except as
set forth in the SEC Documents or in Schedule 3(nn) hereto, during the past five year period, no current
or former officer or director or, to the knowledge of the Company, no current ten percent (10%) or greater stockholder of
the Company or any of its Subsidiaries has been the subject of:

 

(i) a petition under bankruptcy
laws or any other insolvency or moratorium law or the appointment by a court of a receiver, fiscal agent or similar officer for
such Person, or any partnership in which such person was a general partner at or within two years before the filing of such petition
or such appointment, or any corporation or business association of which such person was an executive officer at or within two
years before the time of the filing of such petition or such appointment;

 

    13

     

    

 

(ii) a conviction in a criminal
proceeding or a named subject of a pending criminal proceeding (excluding traffic violations that do not relate to driving while
intoxicated or driving under the influence);

 

(iii) any order, judgment
or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily
enjoining any such person from, or otherwise limiting, the following activities 

 

(1) Acting as a futures commission
merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant,
any other person regulated by the United States Commodity Futures Trading Commission or an associated person of any of the foregoing,
or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any
investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice
in connection with such activity;

 

(2) Engaging in any particular
type of business practice; or

 

(3) Engaging in any activity
in connection with the purchase or sale of any security or commodity or in connection with any violation of securities laws or
commodities laws;

 

(iv) any order, judgment or
decree, not subsequently reversed, suspended or vacated, of any authority barring, suspending or otherwise limiting for more than
sixty (60) days the right of any such person to engage in any activity described in the preceding sub paragraph, or to be
associated with persons engaged in any such activity;

 

(v) a finding by a court of
competent jurisdiction in a civil action or by the SEC or other authority to have violated any securities law, regulation or decree
and the judgment in such civil action or finding by the SEC or any other authority has not been subsequently reversed, suspended
or vacated; or

 

(vi) a finding by a court of
competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any federal commodities
law, and the judgment in such civil action or finding has not been subsequently reversed, suspended or vacated.

 

(oo) Stock Option Plans. Each
stock option granted by the Company was granted (i) in accordance with the terms of the applicable stock option plan of the
Company and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date such stock
option would be considered granted under GAAP and applicable law. No stock option granted under the Company’s stock option
plan has been backdated. The Company has not knowingly granted, and there is no and has been no policy or practice of the Company
to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other
public announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects.

 

(pp) No Disagreements with Accountants
and Lawyers. There are no material disagreements of any kind presently existing, or reasonably anticipated by the Company to
arise, between the Company and the accountants and lawyers presently employed by the Company and the Company is current with respect
to any fees owed to its accountants and lawyers which could affect the Company’s ability to perform any of its obligations
under any of the Transaction Documents.

 

(qq) No Additional Agreements.
The Company does not have any agreement or understanding with any Buyer with respect to the transactions contemplated by the Transaction
Documents other than as specified in the Transaction Documents.

 

(rr) Public Utility Holding Act None
of the Company nor any of its Subsidiaries is a “holding company,” or an “affiliate” of a “holding
company,” as such terms are defined in the Public Utility Holding Act of 2005.

 

(ss) Federal Power Act. None
of the Company nor any of its Subsidiaries is subject to regulation as a “public utility” under the Federal Power Act,
as amended.

 

    14

     

    

 

(tt) Disclosure. The Company
confirms that neither it nor any other Person acting on its behalf has provided any of the Buyers or their agents or counsel with
any information that constitutes or could reasonably be expected to constitute material, non-public information concerning the
Company or any of its Subsidiaries, other than the existence of the transactions contemplated by this Agreement and the other Transaction
Documents. The Company understands and confirms that each of the Buyers will rely on the foregoing representations in effecting
transactions in securities of the Company. All disclosure provided to the Buyers regarding the Company and its Subsidiaries, their
businesses and the transactions contemplated hereby, including the schedules to this Agreement, furnished by or on behalf of the
Company or any of its Subsidiaries is true and correct and does not contain any untrue statement of a material fact or omit to
state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they
were made, not misleading. All of the written information furnished after the date hereof by or on behalf of the Company or any
of its Subsidiaries to each Buyer pursuant to or in connection with this Agreement and the other Transaction Documents, taken as
a whole, will be true and correct in all material respects as of the date on which such information is so provided and will not
contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made
therein, in the light of the circumstances under which they were made, not misleading. No event or circumstance has occurred or
information exists with respect to the Company or any of its Subsidiaries or its or their business, properties, liabilities, prospects,
operations (including results thereof) or conditions (financial or otherwise), which, under applicable law, rule or regulation,
requires public disclosure at or before the date hereof or announcement by the Company but which has not been so publicly disclosed.
The Company acknowledges and agrees that no Buyer makes or has made any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth in Section 2.

 

4. COVENANTS. 

 

(a) Best Efforts. Each Buyer
shall use its best efforts to timely satisfy each of the covenants hereunder and conditions to be satisfied by it as provided in
Section 6 of this Agreement. The Company shall use its best efforts to timely satisfy each of the covenants hereunder and
conditions to be satisfied by it as provided in Section 7 of this Agreement.

 

(b) Amendments to the Registration
Statement; Prospectus Supplements; Free Writing Prospectuses.

 

(i) Reserved.

 

(ii) The Company has not made,
and agrees that unless it obtains the prior written consent of the Buyer it will not make, an offer relating to the Securities
that would constitute an “issuer free writing prospectus” as defined in Rule 433 promulgated under the 1933 Act (an
“Issuer Free Writing Prospectus”) or that would otherwise constitute a “free writing prospectus”
as defined in Rule 405 promulgated under the 1933 Act (a “Free Writing Prospectus”) required to be filed by
the Company or the Buyer with the SEC or retained by the Company or the Buyer under Rule 433 under the 1933 Act. The Buyer
has not made, and agrees that unless it obtains the prior written consent of the Company it will not make, an offer relating to
the Common Shares that would constitute a Free Writing Prospectus” required to be filed by the Company with the SEC or retained
by the Company under Rule 433 under the 1933 Act. Any such Issuer Free Writing Prospectus or other Free Writing Prospectus consented
to by the Buyer or the Company is referred to in this Agreement as a “Permitted Free Writing Prospectus.” The
Company agrees that (x) it has treated and will treat, as the case may be, each Permitted Free Writing Prospectus as an Free
Writing Prospectus of the Company under Rule 433 of the 1933 Act and (y) it has complied and will comply, as the case may
be, with the requirements of Rules 164 and 433 under the 1933 Act applicable to any Permitted Free Writing Prospectus, including
in respect of timely filing with the SEC, legending and record keeping.

 

(c) Prospectus Delivery. As
soon as practicable after execution of this Agreement the Company shall file a Prospectus Supplement with respect to the Common
Shares to be issued on the Closing Date, as required under, and in conformity with, the 1933 Act, including Rule 424(b) thereunder.
The Company, subject to the provisions of Section 4.(b) hereof, shall deliver or make available to the Buyer, without charge,
an electronic copy of each form of Prospectus Supplement, together with the Prospectus, and any Permitted Free Writing Prospectus
on the Closing Date. The Company consents to the use of the Prospectus (and of any Prospectus Supplements thereto) in accordance
with the provisions of the 1933 Act and with the securities or “blue sky” laws of the jurisdictions in which the Common
Shares may be sold by the Buyer, in connection with the offering and sale of the Common Shares and for such period of time thereafter
as the Prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the 1933 Act) is required by the 1933 Act to
be delivered in connection with sales of the Common Shares. If during such period of time any event shall occur that in the judgment
of the Company and its counsel is required to be set forth in the Registration Statement or the Prospectus or any Permitted Free
Writing Prospectus or should be set forth therein in order to make the statements made therein (in the case of the Prospectus,
in light of the circumstances under which they were made) not misleading, or if it is necessary to amend the Registration Statement
or supplement or amend the Prospectus or any Permitted Free Writing Prospectus to comply with the 1933 Act or any other applicable
law or regulation, the Company shall forthwith prepare and, subject to Section 4.(b) above, file with the SEC an appropriate
amendment to the Registration Statement or Prospectus Supplement to the Prospectus (or supplement to the Permitted Free Writing
Prospectus) and shall expeditiously furnish or make available to the Buyer an electronic copy thereof.

 

    15

     

    

 

(d) Stop Orders. The Company
shall advise the Buyer promptly (but in no event later than 24 hours) and shall confirm such advice in writing: (i) of the
Company’s receipt of notice of any request by the SEC for amendment of or a supplement to the Registration Statement, the
Prospectus, any Permitted Free Writing Prospectus or for any additional information; (ii) of the Company’s receipt of
notice of the issuance by the SEC of any stop order suspending the effectiveness of the Registration Statement or prohibiting or
suspending the use of the Prospectus or any Prospectus Supplement, or of the suspension of qualification of the Common Shares for
offering or sale in any jurisdiction, or the initiation or contemplated initiation of any proceeding for such purpose; (iii) of
the Company becoming aware of the happening of any event, which makes any statement of a material fact made in the Registration
Statement, the Prospectus or any Permitted Free Writing Prospectus untrue or which requires the making of any additions to or changes
to the statements then made in the Registration Statement, the Prospectus or any Permitted Free Writing Prospectus in order to
state a material fact required by the 1933 Act to be stated therein or necessary in order to make the statements then made therein
(in the case of the Prospectus, in light of the circumstances under which they were made) not misleading, or of the necessity to
amend the Registration Statement or supplement the Prospectus or any Permitted Free Writing Prospectus to comply with the 1933
Act or any other law or (iv) if at any time following the date hereof the Registration Statement is not effective or is not
otherwise available for the issuance of the Common Shares or any Prospectus contained therein is not available for use for any
other reason. Thereafter, the Company shall promptly notify such holders when the Registration Statement, the Prospectus, any Permitted
Free Writing Prospectus and/or any amendment or supplement thereto, as applicable, is effective and available for the issuance
of the Common Shares. If at any time the SEC shall issue any stop order suspending the effectiveness of the Registration Statement
or prohibiting or suspending the use of the Prospectus or any Prospectus Supplement, the Company shall use best efforts to obtain
the withdrawal of such order at the earliest possible time.

 

(e) Blue Sky. The Company shall,
on or before the Closing Date, take such action as the Company shall reasonably determine is necessary in order to obtain an exemption
for, or to, qualify the Common Shares for sale to the Buyers at the Closing pursuant to this Agreement under applicable securities
or “Blue Sky” laws of the states of the United States (or to obtain an exemption from such qualification), and shall
provide evidence of any such action so taken to the Buyers on or prior to the Closing Date. Without limiting any other obligation
of the Company under this Agreement, the Company shall timely make all filings and reports relating to the offer and sale of the
Common Shares required under all applicable securities laws (including, without limitation, all applicable federal securities laws
and all applicable “Blue Sky” laws), and the Company shall comply with all applicable foreign, federal, state and local
laws, statutes, rules, regulations and the like relating to the offering and sale of the Common Shares to the Buyers.

 

(f) Listing. The Company shall
promptly secure the listing or designation for quotation (as the case may be) of all of the Underlying Securities (as defined below)
upon each national securities exchange and automated quotation system, if any, upon which the Common Stock is then listed or designated
for quotation (as the case may be) (subject to official notice of issuance). The Company shall use its best efforts to maintain
the Common Stock’s (including the Underlying Shares) listing or authorization for quotation (as the case may be) on the Principal
Market, The New York Stock Exchange, the Nasdaq Capital Market, the Nasdaq Global Market or the Nasdaq Global Select Market (each,
an “Eligible Market”). The Company shall pay all fees and expenses in connection with satisfying its obligations
under this Section 4.(f). “Underlying Securities” means the Common Shares and any capital stock of the
Company issued or issuable with respect to the Common Shares, including, without limitation, (1) as a result of any stock
split, stock dividend, recapitalization, exchange or similar event or otherwise and (2) shares of capital stock of the Company
into which the shares of Common Stock are converted or exchanged and shares of capital stock of a successor entity into which the
shares of Common Stock are converted or exchanged.

 

    16

     

    

 

(g) Fees. The Company shall
be responsible for the payment of any placement agent’s fees, financial advisory fees, transfer agent fees, DTC fees or broker’s
commissions (other than for Persons engaged by any Buyer) relating to or arising out of the transactions contemplated hereby (including,
without limitation, any fees or commissions payable to the Placement Agent, who is the Company’s sole placement agent in
connection with the transactions contemplated by this Agreement). The Company shall pay, and hold each Buyer harmless against,
any liability, loss or expense (including, without limitation, reasonable attorneys’ fees and out-of-pocket expenses) arising
in connection with any claim relating to any such payment. Except as otherwise set forth in the Transaction Documents, each party
to this Agreement shall bear its own expenses in connection with the sale of the Common Shares to the Buyers.

 

(h) Pledge of Common Shares.
Notwithstanding anything to the contrary contained in this Agreement, the Company acknowledges and agrees that the Common Shares
may be pledged by a Buyer in connection with a bona fide margin agreement or other loan or financing arrangement that is secured
by the Common Shares. The pledge of Common Shares shall not be deemed to be a transfer, sale or assignment of the Common Shares
hereunder, and no Buyer effecting a pledge of Common Shares shall be required to provide the Company with any notice thereof or
otherwise make any delivery to the Company pursuant to this Agreement or any other Transaction Document. The Company hereby agrees
to execute and deliver such documentation as a pledgee of the Common Shares may reasonably request in connection with a pledge
of the Common Shares to such pledgee by a Buyer.

 

(i) Disclosure of Transactions
and Other Material Information.

 

(i) Disclosure of Transaction.
The Company shall, on or before 9:30 a.m., New York time, on the first (1st) Business Day after the date of
this Agreement, issue a press release (the “Press Release”) reasonably acceptable to the Buyers disclosing all
the material terms of the transactions contemplated by the Transaction Documents. On or before 9:30 a.m., New York time, on the
first (1st) Business Day after the date of this Agreement, the Company shall file a Current Report on Form 8-K
describing all the material terms of the transactions contemplated by the Transaction Documents in the form required by the 1934
Act and attaching all the material Transaction Documents (including, without limitation, this Agreement (and all schedules to this
Agreement) (including all attachments, the “8-K Filing”). From and after the filing of the 8-K Filing, the Company
shall have disclosed all material, non-public information (if any) provided to any of the Buyers by the Company or any of its Subsidiaries
or any of their respective officers, directors, employees or agents in connection with the transactions contemplated by the Transaction
Documents. In addition, effective upon the filing of the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality
or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their
respective officers, directors, affiliates, employees or agents, on the one hand, and any of the Buyers or any of their affiliates,
on the other hand, shall terminate.

 

(ii) Limitations
on Disclosure. The Company shall not, and the Company shall cause each of its Subsidiaries and each of its and their respective
officers, directors, employees and agents not to, provide any Buyer with any material, non-public information regarding the Company
or any of its Subsidiaries from and after the date hereof without the express prior written consent of such Buyer (which may be
granted or withheld in such Buyer’s sole discretion). In the event of a breach of the foregoing covenants or any of the similar
covenants or agreements contained in any other Transaction Document, by the Company, any of its Subsidiaries, or any of its or
their respective officers, directors, employees and agents (as determined in the reasonable good faith judgment of such Buyer),
in addition to any other remedy provided herein or in the Transaction Documents, the Buyer shall deliver written notice to the
Company of such material, non-public information or breach, as well as reasonable details relating thereto. To the extent the Company
has not disclosed such material, non-public information or breach on or prior to the second (2nd) Business Day
after receipt of such notice, then, in addition to any other remedy provided herein or in the Transaction Documents, such Buyer
shall have the right to make a public disclosure, in the form of a press release, public advertisement or otherwise, of such material,
non-public information, as applicable, without the prior approval by the Company, any of its Subsidiaries, or any of its or their
respective officers, directors, employees or agents. No Buyer shall have any liability to the Company, any of its Subsidiaries,
or any of its or their respective officers, directors, employees, affiliates, stockholders or agents, for any such disclosure.
To the extent that the Company delivers any material, non-public information to a Buyer without such Buyer’s consent and
Buyer complies with the notice process contained in this Section 4.(i).(ii), the Company hereby covenants and agrees that such
Buyer shall not have any duty of confidentiality with respect to, or a duty not to trade on the basis of, such material, non-public
information, except as such Buyer may be required to comply with applicable laws. Subject to the foregoing, neither the Company,
its Subsidiaries nor any Buyer shall issue any press releases or any other public statements with respect to the transactions contemplated
hereby; provided, however, the Company shall be entitled, without the prior approval of any Buyer, to make the Press Release and
any press release or other public disclosure with respect to such transactions (i) in substantial conformity with the 8-K
Filing and contemporaneously therewith and (ii) as is required by applicable law and regulations (provided that in the case
of clause (i) each Buyer shall be consulted by the Company in connection with any such press release or other public disclosure
prior to its release). Without the prior written consent of the applicable Buyer (which may be granted or withheld in such Buyer’s
sole discretion), the Company shall not (and shall cause each of its Subsidiaries and affiliates to not) disclose the name of such
Buyer in any filing, announcement, release or otherwise except (x) as is required by applicable law in connection with the filing
of this Agreement and the other Transaction Documents (including signature pages thereto) with the SEC and (y) to the extent such
disclosure is required by applicable law or Primary Market regulations, in which case each Buyer shall be consulted by the Company
in connection with any such disclosure under this subclause (y). Notwithstanding anything contained in this Agreement to the contrary
and without implication that the contrary would otherwise be true, the Company expressly acknowledges and agrees that no Buyer
shall have (unless expressly agreed to by a particular Buyer after the date hereof in a written definitive and binding agreement
executed by the Company and such particular Buyer (it being understood and agreed that no Buyer may bind any other Buyer with respect
thereto)), any duty of confidentiality or a duty not to trade Company securities after the Form 8-K Filing.

 

    17

     

    

 

(j) Closing Documents. On or
prior to fifteen (15) Business Days after the Closing Date, the Company agrees to deliver, or cause to be delivered, to each
Buyer a complete closing set of the executed Transaction Documents and any other document required to be delivered to any party
pursuant to Section 7 hereof or otherwise.

 

(k) Company Lock-Up Agreements.
The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent of the Buyers holding
a majority in interest of the Common Shares, it will not for a period of ninety (90) days after the date of this Agreement (the
“Lock-Up Period”), (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase
any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly
or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for
shares of capital stock of the Company; (ii) file or cause to be filed any registration statement with the Commission relating
to the offering of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable
for shares of capital stock of the Company; or (iii) complete any offering of debt securities of the Company, other than entering
into a line of credit with a traditional bank or (iv) enter into any swap or other arrangement that transfers to another, in whole
or in part, any of the economic consequences of ownership of capital stock of the Company, whether any such transaction described
in clause (i), (ii), (iii) or (iv) above is to be settled by delivery of shares of capital stock of the Company or such other securities,
in cash or otherwise.

 

The restrictions contained in this Section
4(k) shall not apply to (i) the shares of Common Stock and the Placement Agent’s Warrant (as defined in the Placement Agent
Agreement, dated as of June 17, 2019 (the “Placement Agency Agreement”), by and between the Company and Placement Agent)
to be sold pursuant to the Placement Agency Agreement, provided that no amendment to such Placement Agent Warrant shall be made
during such Lock-Up Period (ii) the issuance by the Company of shares of Common Stock upon the exercise of the Placement Agent’s
Warrant (as defined in the Placement Agency Agreement) or a stock option or warrant or the conversion of a security outstanding
on the date hereof, which is disclosed in the Registration Statement, Disclosure Package and Prospectus, and which shall not have
been amended during the Lock-Up Period (iii) the issuance by the Company of stock options, shares of capital stock of the Company
or other awards under any equity compensation plan of the Company and (iv) securities issued pursuant to acquisitions or strategic
transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be
to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner
of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in
addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for
the purpose of raising capital or to an entity whose primary business is investing in securities, provided that in each of (ii),
(iii) and (iv) above, the underlying shares shall be restricted from sale during the entire Lock-Up Period and, provided further
that, in the case of (iv) above, the underlying shares shall also not be entitled to the benefit of any rights regarding the registration
of such underlying shares under the 1933 Act unless such rights are not exercisable until after the Lock-Up Period shall have expired.

 

    18

     

    

 

5. REGISTER; TRANSFER AGENT INSTRUCTIONS; LEGEND. 

 

(a) Register. The Company shall
maintain at its principal executive offices (or such other office or agency of the Company as it may designate by notice to each
holder of Common Shares), a register for the Common Shares in which the Company shall record the name and address of the Person
in whose name the Common Shares have been issued (including the name and address of each transferee), the number of Common Shares
held by such Person. The Company shall keep the register open and available at all times during business hours for inspection of
any Buyer or its legal representatives.

 

(b) Transfer Agent Instructions.
The Company shall issue irrevocable instructions to its Transfer Agent and any subsequent transfer agent in a form acceptable to
each of the Buyers (the “Irrevocable Transfer Agent Instructions”) to issue certificates or credit shares to
the applicable balance accounts at DTC, to either (a) Placement Agent’s balance account with DTC through its Deposit/Withdrawal
at Custodial system, or (b) directly to the account of each Buyer, or its respective nominee(s), at the designated account with
DTC as provided on the Purchaser Signature Page, for the Common Shares. The Company represents and warrants that no instruction
other than the Irrevocable Transfer Agent Instructions referred to in this Section 5.(b) will be given by the Company to its
Transfer Agent with respect to the Common Shares, and that the Common Shares shall otherwise be freely transferable on the books
and records of the Company, as applicable, to the extent provided in this Agreement and the other Transaction Documents. If a Buyer
effects a sale, assignment or transfer of the Common Shares, the Company shall permit the transfer and shall, to the extent required
by the Transfer Agent, promptly instruct its Transfer Agent to issue one or more certificates or credit shares to the applicable
balance accounts at DTC in such name and in such denominations as specified by such Buyer to effect such sale, transfer or assignment.
The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to a Buyer. Accordingly,
the Company acknowledges that the remedy at law for a breach of its obligations under this Section 5.(b) will be inadequate
and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Section 5.(b), that a Buyer
shall be entitled, in addition to all other available remedies, to an order and/or injunction restraining any breach and requiring
immediate issuance and transfer, without the necessity of showing economic loss and without any bond or other security being required.
The Company shall cause its counsel to issue each legal opinion referred to in the Irrevocable Transfer Agent Instructions to the
Transfer Agent at the Closing with respect to the Common Shares. Any fees (with respect to the Transfer Agent, counsel to
the Company or otherwise) associated with the issuance of such opinions or the removal of any legends on any of the Common Shares
shall be borne by the Company.

 

(c) Legends. Certificates and any
other instruments evidencing the Common Shares shall not bear any restrictive or other legend.

 

(d) FAST Compliance. While any Warrants
remain outstanding, the Company shall maintain a transfer agent that participates in the DTC Fast Automated Securities Transfer
Program.

 

6. CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL.

 

The obligation of the Company hereunder
to issue and sell the Common Shares to each Buyer at the Closing is subject to the satisfaction, at or before the Closing Date,
of each of the following conditions, provided that these conditions are for the Company’s sole benefit and may be waived
by the Company at any time in its sole discretion by providing each Buyer with prior written notice thereof:

 

(a) Such Buyer shall have executed each
of the other Transaction Documents to which it is a party and delivered the same to the Company.

 

(b) Such Buyer and each other Buyer shall
have delivered to the account specified by the Company and the Placement Agent, the Purchase Price for the Common Shares being
purchased by such Buyer at the Closing by wire transfer of immediately available funds in accordance with the Company’s instructions
and the Placement Agent shall have delivered such aggregate amount to the account specified by the Company at or prior to the Closing.

 

    19

     

    

 

(c) The representations and warranties
of such Buyer shall be true and correct in all material respects as of the date when made and as of the Closing Date as though
originally made at that time (except for representations and warranties that speak as of a specific date, which shall be true and
correct as of such specific date), and such Buyer shall have performed, satisfied and complied in all material respects with the
covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by such Buyer at or
prior to the Closing Date.

 

7. CONDITIONS TO EACH BUYER’S OBLIGATION TO PURCHASE.

 

The obligation of each Buyer hereunder
to purchase its Common Shares at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following
conditions, provided that these conditions are for each Buyer’s sole benefit and may be waived by such Buyer at any time
in its sole discretion by providing the Company with prior written notice thereof:

 

(a) The Company shall have duly executed
and delivered to such Buyer each of the Transaction Documents and the Company shall have duly executed and delivered to the Placement
Agent for the account of such Buyer such aggregate number of Common Shares set forth across from such Buyer’s name in column
(2) of the Schedule of Buyers as being purchased by such Buyer at the Closing pursuant to this Agreement.

 

(b) Such Buyer shall have received the
opinion of Squire Patton Boggs (US) LLP, the Company’s counsel, dated as of the Closing Date, in the form reasonably acceptable
to such Buyer.

 

(c) The Company shall have delivered to
such Buyer a copy of the Irrevocable Transfer Agent Instructions, in the form reasonably acceptable to such Buyer, which instructions
shall have been delivered to and acknowledged in writing by the Transfer Agent.

 

(d) The Company shall have delivered to
such Buyer a certificate evidencing the formation and good standing of the Company and each of its Subsidiaries in each such entity’s
jurisdiction of formation issued by the Secretary of State (or comparable office) of such jurisdiction of formation as of a date
within ten (10) days of the Closing Date.

 

(e) The Company shall have delivered to
such Buyer a certificate evidencing the Company’s qualification as a foreign corporation and good standing issued by the
Secretary of State (or comparable office) of each jurisdiction in which the Company conducts business and is required to so qualify,
as of a date within ten (10) days of the Closing Date.

 

(f) The Company shall have delivered to
such Buyer a certificate, in the form acceptable to such Buyer, executed by the Secretary of the Company and dated as of the Closing
Date, as to (i) the resolutions consistent with Section 3.(b) as adopted by the Company’s board of directors in
a form reasonably acceptable to such Buyer, (ii) the Certificate of Incorporation of the Company and (iii) the Bylaws
of the Company, each as in effect at the Closing.

 

(g) Each and every representation and warranty
of the Company shall be true and correct as of the date when made and as of the Closing Date as though originally made at that
time (except for representations and warranties that speak as of a specific date, which shall be true and correct as of such specific
date) and the Company shall have performed, satisfied and complied in all respects with the covenants, agreements and conditions
required to be performed, satisfied or complied with by the Company at or prior to the Closing Date. Such Buyer shall have received
a certificate, duly executed by the Chief Executive Officer of the Company, dated as of the Closing Date, to the foregoing effect
and as to such other matters as may be reasonably requested by such Buyer in the form acceptable to such Buyer.

 

(h) The Company shall have delivered to
such Buyer a letter from the Transfer Agent certifying the number of shares of Common Stock outstanding on the Closing Date immediately
prior to the Closing.

 

(i) The Common Stock (A) shall be
designated for quotation or listed (as applicable) on the Principal Market and (B) shall not have been suspended, as of the
Closing Date, by the SEC or the Principal Market from trading on the Principal Market nor shall suspension by the SEC or the Principal
Market have been threatened, as of the Closing Date, either (I) in writing by the SEC or the Principal Market or (II) by
falling below the minimum maintenance requirements of the Principal Market.

 

(j) The Company shall have obtained all
governmental, regulatory or third party consents and approvals, if any, necessary for the sale of the Common Shares, including
without limitation, those required by the Principal Market, if any.

 

    20

     

    

 

(k) No statute, rule, regulation, executive
order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or Governmental Entity
of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by the Transaction Documents.

 

(l) Since the date of execution of this
Agreement, no event or series of events shall have occurred that would reasonably be expected to have or result in a Material Adverse
Effect.

 

(m) The Company shall have obtained approval
of the Principal Market to list or designate for quotation (as the case may be) the Common Shares.

 

(n) From the date hereof to the Closing
Date, (i) trading in the Common Stock shall not have been suspended by the SEC or the Principal Market (except for any suspension
of trading of limited duration agreed to by the Company, which suspension shall be terminated prior to the Closing), and, (ii) at
any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended
or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on the
Principal Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor
shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment
of each Buyer, makes it impracticable or inadvisable to purchase the Common Shares at the Closing.

 

(o) The Registration Statement shall be
effective and available for the issuance and sale of the Common Shares hereunder and the Company shall have delivered to such Buyer
the Prospectus and the Prospectus Supplement as required thereunder.

 

(p) The Company and its Subsidiaries shall
have delivered to such Buyer such other documents, instruments or certificates relating to the transactions contemplated by this
Agreement as such Buyer or its counsel may reasonably request.

 

8. TERMINATION. 

 

In the event that the Closing shall not
have occurred with respect to a Buyer within five (5) days of the date hereof, then such Buyer shall have the right to terminate
its obligations under this Agreement with respect to itself at any time on or after the close of business on such date without
liability of such Buyer to any other party by providing written notice to the Company; provided, however, (i) the right to
terminate this Agreement under this Section 8 shall not be available to such Buyer if the failure of the transactions contemplated
by this Agreement to have been consummated by such date is the result of such Buyer’s breach of this Agreement and (ii) the
abandonment of the sale and purchase of the Common Shares shall be applicable only to such Buyer providing such written notice.
Nothing contained in this Section 8 shall be deemed to release any party from any liability for any breach by such party of
the terms and provisions of this Agreement or the other Transaction Documents or to impair the right of any party to compel specific
performance by any other party of its obligations under this Agreement or the other Transaction Documents.

 

9. MISCELLANEOUS. 

 

(a) Governing Law; Jurisdiction; Jury
Trial. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed
by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule
(whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions
other than the State of New York. The Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith
or under any of the other Transaction Documents or with any transaction contemplated hereby or thereby, and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction
of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action
or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served
in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein
shall be deemed or operate to preclude any Buyer from bringing suit or taking other legal action against the Company in any other
jurisdiction to collect on the Company’s obligations to such Buyer or to enforce a judgment or other court ruling in favor
of such Buyer. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR
THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS
AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

 

    21

     

    

 

(b) Counterparts. This Agreement
may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each party and delivered to the other party. In the event that any signature is
delivered by facsimile transmission or by an e-mail which contains a portable document format (.pdf) file of an executed signature
page, such signature page shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such signature page were an original thereof.

 

(c) Headings; Gender. The headings
of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.
Unless the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter,
singular and plural forms thereof. The terms “including,” “includes,” “include” and words of
like import shall be construed broadly as if followed by the words “without limitation.” The terms “herein,”
“hereunder,” “hereof” and words of like import refer to this entire Agreement instead of just the provision
in which they are found.

 

(d) Severability; Maximum Payment
Amounts. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by
a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended
to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision
shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues
to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited
nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations
or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the
parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s)
with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).
Notwithstanding anything to the contrary contained in this Agreement or any other Transaction Document (and without implication
that the following is required or applicable), it is the intention of the parties that in no event shall amounts and value paid
by the Company and/or any of its Subsidiaries (as the case may be), or payable to or received by any of the Buyers, under the Transaction
Documents (including without limitation, any amounts that would be characterized as “interest” under applicable law)
exceed amounts permitted under any applicable law. Accordingly, if any obligation to pay, payment made to any Buyer, or collection
by any Buyer pursuant the Transaction Documents is finally judicially determined to be contrary to any such applicable law, such
obligation to pay, payment or collection shall be deemed to have been made by mutual mistake of such Buyer, the Company and its
Subsidiaries and such amount shall be deemed to have been adjusted with retroactive effect to the maximum amount or rate of interest,
as the case may be, as would not be so prohibited by the applicable law. Such adjustment shall be effected, to the extent necessary,
by reducing or refunding, at the option of such Buyer, the amount of interest or any other amounts which would constitute unlawful
amounts required to be paid or actually paid to such Buyer under the Transaction Documents. For greater certainty, to the extent
that any interest, charges, fees, expenses or other amounts required to be paid to or received by such Buyer under any of the Transaction
Documents or related thereto are held to be within the meaning of “interest” or another applicable term to otherwise
be violative of applicable law, such amounts shall be pro-rated over the period of time to which they relate.

 

    22

     

    

 

(e) Entire Agreement; Amendments.
This Agreement, the other Transaction Documents and the schedules and exhibits attached hereto and thereto and the instruments
referenced herein and therein supersede all other prior oral or written agreements between the Buyers, the Company, its Subsidiaries,
their affiliates and Persons acting on their behalf, including, without limitation, any transactions by any Buyer with respect
to Common Stock or the Common Shares, and the other matters contained herein and therein, and this Agreement, the other Transaction
Documents, the schedules and exhibits attached hereto and thereto and the instruments referenced herein and therein contain the
entire understanding of the parties solely with respect to the matters covered herein and therein; provided, however, nothing contained
in this Agreement or any other Transaction Document shall (or shall be deemed to) (i) have any effect on any agreements any
Buyer has entered into with, or any instruments any Buyer has received from, the Company or any of its Subsidiaries prior to the
date hereof with respect to any prior investment made by such Buyer in the Company or (ii) waive, alter, modify or amend in
any respect any obligations of the Company or any of its Subsidiaries, or any rights of or benefits to any Buyer or any other Person,
in any separate and unrelated agreement entered into prior to the date hereof between or among the Company and/or any of its Subsidiaries
and any Buyer, or any instruments any Buyer received from the Company and/or any of its Subsidiaries prior to the date hereof,
and all such agreements and instruments shall continue in full force and effect. Except as specifically set forth herein or therein,
neither the Company nor any Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. For
clarification purposes, the Recitals are part of this Agreement. No provision of this Agreement may be amended other than by an
instrument in writing signed by the Company and the Required Holders (as defined below), and any amendment to any provision of
this Agreement made in conformity with the provisions of this Section 9.(e) shall be binding on all Buyers, provided that
no such amendment shall be effective to the extent that it (A) applies to less than all of the holders of the Common Shares
then outstanding or (B) imposes any obligation or liability on any Buyer without such Buyer’s prior written consent
(which may be granted or withheld in such Buyer’s sole discretion). No waiver shall be effective unless it is in writing
and signed by an authorized representative of the waiving party, provided that the Required Holders may waive any provision of
this Agreement, and any waiver of any provision of this Agreement made in conformity with the provisions of this Section 9.(e)
shall be binding on all Buyers, provided that no such waiver shall be effective to the extent that it (1) applies to less
than all of the holders of the Common Shares then outstanding (unless a party gives a waiver as to itself only) or (2) imposes
any obligation or liability on any Buyer without such Buyer’s prior written consent (which may be granted or withheld in
such Buyer’s sole discretion). The Company has not, directly or indirectly, made any agreements with any Buyers relating
to the terms or conditions of the transactions contemplated by the Transaction Documents except as set forth in the Transaction
Documents. Without limiting the foregoing, the Company confirms that, except as set forth in this Agreement, no Buyer has made
any commitment or promise or has any other obligation to provide any financing to the Company, any Subsidiary or otherwise. As
a material inducement for each Buyer to enter into this Agreement, the Company expressly acknowledges and agrees that (x) no
due diligence or other investigation or inquiry conducted by a Buyer, any of its advisors or any of its representatives shall affect
such Buyer’s right to rely on, or shall modify or qualify in any manner or be an exception to any of, the Company’s
representations and warranties contained in this Agreement or any other Transaction Document and (y) unless a provision of
this Agreement or any other Transaction Document is expressly preceded by the phrase “except as disclosed in the SEC Documents,”
nothing contained in any of the SEC Documents shall affect such Buyer’s right to rely on, or shall modify or qualify in any
manner or be an exception to any of, the Company’s representations and warranties contained in this Agreement or any other
Transaction Document. “Required Holders” means (I) prior to the Closing Date, Buyers entitled to purchase,
in the aggregate, at least a majority of the number of Common Shares at the Closing and (II) on or after the Closing Date,
holders of, in the aggregate, at least a majority of the Common Shares as of such time (excluding any Common Shares that may then
be held by the Company or any of its Subsidiaries as of such time).

 

(f) Notices. Any notices, consents,
waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will
be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon delivery, when sent by facsimile
(provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party) or electronic
mail (provided that no automated notice of rejection is delivered to the sender); or (iii) one (1) Business Day after
deposit with an overnight courier service with next day delivery specified, in each case, properly addressed to the party to receive
the same. The addresses, facsimile numbers and e-mail addresses for such communications shall be:

 

    23

     

    

 

	If to the Company:

 

	Ampio Pharmaceuticals, Inc. 
	373 Inverness Parkway, Suite 200 
	Englewood, CO 80122 
	Telephone: (720) 437-6500 
	Facsimile: (720) 437-6501 
	Attention: Chief Financial Officer 
	E-Mail: ggould@ampiopharma.com 

 

With a copy (for informational purposes
only) to:

 

	Squire Patton Boggs (US) LLP
	900 Key Tower 127 Public Square
	Cleveland, OH 44114
	Attention:  Leah Brownlee, Esq.
	Fax No: (216) 479-8780

 

If to the Transfer Agent:

 

	Corporate Stock Transfer, Inc. 
	3200 Cherry Creek South Drive, Suite 430 
	Denver, CO 80209 
	Telephone: (303) 282-4800 
	Facsimile: (303) 282-5800 
	Attention: Daniel Bell 
	E-Mail: dbell@corporatestock.com 

 

If to the Placement Agents (for informational
purposes only) to:

 

	Loeb & Loeb LLP
	345 Park Avenue
	New York, NY 10154
	Attn: Mitchell S. Nussbaum, Esq.
	Fax No.:  (212) 504-3013

 

If to a Buyer, to its address, e-mail address and facsimile
number set forth on the Schedule of Buyers, with copies to such Buyer’s representatives as set forth on the Schedule of Buyers,
or to such other address, e-mail address and/or facsimile number and/or to the attention of such other Person as the recipient
party has specified by written notice given to each other party five (5) days prior to the effectiveness of such change. Written
confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically
or electronically generated by the sender’s facsimile machine or e-mail containing the time, date, recipient facsimile number
and, with respect to each facsimile transmission, an image of the first page of such transmission or (C) provided by an overnight
courier service shall be rebuttable evidence of personal service, receipt by facsimile or e-mail or receipt from an overnight courier
service in accordance with clause (i), (ii) or (iii) above, respectively. To the extent that any notice provided pursuant
to any Transaction Document constitutes, or contains material, non-public information regarding the Company or any of the Subsidiaries,
the Company shall simultaneously file such notice with the SEC pursuant to a Current Report on Form 8-K.

 

(g) Successors and Assigns.
This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns (but excluding
any purchasers of Underlying Securities, unless pursuant to a written assignment by such Buyer). The Company shall not assign this
Agreement or any rights or obligations hereunder without the prior written consent of the Required Holders. A Buyer may assign
some or all of its rights hereunder in connection with any transfer of any of its Common Shares with the prior written consent
of the Company, in which event such assignee shall be deemed to be a Buyer hereunder with respect to such assigned rights.

 

(h) No Third Party Beneficiaries.
This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is
not for the benefit of, nor may any provision hereof be enforced by, any other Person, other than the Indemnitees referred to in
Section 9(k).

 

(i) Survival. The representations,
warranties, agreements and covenants shall survive the Closing. Each Buyer shall be responsible only for its own representations,
warranties, agreements and covenants hereunder.

 

(j) Further Assurances. Each
party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver
all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry
out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

    24

     

    

 

(k) Indemnification.

 

(i) In consideration of each
Buyer’s execution and delivery of the Transaction Documents and acquiring the Common Shares thereunder and in addition to
all of the Company’s other obligations under the Transaction Documents, the Company shall defend, protect, indemnify and
hold harmless each Buyer and all of their stockholders, partners, members, officers, directors, employees and direct or indirect
investors and any of the foregoing Persons’ agents or other representatives (including, without limitation, those retained
in connection with the transactions contemplated by this Agreement) (collectively, the “Indemnitees”) from and
against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses
in connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification hereunder
is sought), and including reasonable attorneys’ fees and disbursements (the “Indemnified Liabilities”),
incurred by any Indemnitee as a result of, or arising out of, or relating to (i) any material misrepresentation or material
breach of any representation or warranty made by the Company or any Subsidiary in any of the Transaction Documents, (ii) any
material breach of any covenant, agreement or obligation of the Company or any Subsidiary contained in any of the Transaction Documents
or (iii) any cause of action, suit, proceeding or claim brought or made against such Indemnitee by a third party (including
for these purposes a derivative action brought on behalf of the Company or any Subsidiary) or which otherwise involves such Indemnitee
that arises out of or results from (A) the execution, delivery, performance or enforcement of any of the Transaction Documents,
(B) any transaction financed or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance
of the Common Shares, (C) any disclosure properly made by such Buyer pursuant to Section 4.(i), or (D) the status
of such Buyer or holder of the Common Shares either as an investor in the Company pursuant to the transactions contemplated by
the Transaction Documents or as a party to this Agreement (including, without limitation, as a party in interest or otherwise in
any action or proceeding for injunctive or other equitable relief), unless such action is based upon a breach of Buyer’s
representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Buyer may have
with any such stockholder or any violations by such Buyer of state or federal securities laws or any conduct by such Buyer which
constitutes fraud, gross negligence, willful misconduct or malfeasance. To the extent that the foregoing undertaking by the Company
may be unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction of each of
the Indemnified Liabilities which is permissible under applicable law.

 

(ii) Promptly after receipt
by an Indemnitee under this Section 9.(k) of notice of the commencement of any action or proceeding (including any governmental
action or proceeding) involving an Indemnified Liability, such Indemnitee shall, if a claim in respect thereof is to be made against
the Company under this Section 9.(k), deliver to the Company a written notice of the commencement thereof, and the Company
shall have the right to participate in, and, to the extent the Company so desires, to assume control of the defense thereof with
counsel selected by the Company and reasonably satisfactory to the Indemnitee; provided, however, that an Indemnitee shall have
the right to retain its own counsel with the fees and expenses of such counsel to be paid by the Indemnitee except to the extent
that: (A) the Company has agreed in writing to pay such fees and expenses; (B) the Company shall have failed promptly
to assume the defense of such Indemnified Liability and to employ counsel reasonably satisfactory to such Indemnitee in any such
Indemnified Liability; or (C) the named parties to any such Indemnified Liability (including any impleaded parties) include
both such Indemnitee and the Company, and such Indemnitee shall have been advised through the reasonable written opinion of its
legal counsel (a copy of which is furnished to the Company) that a conflict of interest is likely to exist if the same counsel
were to represent such Indemnitee and the Company (in which case, if such Indemnitee notifies the Company in writing that it elects
to employ separate counsel at the expense of the Company, then the Company shall not have the right to assume the defense thereof
and such counsel shall be at the expense of the Company), provided further, that in the case of clause (C) above the Company
shall not be responsible for the reasonable fees and expenses of more than one (1) separate legal counsel for the Indemnitees.
The Indemnitee shall reasonably cooperate with the Company in connection with any negotiation or defense of any such action or
Indemnified Liability by the Company and shall furnish to the Company all information reasonably available to the Indemnitee which
relates to such action or Indemnified Liability. The Company shall keep the Indemnitee reasonably apprised at all times as to the
status of the defense or any settlement negotiations with respect thereto. The Company shall not be liable for any settlement of
any action, claim or proceeding effected without its prior written consent, provided, however, that the Company shall not unreasonably
withhold, delay or condition its consent. The Company shall not, without the prior written consent of the Indemnitee, consent to
entry of any judgment or enter into any settlement or other compromise which does not include as an unconditional term thereof
the giving by the claimant or plaintiff to such Indemnitee of a release from all liability in respect to such Indemnified Liability
or litigation, and such settlement shall not include any admission as to fault on the part of the Indemnitee. Following indemnification
as provided for hereunder, the Company shall be subrogated to all rights of the Indemnitee with respect to all third parties, firms
or corporations relating to the matter for which indemnification has been made. The failure to deliver written notice to the Company
within a reasonable time of the commencement of any such action shall not relieve the Company of any liability to the Indemnitee
under this Section 9.(k), except to the extent that the Company is materially and adversely prejudiced in its ability to defend
such action.

 

    25

     

    

 

(iii) The indemnification required
by this Section 9.(k) shall be made by periodic payments of the amount thereof during the course of the investigation or defense,
within ten (10) days after the Company receives invoices and supporting documentation with respect to Indemnified Liabilities
that are actually incurred by the Indemnitee.

 

(iv) The indemnity agreement
contained herein shall be in addition to (A) any cause of action or similar right of the Indemnitee against the Company or
others, and (B) any liabilities the Company may be subject to pursuant to the law.

 

(l) Construction. The language
used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of
strict construction will be applied against any party. No specific representation or warranty shall limit the generality or applicability
of a more general representation or warranty. Each and every reference to share prices, shares of Common Stock and any other numbers
in this Agreement that relate to the Common Stock shall be automatically adjusted for any stock splits, stock dividends, stock
combinations, recapitalizations or other similar transactions that occur with respect to the Common Stock after the date of this
Agreement. It is expressly understood and agreed that for all purposes of this Agreement, and without implication that the contrary
would otherwise be true, neither transactions nor purchases nor sales shall include the location and/or reservation of borrowable
shares of Common Stock.

 

(m) Remedies. Each Buyer and
in the event of assignment by Buyer of its rights and obligations hereunder, each holder of Common Shares, shall have all rights
and remedies set forth in the Transaction Documents and all rights and remedies which such holders have been granted at any time
under any other agreement or contract and all of the rights which such holders have under any law. Any Buyer or such assignee and
holder of Common Shares shall be entitled to enforce such rights specifically (without posting a bond or other security), to recover
damages by reason of any breach of any provision of this Agreement and to exercise all other rights granted by law. Furthermore,
the Company recognizes that in the event that it or any Subsidiary fails to perform, observe, or discharge any or all of its or
such Subsidiary’s (as the case may be) obligations under the Transaction Documents, any remedy at law would inadequate relief
to the Buyers. The Company therefore agrees that the Buyers shall be entitled to specific performance and/or temporary, preliminary
and permanent injunctive or other equitable relief from any court of competent jurisdiction in any such case without the necessity
of proving actual damages and without posting a bond or other security. The remedies provided in this Agreement and the other Transaction
Documents shall be cumulative and in addition to all other remedies available under this Agreement and the other Transaction Documents,
at law or in equity (including a decree of specific performance and/or other injunctive relief).

 

(n) Withdrawal Right. Notwithstanding
anything to the contrary contained in (and without limiting any similar provisions of) the Transaction Documents, whenever any
Buyer exercises a right, election, demand or option under a Transaction Document and the Company or any Subsidiary does not timely
perform its related obligations within the periods therein provided, then such Buyer may rescind or withdraw, in its sole discretion
from time to time upon written notice to the Company or such Subsidiary (as the case may be), any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights.

 

    26

     

    

 

(o) Payment Set Aside; Currency.
To the extent that the Company makes a payment or payments to any Buyer hereunder or pursuant to any of the other Transaction Documents
or any of the Buyers enforce or exercise their rights hereunder or thereunder, and such payment or payments or the proceeds of
such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside,
recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or
any other Person under any law (including, without limitation, any bankruptcy law, foreign, state or federal law, common law or
equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be
satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff
had not occurred. Unless otherwise expressly indicated, all dollar amounts referred to in this Agreement and the other Transaction
Documents are in United States Dollars (“U.S. Dollars”), and all amounts owing under this Agreement and all
other Transaction Documents shall be paid in U.S. Dollars. All amounts denominated in other currencies (if any) shall be converted
into the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation. “Exchange
Rate” means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Agreement, the
U.S. Dollar exchange rate as published in the Wall Street Journal on the relevant date of calculation.

 

(p) Judgment Currency.

 

(i) If for the purpose of obtaining
or enforcing judgment against the Company in connection with this Agreement or any other Transaction Document in any court in any
jurisdiction it becomes necessary to convert into any other currency (such other currency being hereinafter in this Section 9.(p)
referred to as the “Judgment Currency”) an amount due in US Dollars under this Agreement, the conversion shall
be made at the Exchange Rate prevailing on the Business Day immediately preceding:

 

(1) the date actual payment of
the amount due, in the case of any proceeding in the courts of New York or in the courts of any other jurisdiction that will give
effect to such conversion being made on such date: or

 

(2) the date on which the foreign
court determines, in the case of any proceeding in the courts of any other jurisdiction (the date as of which such conversion is
made pursuant to this Section 9.(p)(i)(1) being hereinafter referred to as the “Judgment Conversion Date”).

 

(ii) If in the case of any
proceeding in the court of any jurisdiction referred to in Section 9.(p)(i)(1) above, there is a change in the Exchange Rate
prevailing between the Judgment Conversion Date and the date of actual payment of the amount due, the applicable party shall pay
such adjusted amount as may be necessary to ensure that the amount paid in the Judgment Currency, when converted at the Exchange
Rate prevailing on the date of payment, will produce the amount of US Dollars which could have been purchased with the amount of
Judgment Currency stipulated in the judgment or judicial order at the Exchange Rate prevailing on the Judgment Conversion Date.

 

(iii) Any amount due from the
Company under this provision shall be due as a separate debt and shall not be affected by judgment being obtained for any other
amounts due under or in respect of this Agreement or any other Transaction Document.

 

(q) Independent Nature of Buyers’
Obligations and Rights. The obligations of each Buyer under the Transaction Documents are several and not joint with the obligations
of any other Buyer or any Other Investor, and no Buyer shall be responsible in any way for the performance of the obligations of
any other Buyer or any Other Investor under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Buyer pursuant hereto or thereto, shall be deemed to constitute the Buyers and the Other Investors as,
and the Company acknowledges that the Buyers and the Other Investors do not so constitute, a partnership, an association, a joint
venture or any other kind of group or entity, or create a presumption that the Buyers are in any way acting in concert or as a
group or entity, and the Company shall not assert any such claim with respect to such obligations or the transactions contemplated
by the Transaction Documents or any matters, and the Company acknowledges that the Buyers and the Other Investors are not acting
in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations or the transactions
contemplated by the Transaction Documents. The decision of each Buyer and the Other Investors to purchase Common Shares pursuant
to the Transaction Documents has been made by such Buyer or Other Investor, as the case may be, independently of any other Buyer.
Each Buyer acknowledges that no other Buyer or any Other Investor has acted as agent for such Buyer in connection with such Buyer
making its investment hereunder and that no other Buyer or Other Investor will be acting as agent of such Buyer in connection with
monitoring such Buyer’s investment in the Common Shares or enforcing its rights under the Transaction Documents. Each Buyer
confirms that it has independently participated with the Company and its Subsidiaries in the negotiation of the transaction contemplated
hereby with the advice of its own counsel and advisors. Each Buyer shall be entitled to independently protect and enforce its rights,
including, without limitation, the rights arising out of this Agreement or out of any other Transaction Documents, and it shall
not be necessary for any other Buyer or Other Investor to be joined as an additional party in any proceeding for such purpose.
The use of a single agreement to effectuate the purchase and sale of the Common Shares contemplated hereby was solely in the control
of the Company, not the action or decision of any Buyer, and was done solely for the convenience of the Company and its Subsidiaries
and not because it was required or requested to do so by any Buyer. It is expressly understood and agreed that each provision contained
in this Agreement and in each other Transaction Document is between the Company and a Buyer, solely, and not between the Company
and the Buyers or Other Investors collectively and not between and among the Buyers and Other Investors. No consideration (including
any modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or modification
of any provision of this Agreement unless the same consideration is also offered to all of the parties to this Agreement. For clarification
purposes, this provision constitutes a separate right granted to each Buyer by the Company and negotiated separately by each Buyer,
and is intended for the Company to treat the Buyers as a class and shall not in any way be construed as the Buyers acting in concert
or as a group with respect to the purchase, disposition or voting of Common Shares or otherwise.

 

[signature pages follow]

 

    27

     

    

 

IN WITNESS WHEREOF, each Buyer and
the Company have caused their respective signature page to this Agreement to be duly executed as of the date first written above.

 

	 	COMPANY:
	 	 
	 	AMPIO PHARMACEUTICALS, INC.
	 	 	 
	 	By:	 
	 	 	Name: Michael Macaluso
	 	 	Title: Chief Executive Officer

 

    28

     

    

 

[PURCHASER SIGNATURE PAGES TO AMPIO PHARMACEUTICALS,
INC. SECURITIES PURCHASE 

AGREEMENT]

 

IN WITNESS WHEREOF, the undersigned have
caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.

 

 

	Name of Purchaser:	 

 

	Signature of Authorized Signatory of Purchaser:	 

 

	Name of Authorized Signatory:	 

 

	Title of Authorized Signatory:	 

 

	Email Address of Authorized Signatory:	 

	Facsimile Number of Authorized Signatory:	 

 

	Address for Notice to Purchaser: 	 
	 	 
	 	 
	 	 

 

	Delivery of Common Shares:	DVP through ThinkEquity	DTC delivery and payment by wire

 

DTC Delivery Instructions for Common Shares to Purchaser (if
applicable):

 

	 	 
	 	 
	 	 

 

	Subscription Amount: $ 	 	 

 

Shares:

 

EIN Number:

 

    29

     

    

 

List of Schedules 

 

Schedule 3(a) - Subsidiaries

Schedule 3(g) - Placement Agent Fees and Expenses

Schedule 3(p)- Transactions with Affiliates

Schedule 3(r)- Indebtedness and Other Contracts

Schedule 3(q)(iii) - Reserved Shares

Schedule 3(q)(iv) – Existing Securities; Obligations

Schedule 3(nn)- Management

Schedule 4(g) - Use of Proceeds

 

    30

     

    

 

SCHEDULE OF BUYERS 

 

	Investor	 	Shares	 	Dollars
	 	 	 	 	 

 

    31

     

    

 

COMPANY DISCLOSURE SCHEDULE

 

The following disclosure
schedule (this “Company Disclosure Schedule”) is delivered pursuant to that certain Securities Purchase Agreement
(the “Purchase Agreement”), dated as of June [17], 2019, by and between Ampio Pharmaceuticals, Inc., a Delaware
corporation (the “Company”), and each investor listed on the Schedule of Buyers attached thereto (individually,
a “Buyer” and collectively, the “Buyers”). Unless the context otherwise requires, all capitalized
terms used in this Company Disclosure Schedule shall have the respective meanings assigned to them in the Purchase Agreement.

 

No reference to or
disclosure of any item or other matter in this Company Disclosure Schedule shall be construed as an admission or indication that
such item or other matter is material. No disclosure in this Company Disclosure Schedule relating to any possible breach or violation
of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or
has actually occurred. This Company Disclosure Schedule and the information and disclosures contained herein are intended only
to qualify and limit the representations, warranties and covenants of the Company contained in the Purchase Agreement and shall
not be deemed to expand in any way the scope or effect of any of such representations, warranties or covenants.

 

The contents of all
documents referred to in this Company Disclosure Schedule are incorporated by reference herein as though fully set forth in this
Seller Disclosure Schedule. Any information disclosed in any section of this Company Disclosure Schedule shall be deemed to be
disclosed only for purposes of the corresponding section of the Purchase Agreement, except to the extent is clearly apparent from
the face of the disclosure that the disclosure applies to a representation or warranty contained in another section of the Purchase
Agreement.

 

The bold-faced headings
contained in this Company Disclosure Schedule are included for convenience only, and are not intended to expand the scope of the
information required to be disclosed in this Company Disclosure Schedule.

 

    32

     

    

 

Schedule 3(a)

Subsidiaries

 

None

 

    33

     

    

 

Schedule 3.(g)

Placement Agent Fees and Expenses

 

		1.	The Company will pay the Placement Agent a discount or spread of 7% of the offering price.

 

		2.	The Placement Agent is entitled to a non-accountable expense allowance equal to 1% of the offering price.

 

		3.	The Company has agreed to pay the following expenses of the placement agent relating to the offering: (a) all fees, expenses
and disbursements relating to background checks of our officers and directors in an amount not to exceed $10,000 in the aggregate;
(b) all filing fees and communication expenses associated with the review of this offering by FINRA; (c) all fees, expenses and
disbursements relating to the registration, qualification or exemption of securities offered under the securities laws of foreign
jurisdictions designated by the placement agent, including the reasonable fees and expenses of the placement agent’s blue
sky counsel; (d) $29,500 for the placement agent’s use of Ipreo’s book-building, prospectus tracking and compliance
software for this offering; (e) the costs associated with bound volumes of the public offering materials as well as commemorative
mementos and lucite tombstones, (f) the fees and expenses of the placement agent’s legal counsel incurred in connection with
this offering in an amount up to $75,000; and (g) up to $20,000 of the placement agent’s actual accountable road show expenses
for the offering. The Company has paid the Placement Agent a $25,000 advance applied against these expenses. The Placement Agent
will reimburse the Company for such advance to the extent any such out-of-pocket accountable expenses are not actually incurred
in compliance with FINRA Rule 5110(f)(2)(C) in the event of the termination of the offering of Common Shares.

 

		4.	The Company shall issue the Placement Agent or its designees, at the Closing, warrants to purchase the number of Common Shares
equal to 7% of the aggregate number of Common Shares sold in this offering of Common Shares.

 

    34

     

    

 

Schedule 3.(p)

Affiliate Transactions

 

None

 

    35

     

    

 

Schedule 3(q)(iii)

Convertible Securities Reserved Shares

  

	Reserved Common Stock*
	 
	Common stock outstanding	 	 	111,382,862	**
	Common Stock Reserved for 2010 Plan	 	 	4,159,283	 
	Stock Options Outstanding	 	 	5,496,665	 

 

	Outstanding Warrants
	 
	Shares of our common stock issuable upon the exercise of outstanding warrants	 	 	22,233,191	**

 

* CVI Investments, Inc. owns, or beneficially owns, 10.3% of
the Company’s issued shares.

 

** Does not reflect the pending exercise of warrants to purchase
an aggregate of 325,000 shares of common stock, expected to settle on or about June 17, 2019.

 

    36

     

    

 

Schedule 3(q)(iv)

Existing Securities; Obligations

 

None

 

    37

     

    

 

Schedule 3(r)

Indebtedness and Other Contracts

 

None

    38

     

    

 

Schedule 3.(nn)

Management

 

None

 

    39

     

    

 

Schedule 4(g)

Use of Proceeds

 

We intend to use the net proceeds from
this offering for working capital, including the conduct of a clinical trial, and other general corporate purposes. Accordingly,
our management will have broad discretion in the application of these proceeds. Pending use of the proceeds as described above,
we intend to invest the proceeds in a variety of capital preservation investments, including short term, interest bearing, investment
grade instruments and U.S. government securities

 

    40

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]